Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED] 
Document Date:  14-Sep-2020A Phase 2, Randomized, Active Comparator-Controlled, 
Multicenter, Double-Blind Clinical Trial to Study the Safety and 
Efficacy of Ceftolozane/Tazobactam (MK-7625A) Plus
Metronidazole Versus Meropenem in Pediatric Subjects with 
Complicated Intra-Abdominal Infection
Product:   MK-7625A 1
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialTHIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., 
WHITEHOUSE STATION , NJ, U.S.A.
SPONSOR:
Merck Sharp & Dohme Corp., a subsidiary  of Merck & Co., Inc. 
(here after referred to as the Sponsor or Merck)
One Merck Drive
P.O. Box 100
Whitehouse Station , New Jersey , 08889-0100, U.S.A.
Protocol -specific Sponsor Contact information can be found in the 
Investigator Trial File 
Binder (or equivalent) .
TITLE:
A Phase 2,Randomized, Active Comparator -Controlled, Multicente r, Double -Blind Clinical 
Trial to Study  the Safety  and Efficacy  of Ceftolozane/Tazobactam (MK -
7625A ) Plus 
Metronidazole Versus Meropenem i
n Pediatric Subjects with Complicated Intra-Abdominal 
Infection
IND NUMBER:   104,490
EudraCT NUMBER:   2016-004820-41 
  05L65F
Product:   MK-7625A 2
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialTABLE OF CONTENTS
DOCUMENT HISTORY ..................................................................................................... 10
SUMMARY OF CHANGES ................................................................................................ 11
1.0 TRIAL SUMMARY .................................................................................................. 16
2.0 TRIAL DESIGN........................................................................................................ 18
Trial Design ........................................................................................................... 18
Trial Diagram ........................................................................................................ 21
3.0 OBJECTIVE(S) & HYPOTHESIS(ES) .................................................................. 21
Primary Objective(s) & Hypothesis(es) .............................................................. 21
Secondary Objective(s) & Hypothesis(es) ........................................................... 21
Exploratory Objectives ......................................................................................... 22
4.0 BACKGROUND & RATIONALE .......................................................................... 22
Background ........................................................................................................... 22
Pharmaceutical and Therapeutic Background .................................................... 22
Ceftolozane/Tazobactam .............................................................................. 22
Complicated I ntra-abdominal I nfection ....................................................... 23
Completed Preclinical and Clinical Trials of Ceftolozane/Tazobactam ............. 25
Ongoing Clinical Trials of Ceftolozane/Tazobactam ......................................... 26
Information on Other Trial -related Therap y....................................................... 26
Comparator Therap y.................................................................................... 26
Metronidazole for Adjunctive Anaerobic Coverage .................................... 27
Rational e................................................................................................................ 27
Rationale for the Trial and Selected Subject Population .................................... 27
Rationale for Sample Size............................................................................ 28
Rationale for Dose Selection/Regimen ............................................................... 28
Rationale for Ceftolozane/Tazobactam Dosage ........................................... 28
Rationale for Metronidazole Dosage ........................................................... 32
Rationale for the Use of Comparator ........................................................... 32
Rationale for Comparator Dosage ............................................................... 32 
  05L65F
Product:   MK-7625A 3
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential
Rationale for Duration of Therap y and Optional Oral Step-Down 
Antibiotic Therap y....................................................................................... 33
Rationale for Endpoints ...................................................................................... 34
Rationale for Safety  Endpoints .................................................................... 34
Rationale for Efficacy  Endpoints ................................................................ .34
4.2.3.2.1 Clinical Outcome .................................................................................. 35
4.2.3.2.2 Microbiological Outcome ..................................................................... 36
Rationale for Pharmacokinetic Endpoints ................................................... 38
Benefit/Risk ........................................................................................................... 38
5.0 METHODOLOGY ................................................................................................... 39
Entry Criteria ........................................................................................................ 39
Diagnosis/Condition for Entry  into the Trial ...................................................... 39
Subject I nclusion Criteria .................................................................................... 39
Subject Exclusion Criteria .................................................................................. 41
Trial Treatment(s) ................................................................................................ 44
Intravenous Trial Treatments .............................................................................. 44
Optional Oral Step- down Therap y...................................................................... 47
Trial Treatments: Administrative Considerations ............................................... 48
Dose Selection .................................................................................................... 48
Dose Selection (Preparation) ....................................................................... 48
Timing of Dose Administr ation .......................................................................... 48
Trial Blinding...................................................................................................... 49
Randomization ...................................................................................................... 49
Stratification .......................................................................................................... 49
Concomitant Medications/Vaccinations ( Allowed & Prohibited ).................... 49
Rescue Medications & Supportiv e Care ............................................................. 51
Diet/Activity/Other Considerations ..................................................................... 51
Subject Withdraw al/Discontinuation Criteria ................................................... 51
Discontinuation of Treatment ............................................................................. 51
Withdrawal from the Trial .................................................................................. 52
Subject Replacement Strategy ............................................................................. 52
Beginning and End of the Trial ........................................................................... 52 
  05L65F
Product:   MK-7625A 4
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential
Clinical Criteria for Early Trial Termination ................................................... 53
6.0 TRIAL FLOW CHART ........................................................................................... 54
7.0 TRIAL PROCEDURES ........................................................................................... 57
Trial Procedures ................................................................................................... 57
Administrative Procedures .................................................................................. 57
Informed Consent/Assent ............................................................................. 57
7.1.1.1.1 General Informed Consent/A ssent ........................................................ 57
Inclusion/Exclusion Criteria ........................................................................ 58
Subject I dentifi cation Card .......................................................................... 58
Medical History ........................................................................................... 58
Prior and Concomitant Medications Review ............................................... 58
7.1.1.5.1 Prior Medications .................................................................................. 58
7.1.1.5.2 Concomitant Medications ..................................................................... 59
Assignment of Screening Number ............................................................... 59
Assignment of Treatment/Randomization Number ..................................... 59
Trial Compliance (Medication) .................................................................... 59
Clinical Procedures/Assessments ........................................................................ 59
Body Weight, Height, and Vital Signs ......................................................... 59
Physical Examination ................................................................................... 60
Surgical Wound Examination ...................................................................... 60
Abdominal Sign and Symptom Assessment ................................................ 60
Summary  of Operative Procedures .............................................................. 61
Radiological Examination ............................................................................ 61
Adverse Event Monitoring ........................................................................... 61
Assessment of Clinical Outcome ................................................................ .61
Assessment of Microbiological Outcome .................................................... 61
Assessment of Emergent Infection .............................................................. 61
Laboratory  Procedures/Assessments .................................................................. 61
Laboratory  Safet y Evaluations (Hematology  and Chemistry )..................... 62
Pregnancy  Testing ........................................................................................ 63
Assessment of Creatinine Clearance ............................................................ 63
Intra -abdominal Samples for Culture ........................................................... 63 
  05L65F
Product:   MK-7625A 5
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential
Blood Samples for Culture ........................................................................... 64
Pharmacokinetic Evaluations ....................................................................... 64
Other Procedures ................................................................................................ .64
Withdrawal/Discontinuation ........................................................................ 64
Lost to Follow -up......................................................................................... 65
Unblinded Pharmacist.................................................................................. 65
Subject Blinding/Unblinding ....................................................................... 65
Calibration of Critical Equipment ................................................................ 66
Visit Requirements .............................................................................................. 66
Screening...................................................................................................... 66
Randomization Visit .................................................................................... 67
Clinical Assessment Visits on I ntravenous Study  Treatment ...................... 67
End of IV Treatment Visit ........................................................................... 67
Clinical Assessment Visit on Oral Step -down Therap y.............................. 67
End of Treatment Visit ................................................................................. 68
Test of Cure Visit......................................................................................... 68
Last Follow -up Visit .................................................................................... 68
Subjects Who Prematurely  Discontinue From Study  Treatment or the 
Trial .............................................................................................................. 68
Assessing and Recording Adverse Events .......................................................... 68
Definition of an Overdose for This Protocol and Reporting of Overdose to 
the Sponsor .......................................................................................................... 69
Reporting of Pregnancy  and Lactation to the Sponsor ....................................... 69
Immediate Reporting of Adverse Events to the Sponsor .................................... 70
Serious Adverse Events ............................................................................... 70
Events of Clinical I nterest ............................................................................ 71
Evaluating Adverse Events ................................................................................. 72
Sponsor Responsibility  for Reporting Adverse Events ...................................... 75
TRIAL GOVERNANCE AND OVERSIGHT ................................................... 75
Executive Oversight Committee ......................................................................... 75
Data Monitoring Committee ............................................................................... 75
8.0 STATISTICAL ANALYSIS PLAN ........................................................................ 75
Statistical Analysis Plan Summary ..................................................................... 76 
  05L65F
Product:   MK-7625A 6
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential
Responsibility for Analyses/In -house Blinding .................................................. 77
Hypotheses/Estimation ......................................................................................... 78
Analysis Endpoints ............................................................................................... 78
Safety  Endpoints ................................................................................................ .78
Adverse Events ............................................................................................ 78
Laboratory  Data ........................................................................................... 78
Vital Signs.................................................................................................... 79
Efficacy  Endpoints .............................................................................................. 79
Secondary  Efficacy  Endpoints ..................................................................... 79
Exploratory  Efficacy  Endpoints ................................................................... 79
Pharmacokinetic Endpoints ................................................................................ 80
Analysis Populations ............................................................................................. 80
Safety Anal ysis Populations ............................................................................... 80
Efficacy  Anal ysis Populations ............................................................................ 80
Statistical Methods ................................................................................................ 81
Statistical Methods for Safet y Anal yses............................................................. 81
Statistical Methods for Efficacy  Anal yses.......................................................... 83
Summaries of Baseline Characteristics, Demographics, and Other Anal yses....85
Analy ses of Baseline Characteristics and Demographics ............................ 85
Population Pharmacokinetic A nalyses......................................................... 86
Interim Analyses ................................................................................................... 86
Multiplicity ............................................................................................................ 86
Sample Size and Power Calculations .................................................................. 86
Subgroup Analyses ............................................................................................... 87
Compliance (Medication Adherence) .................................................................. 88
Extent of Exposure ................................................................................................ 88
9.0 LABELING, PACKAGING, STORAGE AND RETURN OF CLINICAL 
SUPPLIES ................................................................................................................. 88
Investigational Product ........................................................................................ 88
Packaging and Labeling Information ................................................................ .89
Clinical Supplies Disclosure ................................................................................. 90
Storage and Handling Requirements .................................................................. 90 
  05L65F
Product:   MK-7625A 7
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential
Discard/Destruction/Returns and Reconciliation .............................................. 90
Standard Policies ................................................................................................... 90
10.0 ADMINISTRATIVE AND REGULATORY DETAILS ....................................... 91
Confidentiality ....................................................................................................... 91
Confidentiality  of Data ....................................................................................... 91
Confidentiality  of Subject Records ..................................................................... 91
Confidentiality  of Investigator Information ........................................................ 91
Confidentiality  of IRB/IEC I nformation ............................................................. 92
Compliance with Financial Disclosure Requirements ....................................... 92
Compliance with Law, Audit and Debarment ................................................... 92
Compliance with Trial Registration and Results Posting Requirements ........ 94
Quality Management System ............................................................................... 94
Data Management ................................................................................................ .94
Publications ........................................................................................................... 95
11.0 LIST OF REFERENCES ......................................................................................... 96
12.0 APPENDICES ........................................................................................................... 99
Merck Code of Conduct for Clinical Trials ........................................................ 99
Approximate Blood Volumes Drawn/Collected by Trial Visit ....................... 101
List of Abbreviations and Definitions of Terms ............................................... 102
13.0 SIGNATURES ......................................................................................................... 105
Sponsor's Representative ................................................................................... 105
Investigator .......................................................................................................... 105 
  05L65F
Product:   MK-7625A 8
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialLIST OF TABLES
Table 1 Ceftolozane Exposure and Target Attainment Summary  for Simulated Adult 
and Pediatric Subjects ............................................................................................ 30
Table 
2Tazobactam Exposure and Target Attainment Summary  for Simulated Adult 
and Pediatric Subjects ............................................................................................ 31
Table 
3Clinical Outcome Categories .................................................................................. 36
Table 4 Microbiologica l Outcome Categories..................................................................... 37
Table 
5Emergent Infection Categories ............................................................................... 38
Table 
6Intravenous Trial Treatments .................................................................................. 44
Table 
7Recommended Oral Step -down Therap y Options .................................................. 47
Table 
8Laboratory  Safet y Evaluations ................................................................................ 62
Table 
9Evaluating Adverse Events ..................................................................................... 73
Table 
10Efficacy  Anal ysis Populations ................................................................................ 81
Table 
11Analy sis Strategy for Safety  Parameters ................................................................ 82
Table 
12Analy sis Strategy  for Efficacy  Variables ............................................................... 84
Table 
13Estimated Two-sided 95% Confidence Intervals Based on Different Assumed 
Observed Rates of Efficacy  Endpoints ................................................................... 84
Table 
14Estimated Treatment Differences and Two -sided 95% Confidence Intervals ....... 87
Table 15 Product Descriptions .............................................................................................. 89
Table 
16Approxi mate Blood Volumes Collected by Trial Visit........................................ 101 
  05L65F
Product:   MK-7625A 9
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialLIST OF FIGURES
Figure 1 Trial Diagram ...................................................................................................... 21 
  05L65F
Product:   MK-7625A 10
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialDOCUMENT HISTORY
Document Date of Issue Overall Rationale
Amendment 3 14-SEP- 2020 Due to enrollment challenges in the remaining age groups in both thistrial 
in pediatric subjects with cIAI (MK -7625A -035) and also in the companion 
trial in pediatric subjects with cUTI (MK7625A -034), individual study  age 
group minimum requirement s for Groups 3- 5 were removed in both studies,
and the overall combined enrollment minimum targets for Groups 3 and 5 
were also reduced to facilitate more timely  availability  of these important 
pediatric data to health care providers and patients. T hese changes do not 
impact the key goals or scientific validity  of either study .
Amendment 2 26-APR - 2019 Enrollment targets for Groups 3-5 were applied across the present trial in 
pediatric subjects with cIAI (MK -7625A -035) and the companion trial in 
pediatric subjects with cUTI (MK -7625A -034).
Amendment 1/
Ukraine specific amendment30-APR - 2018 Country -specific amendment to exclude enrollment of subjects <2 years old 
(Groups 4 and 5) in Ukraine.
Original Protocol 21-MAR - 2017 Not applicable. 
  05L65F
Product:   MK-7625A 11
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialSUMMARY OF CHANGES
PRIMARY REASON(S) FOR THIS AMENDMENT:
Section Number (s) Section Title (s) Description of Change (s) Rationale
1.0
2.1
4.2.1.1
5.2.1
5.4Trial Summary
Trial Design
Rationale for Sample Size
Intravenous Trial Treatments
StratificationRemoved minimum number of at 
least 4 subjects 
per study  (MK-
7625A-034 and MK-7625A -035) 
in Groups 3, 4, and 5.
Reduced minimum enrollment 
targets for Groups 3 and 5 across 
both studies.Due to enrollment challenges in the 
remaining age groups, individual 
study  age group minimum
requirement sfor Groups 3-5 were 
removed in both the M
K-7625A- 034 
and MK-7625A- 035 studies .  
Additionally ,the overall combined 
enrollment minimum targets for 
Groups 3 and 5 were reduced to 
facilitate more timel y availability  of 
these important pediatric data to health
care providers and patients. These 
chang es do not impact the key  goals or 
scientific validity  of either study . 
  05L65F
Product:   MK-7625A 12
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialADDITIONAL CHANGE (S)FOR THIS AMENDMENT:
Section Number (s) Section Title (s) Description of Change (s) Rationale
1.0
5.1.2
5.1.3
5.10
6
7.1.1.1
7.1.1.1.1
7.1.1.3
7.1.5.1
7.2
7.2.2
7.2.3.1
7.2.3.2
10.1.2Trial Summary
Subject I nclusion Criteria
Subject Exclusion Criteria
Beginning and End of the Trial
Trial Flow Chart
Informed Consent/Assent
General Informed Consent/Assent
Subject I dentification Card
Screening
Assessing and Recording Adverse 
Events
Reporting of Pregnancy  and 
Lactation to the Sponsor
Serious Adverse Events
Events of Clinical I nterest
Confidentiality  of Subject 
RecordsUpdated text for informed 
consent processUpdated to align with Merck 
standard protocol template 
  05L65F
Product:   MK-7625A 13
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialSection Number (s) Section Title (s) Description of Change (s) Rationale
2.1
5.1.2Trial Design
Subject I nclusion CriteriaReworded language regarding 
the enrollment target for the 
percentage of subjects with a 
diagnosis of complicated 
appendicitis.To provide additional flexibility  in 
the number of subjects enrolled 
with a diagnosis of complicated 
appendicitis.
4.2.3.2.2 Microbiological Outcome Removed language that 
emergent infections are 
considered to have an 
unfavorable microbiological 
response.As microbiological outcome is 
meant to capture the persistence or 
eradication specifically of the 
baseline pathogen, emergent 
infections will not contribute to the 
microbiological outcome. This 
change aligns with other studies in 
the ZERBAXA program, wherein 
emergent infections are distinct 
from the overall microbiological 
outcome endpoint and are described 
separately  in the CSR.
Table 5: “Emergent Infection 
Categories”Added “and through the TOC 
visit” to the definition of new 
infection.To clarify  the window in which new 
infections will be r ecorded.
5.1.3 Subject Exclusion Criteria For chronic administration of 
systemic corticosteroids that 
could qualify  a s an 
immunosuppressing condition 
at screening, added the non-
weight -based definition for 
participants weighing >20 kg. To align the pediatric -specific 
definition of immunosuppressi on 
due to corticosteroid use with other 
protocols in the ZERBAXA 
program. 
  05L65F
Product:   MK-7625A 14
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialSection Number (s) Section Title (s) Description of Change (s) Rationale
5.2.5
6.0Timing of Dose Administration
Trial Flow ChartAdded text clarifying 
maximum duration of 
antibiotics. To clarify  that the final day  of study 
treatment may extend into Day 15 
to accommodate different start and 
stop times of the IV study treatment 
and/or dosing schedules of the oral 
step-down therap y.
5.8.1 Discontinuation of Treatment Added “required for IV study 
treatment only” to 
discontinuation criteria for 
developme nt of moderate or 
severe impairment of renal 
function. The lower limit of 50mL/min/1.73 
m2only a pplies to 
ceftolozane/tazobactam and not to 
the various optional oral step- down 
treatment options.
5.10 Beginning and End of the Trial Text defining the end of the 
trial as the last subject’s last 
visit or contact was changed to 
defining the end of the trial as 
when the last data is available 
in either study , MK -7625A -034 
or MK-7625A-035, whichever 
occurs later.Updated to reflect the fact that the 
safet y data will be combined for 
analysis across the 2 studies, thus 
the final analy sis cannot begin until 
both studies are completed and final 
data from both trials are available. 
  05L65F
Product:   MK-7625A 15
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialSection Number (s) Section Title (s) Description of Change (s) Rationale
7.1.4.4 Subject Blinding/Unblinding Updated template text to 
describe who may be unblinded 
following unblinding .This revision will allow greater 
flexibility  when describing who 
may become unblinded to a single 
participant ’s treatment following an 
unblinding and allows the principal 
investigator, site personnel, and 
Sponsor personne l to conduct 
appropriate follow -up medical care 
for the participant once an 
emergency  unblinding has taken 
place .
8.11
8.12Compliance (Medication 
Adherence)
Extent of ExposureUpdated the IV study treatment 
and overall study  treatment 
(including oral step-down 
therap y) compliance definition 
and how exposures will be 
summarized.It is clinically  informative to know 
the compliance and extent of 
exposure for treated subjects.  In 
addition, subjects overall study 
treatment exposure is an important 
criterion to evaluate the CE analysis 
population. 
Global Global Minor editorial and document 
formatting revisions.Minor syntax and grammar edits 
made for clarit y and correctness.
No additional changes. 
  05L65F
Product:   MK-7625A 16
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential1.0TRIAL SUMMARY
Abbreviated Title MK-7625A Plus Metronidazole versus Meropenem in Pediatric cIAI
Sponsor Product Identifiers MK-7625A
Ceftolozane/tazobactam
Trial Phase 2
Clinical Indication Treatment of complicated intra -abdom inal infection (cIAI)
Trial Type Interventional
Type of control Active control 
Route of administration Intravenous (IV) with optional oral step -down therapy
Trial Blinding Double -blind
Treatment Groups Subjects will be randomized to the experimental 
(ceftolozane/tazobactam + metronidazole) or comparator (meropenem + 
placebo) treatment arm to receive IV study treatment administered as a 
60-minute(±10 minutes) infusion as follows:
Group 1 (Ages 12to <18 years, n ≥50combined with Group 2 ):
Ceftolozane 1 g and tazobactam 0.5 g IV every 8 hours and 
metronidazole 10 mg/kg IV every 8 h ours (maximum dose 1.5 g/day) 
OR
Meropenem 20mg/kg (maximum 1g/dose) IV every 8 hours and 
placebo for metronidazole IV every 8 h ours
Group 2 (Ages 6 to <12 years, n ≥50 combined with Group 1):
Ceftolozane 20mg/kg and tazobactam 10mg/kg (maximum 
ceftolozane 1 g and tazobactam 0.5 g/dose) IV every 8 hours and 
metronidazole 10 mg/kg IV every 8 h ours (maximum dose 1.5 g/day) 
OR
Meropenem 20mg/kg (maximum 1g/dose) IV every 8 hours and 
placebo for metronidazole IV every 8 h ours
Group 3(Ages 2 to <6 years, n≥57combined with same age group in 
MK-7625A -034:
Ceftolozane 20mg/kg and tazobactam 1
0mg/kg (maximum 
ceftolozane 1 g and tazobactam 0.5 g/dose) IV every 8 hours and 
metronidazole 10 mg/kg IV every 8 h ours (maximum dose 1.5 g/day) 
OR
Meropenem 20mg/kg (maximum 1g/dose) IV every 8 hours and 
placebo for metronidazole IV every 8 h ours
Group 4(Ages 3 months to <2 years, n≥24 combined with same age 
group in MK -7625A -034:
Ceftolozane 2
0mg/kg and tazobactam 10mg/kg (maximum 
ceftolozane 1 gand tazobactam 0.5 g/dose ) IV every 8 hours and 
metronidazole 10 mg/kg IV every 8 h ours (maximum dose 1.5 g/day) 
OR
Meropenem 20mg/kg (maximum 1g/dose) IV every 8 hours and 
placebo for metronidazole IV every 8 h ours
Group 5(Ages birth [>32 weeks gestational age and ≥7 days postnatal] 
to <3 months, n ≥21 combined with same age group in MK -7625A -034: 
  05L65F
Product:   MK-7625A 17
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialCeftolozane 20mg/kg and tazobactam 10mg/kg (maximum 
ceftolozane 1 gand tazobactam 0.5 g/dose )IV every 8 hours and 
metronida zole IV every 8 -12 hours (see below for metro nidazole dosing 
for Group 5)
OR
Meropenem 20mg/kg *(maximum 1g/dose) IV every 8 hours and 
placebo for metronidazole IV every 8 h ours
*NOTE: Some literature supports a higher meropenem dosage (up to
30mg/kg every  8 hours) for subjects 14 days to <3 months of age;
therefore ,meropenem dosing up to 30 mg/kg every 8 hours maybe 
used for subjects 14days to <3 months of age at the investigator’s 
discretion.
Metronidazole Dosing for Group 5
Subjects >28 days of age:
Metronidazole 10 mg/kg every 8 h ours (maximum dose 1.5 g/day)
For subjects ≤28 days of age the suggested dosing regimen is listed 
below ;however ,other site-specific standard ofcare metronidazole 
dosing may be used at the investigator’s discretion.
Subjects ≤28 days of age and ≤2 kg:
Metronidazole 15 mg/kg loading dose, then 7.5 mg/kg/dose every 12 
hours
Subjects ≤28 days of age and >2 kg:
Metronidazole 15 mg/kg loading dose, 10 mg/kg dose every 8 h ours
NOTE: 
Subjects 7 to 28 days of age who receive metronidazole with a 
frequency other than every 8 hours must receive placebo at the 
same frequency to maintain blinding .
In Ukraine, enrollment will be limited to subjects 2 years to < 18 
years of age (Groups 1-3). Enrollment of subjects < 2 years old 
(Groups 4 -5) is not applicable at Ukrainian study sites .
Number of trial subjects Approx imately 240 (com bined across MK-7625A -034 and MK -7625A -
035) subjects w ill be enrolled.
Estimated duration of trial The Sponsor estimates that the trial will require approximately 3years 
from the time the first subject (or their legally acceptable 
representative) provides documented informed consent/assent until the 
last subject’s last study -related contact .
Duration of P articipation Each subject will participate in the trial for approximately 5 to 7 weeks 
from the time the subject or subject’s legal representative provides 
documented informed consent until the last subject’s last study -related 
contact. After a screening phase of up to 48 hours, each subject will 
receive study treatment (IV only or IV + oral) for a minimum of 5 days 
to a maximum of 14 days. After the end of treatment, each subject 
enters a follow -up phase consisting of a Test of Cure (TOC) Visit 7 to 
14 days after the last dose of study treatment and a Last Follow -up 
(LFU) Visit 21 to 28 days after the last dose of study treatment.
Randomization Ratio 3:1 for ceftolozane/tazobactam + metronidazole: meropenem + 
placebo 
  05L65F
Product:   MK-7625A 18
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialA list of abbreviations used in this document can be found in Appendix 12.3.
2.0TRIAL DESIGN
Trial Design
This is a Phase 2 randomized, active comparator -controlled, multicenter, double -blind trial 
evaluating the safety and efficacy  of ceftolozane/tazobactam (MK- 7625A) plus 
metronidazole versus meropenem plus placebo in pediatric subjects from birth (defined as 
>32 weeks gestational age and ≥7 day s postnatal) to <18 years of age with complicated intra -
abdominal infection (cIAI). 
MK-7625A -034 is a companion Phase 2randomized, double -blind trial of 
ceftolozane/tazobactam versus meropenem in pediatric subjects with cUTI; MK-7625A -034 
and MK-7625A -035 will be pooled together fora combined safety  database. Thus, 
approximately 240subjects (combined across MK-7625A -034 and MK-7625A -035) will be 
stratified by age to receive study  treatment. Afterminimum enrollment targets for each age 
group are met(202subjects total), additional subjects (combined across MK-7625A -034 and 
MK-7625A -035) will be enrolled in an y of the 5age groups.
NOTE: Approximately  90% of the randomized population will consist of subjects with a 
diagnosis ofcomplicated appendicitis. 
In MK-7625A -035, subjects will be randomized in a 3:1 ratio to receive IV 
ceftolozane/tazobactam plus metronidazole or meropenem plus placebo . After receiving at 
least 9 doses of double -blind IV study treatment, subjects in either treatment arm may be 
switched to open -label ,standard ofcare oral step- down antibiotic therap y at the 
investigator’s discretion. Oral step- down therap y is considered study  treatment. 
Recommendations for oral step- down therapy  are provided in Section 5.2.2 –Optional Oral 
Step-down Therap y.
The total duration of study  treatment (IV only or IV + oral) is a minimum of 5 days and a 
maximum of 14 day s.
Subjects will be randomized to the experimental (ceftolozane/tazobactam + metronidazole) 
or comparator (meropenem + placebo) treatment arm to receive IV study treatment 
administered as a 60 -minute(±10 minutes) infusion as follows:
Group 1 (Ages 12to <18 y ears, n≥ 50combined with Group 2):
Ceftolozane 1 g and tazobactam 0.5 gIV every 8 hours and metronidazole 10mg/kg IV 
every  8 hours (maximum dose 1.5 g/day ) 
OR
Meropenem 20 mg/kg (maximum of 1 g/dose) IV every  8  h ours and placebo for 
metronidazole IV every  8 hours 
  05L65F
Product:   MK-7625A 19
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialGroup 2 (Ages 6 to <12 y ears, n ≥50 combined with Group 1):
Ceftolozane 20 mg/kg and tazobactam 10 mg/kg (maximum ceftolozane 1g and tazobactam 
0.5 g/dose )IV every  8 hours and metronidazole 10 mg/kg IV every  8 hours (maximum dose 
1.5 g/day ) 
OR
Meropenem 20 mg/kg (maximum of 1 g/dose) IV every  8  h ours and placebo for 
metronidazole IV every  8 hours
Group 3(Ages 2 to <6 y ears, n≥57 combined with same age group in MK -7625A -034:
Ceftolozane 20mg/kg and tazobactam 10mg/kg (maximum ceftolozane 1g and tazobactam 
0.5 g/dose )IV every  8 hours and metronidazole 10mg/kg IV every  8 hours (maximum dose 
1.5 g/day ) 
OR
Meropenem 20 mg/kg (maximum of 1 g/dose) IV every  8  h ours and placebo for 
metronida zole IV every  8 hours
Group 4(Ages 3 months to <2 years, n≥24 combined with same age group in MK- 7625A-
034:
Ceftolozane 20 mg/kg and tazobactam 10mg/kg (maximum ceftolozane 1g and tazobactam 
0.5 g/dose )IV every  8 hours and metronidazole 
10 mg/kg IV every  8 hours (maximum dose 
1.5 g/day ) 
OR
Meropenem 20 mg/kg (maximum of 1 g/dose) IV every  8  h ours and placebo for 
metronidazole IV every  8 hours
Group 5(Ages birth [>32 weeks gestational age and ≥7 days postnatal] to <3 months, n≥21
combined with same age group in MK -7625A-034:
Ceftolozane 20 mg/kg and tazobactam 10 mg/kg (maximum ceftolozane 1g and tazobactam 
0.5 g/dose )IV every  8 hours and metronidazole IV every  8to 12 hours (see Table 6for 
metronidazole dosing in Group 5)
OR
Meropenem 20mg/kg*(maximum of 1 g/dose) IV every  8  h ours and placebo for 
metronidazole IV every  8 hours
*NOTE: There is literature that 
supports a higher meropenem dosage (up to 30 mg/kg every 
8
hours ) for subjects 14 days to <3 months of age. Therefore ,meropenem dosing up to 30 
mg/kg every  8  h ours may be used for subjects 14 days to <3 months of age at the 
investigator’s discretion.
NOTE:
Subjects 7 to 28 day s of age who receive metronidazole dosing with a frequency  other 
than every  8 hours must receive placebo dosing at the same frequency  to maintain 
blinding. 
  05L65F
Product:   MK-7625A 20
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialIn Ukraine, enrollment will be limited to subjects 2 years to < 18 years of age 
(Groups 1-3). Enrollment of subjects < 2 years old (Groups 4-5) is not applicable at 
Ukrainian stud y sites .
Clinical and microbiological assessments will be performed at the following visits:
End of IV Treatment Visit (EOIV)
End of Treatment Visit (EOT )
Test of Cure Visit (TOC )
NOTE: For subjects who receive IV study  treatment only (without optional oral step- down 
therap y),a separate assessment does not need to be performed at the EOT Visit; the EOIV 
Visit will serve as the EOT Visit .
Specific procedures to be performed during the trial, as well as their prescribed times and 
associated visit windows, are outlined in the Trial Flow Chart -
Section 6.0. Details of each 
procedure are provided in Section 7
.0 –Trial Procedures. 
  05L65F
Product:   MK-7625A 21
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential
Trial Diagram
The trial design is depicted in Figure 1.
Figure 1 Trial Diagram
3.0OBJECTIVE(S) & HYPOT HESIS(ES)
In male and female subjects from birth (>32 weeks gestational age and ≥7 days postnatal) to 
<18 y ears of age with cIAI:
Primary Objective(s) & Hypothesis (es)
To evaluate the safet y and tolerabilit y of ceftolozan e/tazobactam plus metronidazole 
compared with that of meropenem
Secondary Objective(s) & Hyp othesis(es)
1.To evaluate the efficacy  of ceftolozane/tazobactam plus metronidazole compared 
with that of meropenem with respect to clinical response at the EOT and TOC Visit s
 
  05L65F
Product:   MK-7625A 22
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential2.To evaluate theefficacy  of ceftolozane/tazobactam plus metronidazole compared 
with that of meropenem with respect to per-subject microbiological response atthe 
EOT and TOC Visit s
Exploratory Objectives
1.To evaluate the pharmacokinetics (PK) of ceftolozane and tazobactam
2.To evaluate the efficacy  of ceftolozane/tazobactam plus metronidazole compared 
with that of meropenem with respect to clinical response at the EOIV Visit
3.To evaluate the efficacy  of ceftolozane/tazobactam plus metronidazole compared 
with that of meropenem with respect to per-subject microbiological response at the 
EOIV Visit
4.To evaluate the efficacy  of ceftolozane/tazobactam plus metronidazole compared 
with that of meropenem with respect to per-pathogen microbiological response at the 
EOIV, EOT, and TOC Vis its
NOTE: For subjects who receive IV study  treatment only (without optional oral step- down 
therap y),a separate assessment does not need to be performed at the EOT Visit; the EOIV 
Visitwill serve as the EOT Visit.
4.0BACKGROUND & RATIONA LE
Background
Refer to the IB/approved labeling for detailed background information on 
ceftolozane/tazobactam.
Pharmaceutical and Therapeutic Background
Ceftolozane/Tazobactam
Ceftolozane/tazobactam, a novel combination of ceftolozane and the β-lactamase inhibitor 
(BLI), tazobactam, is used to treat serious bacterial infections. Ceftolozane is a member of 
the cephalosporin class of antibiotics, which is well characterized in ter ms of safety, efficacy , 
and general antimicrobial profile. While ceftolozane alone represents an important 
therapeutic option for the treatment of infections caused by Pseudomonas aeruginosa, the 
efficacy  of ceftolozane for the treatment of suspected gram -negative infections in general 
could be compromised by the spread of extended -spectrum β-lactamase (ESBL) -producing 
bacteria. Combining ceftolozane with a BLI, such as tazobactam, broadens its in vitro 
spectrum of activit y to include man y drug-resistant Enterobacteriaceae and is, thereby , likely 
to improve its clinical utility  against gram -negative bacteria.
Ceftolozane (both alone and in combination with tazobactam) exhibits time -dependent killing 
activity  against various gram -negative organisms, including drug-resistant P. aeruginosa. 
Ceftolozane/tazobactam has been shown to be active against strains of P. aeruginosa that are 
resistant to carbapenems, cephalosporins, fluoroquinolones, and/or aminogl ycosides, 
including the majorit y of multidrug -resistant (MDR) isolates. The in vitro activit y of  
  05L65F
Product:   MK-7625A 23
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidentialceftolozane/tazobactam against the majority  of ESBL -producing gram -negative bacilli and 
important anaerobic pathogens such as Bacteroides fragilis is greater than that of ceftolozane 
alone. Ceftolozane/tazobactam has no activity  against enterococci and staphy lococci. 
Compared with other cephalosporins, ceftolozane requires a lower percentage of time above 
the minimum inhibitory  concentration (T >MIC) of 8 µg/mL to achieve bacteriostasis (21% to 
29%) or 1-log killing (27% to 35%) in animal models. Additionally , ceftolozane/tazobactam 
was superior to piperacillin/tazobactam against ESBL -producing Escherichia coli in a mouse 
sepsis model.
Clinical trials in adults have shown that the PK of ceftolozane/tazobactam is linear across a 
wide range of doses (up to 4.5g [3 g ceftolozane/1.5 g tazobactam] as a single dose), 
distributes primarily  to the extracellular fluid, has a relatively  short terminal elimination half -
life (approximately  2to 3hours for ceftolozane and 1 hour for tazobactam), and has low 
protein -binding (approximately  16% to 21% for ceftolozane and 30% for tazobactam). In 
adults, at the approved dose of 1.5 g, the mean (coefficient of variation [%CV ]) values for 
area under the concentration -time curve (AUC) on Day 1  w ere 172 (14) and 
24.4 (18) µg•h/mL for ceftolozane and tazobactam, respectivel y. The mean (%CV) values for 
maximum observed concentration (Cmax) on Day 1 were69.1 (11) and 18.4 (16) µg/mL for 
ceftolozane and tazobactam, respectively . As ceftolozane/tazobactam is primarily  removed 
from the systemic circulation by renal excretion, dose adjustments are necessary  in some 
subjects with renal impairment.
The safet y and efficacy of ceftolozane/tazobactam was shown in Phase 3 trials in adult 
subjects with complicated urinary  tract infections (cUTI) and cIAI. In these Phase 3 trials, the 
overall incidence of TEAE s was similar in the ceftolozane/tazobactam and comparator 
treatment arms. Ceftolozane/tazobactam was found to be noninferior to the comparator in 
these Phase 3 trials.
In summary , ceftolozane is a novel cephalosporin antibiotic that, in combination with a 
potent BLI, tazobactam, has broad -spectrum antibacterial coverage against 
Enterobacteriaceae, including ESBL -producing strains, and MDR P. aeruginosa. 
Ceftolozane/tazob actam is approved for use in adult patients with cUTI, including 
pyelonephritis, and cIAI (in combination with metronidazole) at a dose of 1.5 g 
(1gceftolozane/0.5 g tazobactam) every  8  h ours. Both in vitro and in vivo safet y and 
efficacy  data support it s continued clinical investigation in the pediatric population .
Complicated Intra -abdominal Infection
Uncomplicated IAI is characterized by involvement of a single infected abdominal organ 
without anatomical disruption; in contrast, cIAI is characterized by extension of infection 
into the peritoneal space, manifesting as abdominal abscess or diffuse peritonitis [1].
Primary  peritonitis, defined as microbial infection of the peritoneum and peritoneal fluid 
without accompanying gastrointestinal (GI) or other visceral perforation, abscess or localized 
IAI, rarel y develops in healthy  adults but mainly  occurs in infancy  and early  childhood and in 
adult cirrhotic patients [2]. Secondary peritonitis, the most common form of cIAI, typically  
  05L65F
Product:   MK-7625A 24
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidentialresults from loss of integrity of the GI tract or infected viscera. Common causes of secondar y 
bacterial peritonitis include penetrating or blunt abdominal trauma, appendicitis, 
diverticuliti s, gastroduodenal ulcer perforation, biliary  tract infections, and postoperative 
complications after abdominal procedures. Necrotizing enterocolitis (NEC), an inflammatory 
bowel necrosis that generally  presents within the first 2 weeks of life and affects the terminal 
ileum ,is the most common cause of secondary  peritonitis in neonates [3]. In older pediatric 
patients, secondary  peritonitis is predominantly  associated with complicated appendicitis, 
although it also occurs as a result of intussusception, incarcerated hernia, volvulus ,or rupture 
of a Meckel’s diverticulum. I n a study  of community -acquired cIAI in pediatric patients aged 
from 1 month to 15 years, the vast majority  of infections were complicated appe ndicitis 
(113/123, 92%) [4]. Complicated appendicitis arising from ruptured or gangrenous acute 
appendicitis is associated with significant increases in morbidit y and length of 
hospitalization; perforation rates are as high as 82% for pediatric patients under 5years and 
100% for pediatric patients under 1 y ear[5].
The microbiology  of cIAI is predominantl y related to the site of loss of integrit y within the 
GI tract and the level of disruption; as the lower GI tract contains hundreds of bacterial 
species at high concentrations, cIAI arising from the lower GI tract is likely  to be 
polymicrobial in nature [6]. Infections derived from the colon are linked w ith facultative and 
obligate anaerobic organisms, gram -negative organisms (Enterobacteriac eae), other gram -
negative bacilli and enterococci [6]. In a  study of 100 pe diatric patients with ruptured 
appendi ces, 144 aerobic isolates and 310 anaerobic isolates were detected, with the 
predominant aerobic bacteria being E. coli, alpha -hemoly tic streptococci, gamma -hemol ytic 
streptococci, group D enterococcus, and P. aerugino sa. Gram -negative bacilli (Bacteroides 
fragilis group and pigmented Prevotella and Porphyromonas ), gram -positive anaerobic 
cocci, Fusobacterium spp, and Clostridium spp were the most common anaerobic isolates [7]. 
NEC is associated with fewer anaerobic isolates; aerobic species including Klebsiella , 
Enterobacter and Streptococcus spp are instead frequently reported.
Nosocomially -acquired pathogens associated with a high degree of antibiotic resistance 
include strains of P. aeruginosa , S. marcescens , Acinetobacter ,and Providencia spp. 
Furthermore, drug-resistant pathogens such as ESBL -producing Enterobacteriaceae, 
methicillin -resistant Staphylococcus aureus (MRSA), and vancom ycin-resistant enterococci 
may present in cIAI [8].
Intra-abdominal infection typicall y presents with acute onset abdominal pain associated with 
symptoms of gastrointestinal dysfunction such as anorexia, nausea or vomiting. In addition 
patients with cIAI will often display  systemic signs of inflammation. A perforated viscera is 
likely  to induce a systemic response, and such patients will often be febrile and tachycardic
[9].
The treatment of cIAI involves a multifaceted approach including a source control procedure 
to drain infected foci and control ongoing peritoneal contamination as well as adjunctive 
antimicrobial treatment.
The importance of antimicrobial therap y selection has been highlighted in an analysis of 
clinical data generated in the Netherlands, which show ed that hospitalized patients with  
  05L65F
Product:   MK-7625A 25
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidentialnosocomial cIAI who had not been administered appropriate therapy  (16%) were at over 
3-fold higher risk of clinical failure in relation to those thathad. As a result, antimicrobial 
selection has significant implications in relation to both patient care and associated health
care costs [2].
As cIAI is associated with mixed aerobic and anaerobic bacteria that act in synergy  to 
increase pathogenicity , appropriate antimicrobial therap y should include either broad -
spectrum agents or drug combinations to effectively  combat infection. Thus, broad -spectrum 
empiric therap y of suspected or confirmed pediatric cIAI is indicated and treatment with 
carbapenems (imipenem or meropenem), piperacillin -tazobactam, ticarcillin -clavulanate, or 
an extended- spectrum cephalosporin (cefotoxime, ceftriaxone, ceftazidime ,or cefepime) 
with metronidazole is recommended [10].
Completed Preclinical and Clinical Trials of Ceftolozane/Tazobactam
Refer to the IB/approved labeling for detailed information on preclinical and completed 
clinical trials of ceftolozane/tazobactam.
The primary  data suppo rting the efficacy  of ceftolozane/tazobactam in the cIAI indication 
was derived from 2 large, identical, global, multicenter, randomized, double -blind, 
active- controlled Phase 3 trials (CXA -cIAI-10-08 [MK-7625A -003] and CXA -cIAI-10-09 
[MK -7625A -004]). In both trials, adult subjects were randomized 1:1 to receive either IV 
ceftolozane/tazobactam 1.5 g (ceftolozane 1g/tazobactam 0.5 g) every  8hours plus 
metronidazole 500 mg every  8 hours or IV meropenem 1 gevery  8 hours administered for 
4to 14 days. The results indicated that ceftolozane/tazobactam plus metronidazole was 
noninferior to meropenem in the treatment of cIAI in adults .
In the treatment of adult subjects with nosocomial pneumonia (NP) (MK- 7625A -008), 
ceftolozane/tazobactam 3 g (2 g ceftolozane a nd 1 g tazobactam) IV every  8  h ours 
demonstrated noninferiority  compared to meropenem 1 g IV every 8  hours for FDA and 
EMA primary  and key secondary  efficacy  endpoints. Overall, both treatment groups 
demonstrated comparable per-pathogen clinical cure and microbiological eradication rates at 
the TOC visit against frequentl yisolated pathogens, including P. aeruginosa, 
Enterobacteriaceae, and Haemophilus influenzae .
The pediatric development program for ceftolozane/tazobactam include da pediatric PK and 
safet y trial of ceftolozane/tazobactam, CXA -PEDS -13-08 (MK- 7625A -010) [11].This was a 
Phase 1, multicenter, single -dose, noncomparative , open -label trial in pediatric subjects with 
proven or suspected gram -negative infection or for peri-operative prophy laxis . This study 
had 6age-based cohorts and enrolled a total of 43 subjects; 37 (86.0%) received study  drug.
Doseselections of ceftolozane/tazobactam for each age group (Group 1: ages ≥12 to 18 
years, Group 2: ages ≥7 to 12 years, Group 3: ages ≥2 to 7 years, Group 4: ages ≥3 months 
to 2 years, Group 5: 32weeks gestation, 7 days postnatal to 3months, and Group 6: 32 
weeks gestation, 7days postnatal to 3 months) were projected to achieve exposures similar 
to those observed in adults who received the approved dose forcUTI and cIAI. Ceftolozane 
and tazobactam PK parameters were generall y comparable across Groups 1 to 4 (ages 3 
months to <18 years). Subjects in Groups 5 and 6 (birth [7 days postnatal] to <3 months of  
  05L65F
Product:   MK-7625A 26
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidentialage) had a lower CL than older children; however, there was no consistent trend in the 
weight -normalized CL across Groups 1to 6. Data from MK-7625A -010 were used to 
determine appropriate doses for the present trial, as detailed in Section 4.2.2.1 –Rationale for 
Ceftolozane/Tazobactam Dosage.
Ceftolozane/tazobactam administered as a single, age-based dose was generally  well 
tolerated in MK-7625A -010. Overall, 11 subjects (29.7%) experienced a total of 26 TEAEs.  
No severe TEAEs or TEAEs leading to discontinuation of study  treatment were reported, and 
there were no deaths during the trial. Two subjects had nonserious treatment -related TEAEs 
(1 subject in Group 1 with dizziness and 1 subject in Group 3 [30/15 mg/kg dose] with 
bradycardia and tachycardia). Three subjects had SAEs (1 subject from Group 1 with 
pneumonia, 1 subject from Group 2 with infective pulmonary  exacerbation of cystic fibrosis, 
and 1 subject from Group 4 [30/15 mg/kg dose] with device -related sepsis), which were all 
deeme d unrelated to trial treatment. No subject in Groups 5 or 6 experienced a treatment -
related TEAE or SAE. No clinically  significant laboratory  abnormalities or changes in 
electrocardiograms were observed after administration of ceftolozane/tazobactam.
Ongoing Clinical Trials of Ceftolozane/Tazobactam
Refer to the IB for detailed information for ongoing clinical trials of ceftolozane/tazobactam .
In addition to the present trial, the current clinical development program for 
ceftolozane/tazobactam includes 4ongoing/planned clinical studies: 1) a Phase 3, 
randomized, double -blind, active comparator -controlled study  c omparing 
ceftolozane/tazobactam plus metronidazole versus meropenem in adult Chinese subjects with 
cIAI, 2) a Phase 2, randomized, double -blind, active comparator -controlled study comparing 
ceftolozane/tazobactam versus meropenem in pediatric subjects with cUTI, including 
pyelonephritis, 3) a Phase 1, open -label, noncomparative study  evaluating the safet y, 
tolerability , and PK of ceftolozane/tazobactam in pediatric subjects with NP, and 4) a Phase 
1, non-randomized, single -arm, single -site, fixed -sequence open -label, PK, safety , and 
tolerability  study  of ceftolozane/tazobactam in healthy  Chinese subjects .
Information on Other Trial -related Therapy
Comparator Therapy
Subjects in the comparator arm of the present trial will receive IV meropenem (Table 6).
Meropenem is a carbapenem antibiotic indicated as single -agent therap y for the treatment of 
complicated appendicitis and peritonitis caused by viridans group streptococci, E. coli, 
Klebsiel la pneumoniae, P. aeruginosa, B. fragilis B.thetaiotaomicron, and 
Peptostreptococcus species . See Section 4.2.2.3 –Rational for the Use of Comparator and 
Section 4.2.2.4 –Rationale for Comparator Dosage for additional details on the efficacy  and 
safet y of meropenem in the treatment of cIAI. 
Meropenem exerts its bactericidal activity  by inhibiting bacterial cell wall synthesis in gram -
positive and gram -negative bacteria through binding to penicillin -binding –proteins. Like 
other β-lactam antibiotics, the T>MI C for meropenem has been shown to best correlate with 
efficacy . In preclinical models, meropenem demonstrated activity when plasma  
  05L65F
Product:   MK-7625A 27
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidentialconcentrations exceeded the MIC of the infecting organisms for approximately  40% of the 
dosing interval.
Metronidazole for Adjunctive Anaerobic Coverage
Subjects in the ceftolozane/tazobactam arm of this trial will receive adjunctive therap y with 
IV metronidazole ( Table 6).
Metronidazole injection, USP, is a parenteral formulation of the synthetic nitroimidazole 
antibacterial agent 2 -methy l-5-nitro -1H-imidazole -1-ethanol. 
The addition of metronidazole in combination with ceftolozane/tazobactam ensures coverage 
of intra-abdominal infections caused by anaerobic bacteria including Bacteroides species 
including the B.fragilis group (B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, 
Bvulgatus ), Clostridium species, Eubacterium species, Peptococcus species ,and 
Peptostreptococcus spec ies.
Metronidazole is recommended as part of combination therap y for empiric treatment of cIAI 
in children in the Infectious Diseases Societ y of America (IDSA) guidelines on treatment of 
cIAI [1].
Rationale
Rationale for the Trial and Selected Subject Population
Clinical trials have indicated that ceftolozane is well tolerated and generally  safe in healthy 
adult subjects, adult subjects with varying degrees of renal impairment, and adult subjects 
with cIAI or cUTI. The Phase 1 PK and safety  trial in pediatric subjects (CXA -PEDS -13-08 
[MK-7625A -010]; see Section 4.1.2 –Completed Preclinical and Clinical Trials of 
Ceftolozane/Tazobactam used an adaptive trial design wherein enrollment of Groups 1 to 4 
(ages 3months to <18years) was conducted in parallel but enrollment of Groups 5 and 6 
(ages birth to <3 months) did not begin until PK assessments and subject safet y data from the 
older age groups were reviewed. Data from this trial revealed that ceftolozane/tazobactam 
doses resulting in exposures similar to those observed in adult subjects with cUTI orcIAI 
were safe and well tolerated in pediatric subjects.
The present trial (MK- 7625A -035) will enroll pediatric subjects from birth to <18 years of 
age(from 2 years to < 18 years of age in Ukraine) who present with cIAI to establish the 
safet y and efficacy  of ceftolozane/tazobactam in this population. The pediatric dosing 
recommendations (see Section 4.2.2.1 –Rationale for Ceftolozane/Tazobactam Dosage for 
rationale for dose selection) were developed using data from subjects from birth (>32 weeks 
gestational ageand≥7 days postnatal) to <18 years of age; no data were available from 
subjects ≤32 weeks gestational age or <7 days postnatal to <3 months of age. Neonatal renal 
function is closely  related to both gestational age and postnatal age. Because serum creatinine 
fluctuates in the first week of life, the revised Schwartz equation [12], which will be used to 
calcula te renal function in this population, is not recommended for use until after the first  
  05L65F
Product:   MK-7625A 28
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidentialweek of life. Therefore, the present trial defines “birth” as >32 weeks gestational age and ≥7 
days postnatal.
Because ceftolozane/tazobactam was well tolerated in the Phase 1 pediatric PK and safety 
trial ( CXA -PEDS -13-08 [MK-7625A -010]) , parallel enrollment into active and comparator 
groups is considered appropriate for the present trial. Investigators, Sponsors, trial personnel, 
and subjects will all be blinded to preve nt bias in treatment allocation and in the assessment 
of safet y and efficacy . Likewise, randomization will be used to produce similar treatment 
arms and reduce bias.
Rationale for Sample Size
This trial is being conducted to establish the safet y and tolera bility  of ceftolozane/tazobactam 
in pediatric subjects with cIAI.  The efficacy  of ceftolozane/tazobactam in pediatric subjects 
with cIAI may be extrapolated from the corresponding adult trials . Therefore, the calculation 
of cumulative sample size for thistrial is based on obtaining sufficient data to evaluate the 
safet y of this drug in pediatric subjects by combining safet y data from the present trial and 
MK-7625A -034 (the companion trial in pediatric subjects with cUTI )(see Section 8.9—
Sample Size and Power Calculations) . Combining subjects across both studies is intended to 
provide flexibility  and enable timely  enrollment of the trials. In addition, a minimum 
enrollment target of at least 4 subjects in Groups 3-5 are in place to ensure data are obtained 
for these age groups from subjects with cIAI. This is an exploratory  trial and is not powered 
to test formal hy potheses.
Approximately 240 subjects (combined across MK-7625A -034 and MK-7625A -035) will 
receive study  treatment (approximately  180 ceftol ozane/tazobactam -treated and 60 
comparator -treated subjects ). After the minimum enrollment targets for each age group are 
met (202 subjects total), additional subjects (combined across MK-7625A -034 and MK-
7625A -035) will be enrolled in any  of the 5age gro ups. 
Rationale for Dose Selection/Regimen
Rationale for Ceftolozane/Tazobactam Dosage
The proposed ceftolozane/tazobactam pediatric doses were projected using a population PK 
approach using data from 13 clinical studies (12 adult studies and 1 pediatric study). The PK 
analysis showed that 2 -compartment models best described the concentration -time profiles of 
ceftolozane and tazobactam. The fit of the models was improved by including allometric 
scaling using body weight as a covariate on clearance (CL), central volume of distribution 
(Vc), peripheral volume of distribution (Vp), and intercompartmental clearance (Q, for 
tazobactam only). In the final models, renal function (estimated glomerular filtration rate 
[eGFR ]) was included as a covariate on CL for ceftolozane. For tazobactam, presence of 
infection (as a categorical variable: Presence or absence) was also a significant covariate on 
CL for tazobactam. Tazobactam CL for subject s was estimated to be 67.7% of the CL for 
those without infection. Infection status did not appear to be a significant covariate on the PK 
of ceftolozane. 
  05L65F
Product:   MK-7625A 29
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialThe final PK models for ceftolozane and tazobactam were used to simulate the AUC from 0 
to 8 hours (AUC 0-8) and the Cmaxin pediatric subjects with infections on Day 3, which was 
shown to provide stead y-state exposures. To provide a benchmark for evaluating the safet y of 
ceftolozane and tazobactam in simulated pediatric subject s, Day 3  p lasma exposure 
parameters for adult subject s were simu lated. For predicting efficacy  of the doses, probability  
of target attainment (PTA) after the first dose for adult subject s and 5 pediatric age groups 
was also simulated.
The criteria used in evaluating the appropriateness of doses were:
The 95th percentil e of pediatric ceftolozane and tazobactam exposures (AUC and 
Cmax) on Day 3 not exceeding the corresponding 95th percentile of adult exposures; 
and 
The ceftolozane Day 1 PTA (initial dose) ≥90% based on concentrati ons exceeding 
an MIC of 4 µg/mL (the Clinical and Laboratory  Standards Institute [CLSI]
breakpoint) for at least 30% of the dosing interval and a tazobactam Day 1 PTA 
≥90% based on concentrations exceeding a threshold concentration of 1 µg/mL for at 
least 20% of the dosing interval.
Similar to other β-lactams, the PK target that best correlates with in vivo efficacy  for 
ceftolozane is the percentage of the dosing interval during which the free concentration of 
ceftolozane in plasma exceeds the MIC (% fT>MIC). A %fT>MIC of 30% was selected as 
the criterion because data from a neutropenic mouse thigh infection model showed that the 
%fT>MIC ranged from 26.7% to 35.3% for a 1-log kill [13]. The CLSI breakpoints are 
2µg/mL  for Enterobacteriac eaeand 4 µg/mL  for Pseudomonas aeruginosa . The higher 
breakpoint of 4 µg/mL  was chosen to ensure coverage for both organisms.
Because tazobactam does not have intrinsic antibacterial activity , an MIC cannot be 
determined. Instead, the threshold drug concentration ( Ct) needed to effectively  neutralize the 
β-lactamase enzyme produced by  bacteria is used for target attainment [14]. Time above a C t
of 1µg/mL for free tazobactam exposures of 20%, which is supported by data from a mouse 
model and clinical studies, was used.
Based on the exposure and PTA criteria described above, the simulations in pediatric subjects 
indicated that the following doses are appropriate for evaluation in this trial:
12 to <18 years of age: Ceftolozane 1 g with tazobactam 0.5 g via a 60-minute (±10 
minutes) IV infusion every 8 hours
<12 years of age: Ceftolozane 20 mg/kg with tazobactam 10 mg/kg via a 60-minute 
(±10 minutes) IV infusion every  8 hours (not to exceed a dose of ceftolozane 1g and 
tazobactam 0.5
g)
The ceftolozane and tazobactam exposures and PTA for adult and pediatric subjects at these 
doses are summarized in Table 1and Table 2, respectivel y . As shown in these tables, the 
selected doses provide exposures for the age groups that do not exceed the corresponding 
95th percentile of adult exposures and achieve PTAs ≥90%. 
  05L65F
Product:   MK-7625A 30
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialTable 1 Ceftolozane Exposure and Target Attainment Summary for Simulated Adult and Pediatric Subjects
Param eter StatisticAdult Subject s 
(n=1000)Pediatric Age Groupa
1
1000 m g 
(n=1200)2 
20 m g/kg 
(n=1000)3 
20 m g/kg 
(n=1000)4 
20 m g/kg 
(n=1000)5 
20 m g/kg 
(n=1200)
Age (y ears) Mean (SD) 53.57 (19.09) 15.00 (1.74) 9.52 (1.45) 4.51 (1.45) 0.80 (0.44) 0.13 (0.07)
Median 56.00 14.99 9.53 4.53 0.71 0.12
5th, 95th 22.0, 81.0 12.3, 17.7 7.3, 11.8 2.2, 6.7 0.3, 1.7 0.0, 0.2
AUC 0-8
(μgh/mL), Day 
3Mean (SD) 213.36 (171.91) 172.11 (78.76) 176.08 (69.92) 153.13 (60.32) 162.04 (63.15) 157.36 (65.19)
Median 176.00 160.00 161.00 141.00 149.00 147.00
5th, 95th 95.3, 388.0 73.2, 319.0 90.3, 315.0 77.0, 268.0 81.2, 276.5 71.3, 282.5
Cmax(μg/mL), 
Day 3Mean (SD) 69.66 (45.09) 86.04 (36.25) 92.68 (29.84) 82.37 (23.96) 74.37 (19.33) 62.06 (15.18)
Median 56.10 80.35 86.90 79.35 72.40 60.15
5th, 95th 32.9, 154.0 37.8, 154.0 53.1, 150.0 47.8, 125.0 45.9, 109.0 39.9, 89.4
Target 
attainmentb
Day 1N(%) 1000 (100.0) 1188 (99.0) 995 (99.5) 992 (99.2) 1000 (100.0) 1196 (99.7)
5th, 95th = 5th, 95th percentiles; AUC 0-8=area under the concentration -time curve from time of drug administration (time 0) to 8 hours; C max=maximum 
observed concentration; h = hours; N =number of subjects achieving target attainment; n =number of subjects; SD =standard deviation
aAge Group 1,12years age<18years; Age Group 2, 7yearsage<12years; Age Group 3, 2years age<7years; Age 
Group 4, 3monthsage<2years; Age Group 5, 7days postnatal age<3months.
bFor ceftolozane, minimum effective concentration is4μg/mL and target is attainment of this concentratio n for 30% of the 8 -hourdosing interval. 
  05L65F
Product:   MK-7625A 31
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialTable 2 Tazobactam Exposure and Target Attainment Summary  for Simulated Adult and Pediatric Subjects
Param eter StatisticAdult 
Subject s 
(n=
1000)Pediatric Age Groupa
1 
500 m g
(n=1200)2 
10 m g/kg
(n=1000)3
10 m g/kg
(n=1000)4 
10 m g/kg
(n=1000)5 
10 m g/kg
(n=1200)
Age (years) Mean (SD) 46.37 (18.72) 15.00 (1.74) 9.52 (1.45) 4.51 (1.45) 0.80 (0.44) 0.13 (0.07)
Median 44.00 14.99 9.53 4.53 0.71 0.12
5th, 95th 20.0, 78.0 12.3, 17.7 7.3, 11.8 2.2, 6.7 0.3, 1.7 0.0, 0.2
AUC 0-8 
(μgh/mL), Day 
3Mean (SD) 80.71 
(148.87)37.12 (23.29) 38.02 (24.49) 30.22 (19.18) 29.87 (19.05) 26.77 (16.50)
Median 29.80 31.20 32.30 26.10 25.00 22.30
5th, 95th 15.4, 379.0 12.4, 83.1 12.3, 84.5 10.2, 62.9 10.0, 63.5 8.4, 57.3
Cmax(μg/mL), 
Day 3Mean (SD) 30.30 (34.73) 27.92 (14.51) 29.19 (14.69) 24.04 (11.78) 21.69 (10.54) 18.37 (8.81)
Median 17.70 24.75 26.45 21.80 19.50 16.80
5th, 95th 10.3, 108.0 10.7, 54.6 11.7, 57.7 9.6, 46.1 8.5, 42.2 7.6, 35.2
Target 
attainmentbDay 1N(%) 1000 (100.0) 1169 (97.4) 978 (97.8) 950 (95.0) 958 (95.8) 1116 (93.0)
5th, 95th = 5th, 95th percentiles; AUC 0-8,area under the concentration -time curve from time of drug administration (time 0) to 8 hours; C max,maximum 
observed concentration; N, number of subjects achieving target attainment; n, number of subjects; SD, standard deviation
aAge Group 1, 12 years age<18years; Age Group 2,7yearsage<12years; Age Group 3,2years age<7years; Age 
Group 4,3monthsage<2years; Age Group 5,7days postnatal age<3months.
bFor tazobactam, threshold concentration is1μg/mL and target is attainment of this concentration for 20% of the 8 -hourdosing interval. 
  05L65F
Product:   MK-7625A 32
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialVary ing age-appropriate volumes of a fixed concentration of ceftolozane/tazobactam will be 
administered IV to achieve the intended dose in each pediatric subject. The same IV 
formulation will be used across all age groups .
Rationale for Metronidazole Dos age
Data on the PK and ideal dosing of metronidazole in pediat ric patients arelimited, especially 
for pediatric patients less than 1 month of age. As a result, dosing recommendations are 
highl y variable without an accepted standard [15]. Suggested dosing recommendations for 
subjects <1 month old outlined in the protocol are based on one of the more frequentl yused 
dosing schedules [16]. However, to allow for potential variations in metronidazole dosing 
between different sites participating in this trial, the protocol allows for the use of site-
specific standard ofcare dosing in subjects <1 month of age. Sites that use dosing schedules 
other than every  8 hours must adjust the blinding of placebo in subjects randomized to the 
meropenem arm.
In older pediatric patients, metronidazole dosing is more standardized. The dose of 
metronidazole for pediatric patients >1 month old chosen for this trial (30 mg/kg divided 
every  8 hours) is based on dosing recommendations from the IDSA guidelines on treatment 
of cIA I[1].
Rationale for the Use of Comparator
As described in Section 4.1.4.1 –Comparator Therapy , meropenem is indicated for treatment 
of IAI in adult and pediatric patients (3 months o f age and older) caused by  single or multiple 
bacteria sensitive to meropenem.
Meropenem is also one of several regimens recommended for empiric treatment of cIAI in 
pediatric patients by  the Surgical Infection Society  and IDSA current treatment guidelines [1]
and there is significant clinical experience from both clinical trials and post-marketing data 
for the use of meropenem in the treatment of pediatric cIAI. It is the optimal choice of 
comparator for ceftolozane/tazobactam as the every  8-hour dosing interval facilitates 
blinding.
In addition, the use of meropenem in this trial will allow for an adequately sized safet y 
database when data from this trial are pooled with the companion Phase 2 trial of 
ceftolozane/tazobactam in pediatric subjects with cUTI ( MK-7625A -034), which also utilizes 
meropenem as the comparator (see Section 4.2.1.1 –Rationale for Sample Size). Available 
Phase 3 comparative safety  data for ceftolozane/tazobactam versus meropenem from trials in 
adults with cIAI[1]will allow comparison of the safet y profiles of ceftolozane/tazobactam 
and meropenem in pediatric and adult subjects .
Rationale for Comparator Dos age
The meropenem dose for Groups 1through 4(20 mg/kg IV every  8 hours [maximum of 1 
g/dose]) was chosen for this trial based on the approved dosage regimen for the treatment of 
cIAI [17]. 
  05L65F
Product:   MK-7625A 33
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialSafety  and efficacy  data of meropenem in pediatric patients under 3 months of age are 
limited, and the optimal dose regimen for this age group has not been identified. However, a 
trial in 200critically  ill preterm and term infants (<91 days of age) with suspected or 
confirmed IAI show ed that meropenem was safe and well tolerated at the 20 mg/kg dose
[15]. Limited data on the PK of meropenem suggest that drug disposition in young infants 
may differ significantl y from that in adults, likely  related to developmental differences in 
renal function and differences in body composition seen in young infants. As a result, some 
sources recommend higher meropenem doses (up to 30 mg/kg IV every 8 hours) for the 
treatment of serious infections in neonates [18]. To accommodate potential variations in 
standard ofcare dosing, the protocol allows for a range of weight -based dosing schemes
between 20mg/kg and 30 mg/kg forsubjects in Group 5(birth [defined as >32 weeks 
gestational age and ≥7 day s postnatal] to <3 months of age).
To ensure blinding, each dose of meropenem will be administered as a 60-minute (±10 
minutes) infusion (versus the 30- minute infusion noted in the prescribing i nformation )[17] to 
match the duration of infusion of ceftolozane/tazobactam. As described in Section 4.1.4 –
Information on Other Trial- related Therap y, the efficacy  of meropenem, like other β-lactam 
antibiotic s, is dependent on the T>MI C of the pathogens being treated. Therefore, the 
efficacy  of meropenem is not affected by prolonging the infusion. In addition, infusions of 
meropenem longer than 1 hour have been administered to patients with satisfactory  result s 
and without additional safety or tolerabilit y risk [19].
Therefore, the Sponsor believes the dosage regimen of meropenem in this trial is a clinically 
appropriate and acceptable comparator with which to evaluate the safety  and efficacy  of 
ceftolozane/tazobactam in pediatric cIAI .
Rationale for Duration of Therapy and Optional Oral Step -Down Antibiotic 
Therapy 
Current guidelines for the treatment of cIAI recommend 4 to7 days of antibiotic therapy 
after adequate source control is achieved [1]. However, some ty pes of pediatric cIAI, such as 
NEC, may require a longer duration of therapy  of up to 14 days. Because subjects may be
enrolled and started on study  treatment before adequate source control is achieved and 
because some types of pediatric cIAI may require longer treatment courses, subjects in the 
present trial will receive 5 to14 day s ofIV stud y treatment.
After receivin g at least 9doses of IV study  treatment, subjects may be switched to oral 
step- down therapy  at the investigator’s discretion based on the subject’s clinical condition 
(Section 5.2.2 –Optional Oral Step-down Therapy ). The requirement of 72hours (9 doses)
of IV study  treatment allows for evaluation of the safety , efficacy , and PK of 
ceftolozane/tazobactam while minimizing the need for prolonged hospitalization and IV 
access .  
  05L65F
Product:   MK-7625A 34
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential
Rationale for Endpoints
Rationale for Safety Endpoints
To evaluate the safet y andtolerability  of ceftolozane/tazobactam in pediatric subjects, the 
incidence, severit y, and type of AEs will be tabulated (see Section 7.2–Assessing and 
Recording Adverse Events). 
Laboratory  data will be summarized by the type of laboratory  test. Descri ptive statistics of 
temperature, heart rate, respiratory  rate, and blood pressure (s ystolic and diastolic) values and 
changes from baseline will be summarized at each scheduled timepoint.
Subjects may be asked to return for unscheduled visits in order to perform additional safety 
monitoring.
See Section 8.4.1 –Safety  Endpoints for details about the analysis of safety  endpoints and 
Section 8.5.1 – Efficacy  Endpoints for details about th e safet y analysis population .
Rationale for Efficacy Endp oints
Because the mechanism of action and the potency  of ceftolozane/tazobactam should be the 
same across all ages, adult and pediatric PK data can be compared to extrapolate the efficacy 
of ceftolozane/tazobactam from adult subjects to pediatric subjects. There fore, efficacy  is 
evaluated assecondary  and exploratory  objectives in this trial. There are no prespecified 
statistical hypotheses for this trial. The trial is not powered to statistically  compare the 
efficacy  of ceftolozane/tazobactam versus meropenem.
The secondary  efficacy  endpoints are:
Clinical success rate at the EOT and TOC Visits, defined as the proportion of subjects 
in the anal ysis population who have a clinical response of cure.
Per-subject microbiological success rate at the EOT and TOC Visits, defined as the 
proportion of subjects in the analysis population who have microbiological 
eradication or presumed eradication of all baseline pathogens .
The exploratory  efficacy  endpoints are:
Clinical success rate at the EOIV Visit , defined as the propor tion of subjects in the 
analysis population who have a clinical response of cure or partial improvement.
NOTE : At EOIV, clinical success is defined as cure or partial improvement. At EOT 
and TOC, clinical success is defined as cure. The definition for clinical success at the 
EOIV Visit includes partial improvement to accommodate those subjects with partial 
improvement who are switched to oral step- down therap y at this time point.  
  05L65F
Product:   MK-7625A 35
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialPer-subject microbiological success rate at the EOIV Visit , defined as the proportion 
of subjects in the analy sis population who have a microbiological outcome of 
eradication or presumed eradication of all baseline pathogens .
Per-pathogen microbiological success rate at the EOIV, EOT, and TOC Visit s, 
defined as the proportion of baseline pathogens that have an outcome of 
microbiological eradication or presumed eradication .
NOTE: For subjects who receive IV study  treatment only (without optional oral step- down 
therap y), a separate assessment does notneed to be performed at the EOT Visit; the EOIV 
Visit will serve as the EOT Visit .
4.2.3.2.1 Clinical Outcome
Investigators will determine clinical outcomes at the EOIV, EOT, and TOC Visit s according 
to the defin itions in Table 3. Subjects with failure or indeterminate outcomes will be 
considered to have an unfavorable clinical response.
For subjects who receive only IV study treatment and are notswitched to oral step-down 
therap y, the EOIV assessment serves as the EOT assessment and these subjects do not have a 
separate EOT assessment. Subjects who are switched to oral step
-down therap y will have 
both an EOIV and EOT assessment.
At EOIV, clinical success is defined as cure or partial improvement. At EOT 
and TOC, 
clinical success is defined as cure. Subjects with failure or indeterminate clinical outcomes 
will be considered to have an unfavorable clinical response.
Failure will be carried forward; subjects who are assessed as a failure before the TOC Visit
should have “failure” recorded on the TOC V isit electronic case report form (eCRF ). These 
subjects should attend the TOC Visit but will not have a new clinical outcome assessment at 
this visit.
Subjects who discontinue IV study  treatment or discontinue from the trial prior to receiving 9 
doses of IV study  treatment for reasons other than those meeting the definition of failure will
be assessed with a clinical 
outcom e of indeterminate. See also Section 5.8 – Subject 
Withdrawal/Discontinuation Criteria, Section 7.1.4.1 – Withdrawal/Discontinuation, and 
Section 7.1.5.9 – Subjec ts Who Prematurely  Discontinue F rom Study  Treatment or the Trial . 
  05L65F
Product:   MK-7625A 36
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialTable 3 Clinical Outcome Categories
Outcom e Definition
Cure Com plete resolution or marked improvement insigns and 
symptoms of the cIAI or return to preinfection signs and symptoms 
such that no further antibiotic therapy (IV or oral) or surgical or 
drainage procedure is required for treatment of the cIAI.
Partial improvement 
(only at the EOIV Visit forsubjects 
who switch to oral step -down therapy)Partial resolution of signs and symptoms of the cIAI such that no 
further IV antibiotic therapy is required for the treatment of the 
cIAI; however, additional oral step -down therapy is required.
Failure Any of the following is considered a clinical outcome of failure:
Requirement of antibiotic therapy beyond the protocol -defined 
treatment duration of 14 days.
Persisting or recurrent infection within the abdomen requiring 
additional intervention, including nonstudy antibiotics or repeat 
surgical intervention.
NOTE: Repeat percutaneous aspiration of an abscess within 72 
hours of the original aspiration, without worsening clinical 
signs and symptoms, is not considered a failure. How ever, the 
need to repeat any procedure after 72 hours of study treatment 
to cure the infection should be considered a failure. 
Exploratory or diagnostic procedures with no evidence of an 
ongoing infection are not considered a failure.
Post-surgical wound infection with signs of local infection, 
such as purulent exudate, erythema, or warmth that requires 
additional antimicrobial therapy and/o r nonroutine wound care.
Death related to IAI
Indeterminate Trial data are not available for evaluation of efficacy for any 
reason, including death during the trial period unrelated to the cIAI 
or extenuating circumstances which preclude classification as cure, 
partial improvement, or failure (eg, subject is lost to follow -up).
cIAI = complicated intra -abdominal infection; EOIV = End of IV Treatment; IV = intravenous
4.2.3.2.2 Microbiological Outcome
All microbiological outcomes will be based on laboratory  results and determined by the 
Sponsor .Investigators are not responsible for assessment of microbiological outcomes.
Per-subject Microbiological O utcome
An overall microbiological response will be determined for each subject based on the 
individual microbiological response for each baseline pathogen. Microbiological response 
categories are eradication, presumed eradication, persistence, presumed persistence, 
persistence acquiring resistance, and indet erminate as defin ed in Table 4. Eradication or 
presumed eradication will be considered favor able microbiological responses; i n order for the 
subject to have a favorable overall microbiological response (ie, eradication or presumed 
eradication), each baseline pathogen must have a favorable microbiological outcome . 
  05L65F
Product:   MK-7625A 37
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialPer-pathogen Microbiological Outcome
The per-pathogen microbiological outcome will be determined for each baseline infecting 
pathogen isolated by the Sponsor (see Table 4). E radication or presumed eradication will be 
considered favor able microbiological responses . 
Table 
4 Microbiological Outcome Categories
Outcom eaDefinitiona
EradicationbAbsence of the baseline pathogen (s)in a postbaseline specimen 
appropriately obtained from the original site of infection.
Presumed eradicationbAbsence of material to culture in a subject who is assessed as having 
partial improvement, or clinical cure.
Persistence Presence of the baseline pathogen(s) in an appropriately obtained 
postbaseline specimen from the site of infection or surgical wound.
NOTE: Cultures from indwelling drains are not considered appropriate. 
Presumed persistence Absence of material to culture in a subject who is assessed as a clinical 
failure.
Persistence acquiring resistance Presence of baseline pathogen(s) in an appropriately obtained 
postbaseline specimen where the baseline pathogen(s) was susceptible to 
study treatment pretreatment and is resistant to study treatment post-
treatment.
Indeterminate Baseline culture either not obtained or has no growth.
Postbaseline culture was not obtained and clinical assessment was 
not possible.
Any other circumstance that makes it impossible to define the 
microbiological response (eg, subject lost to follow -up).
aThe per- pathogen microbiological outcome will be determined for each baseline infecting pathogen 
isolated by the Sponsor.
bEradication or presumed eradication will be considered favorable microbiological responses.
Emergent Infection
Pathogens isolated after baseline will be assessed for the outcome of superinfection or new 
infection, as defined in Table 5. 
  05L65F
Product:   MK-7625A 38
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialTable 5 Emergent Infection Categories
Outcom e Definition
Superinfection Isolation of a pathogen, other than the original baseline pathogen(s), 
from an appropriately obtained post baseline specimen in a subject while 
on study treatm ent.
New  infection Isolation of a pathogen, other than the original baseline pathogen(s), 
from an appropriately obtained post baseline specimen in a subject after 
administration of the last dose of study treatm ent and through the 
TOC visit .
See Section 8.4.2 -Efficacy  Endpoints for details about efficacy  analyses and Section 8.5.2 –
Efficacy  Anal ysis Populations for details about the efficacy  anal ysis populations.
Rationale for Pharmacokinetic Endpoints
Whole blood samples (250 µL) will be collected at the time points specified in Section 6.0 –
Trial Flow Chart for determination of plasm a concentrations of ceftolozane , tazobactam, and 
tazobactam M1. Specific information about PK sample collection is provided in 
Section 7.1.3.6 –Pharmacokinet ic Evaluations . These samples will provide pediatric PK data 
in the target population and will support further evaluation of the PK profiles of ceftolozane 
and tazobactam by confirming whether subjects achieve percentage of dosing interval during 
which free concentration of drug (ceftolozane) exceeds the MIC (%fT>MIC )of at least 30% 
(for an MIC of 4 µg/mL) for ceftol ozane and percentage of dosing interval during which free 
concentration of drug (tazobactam) exceeds the Ct (%fT>C t)of at least 20% (for a threshold 
concentration of 1 µg/mL) for tazobactam .
Pharmacokinetic data may also aid in the assessment of the clinical relationship between 
ceftolozane and tazobactam plasma concentrations and efficacy  in the pediatric population. 
See Section 8.4.3 –Pharmacokinetic Endpoints for details about anal ysis of PK endpoints .
Benefit/Risk
It cannot be guaranteed that subjects in clinical trials will directly  benefit from treatment 
during participation ,as clinical trials are designed to provide information about the safety 
and effectiveness of an investigational medicine.
This trial will include pediatric subjects who require IV antibiotics for treatment of cIAI. If 
randomized to receive ceftolozane/tazobactam + metronidazole, subjects will receive an 
antibiotic regimen that is active against organisms frequentl yisolated from pediatric patients 
with cIAI and that has proven to be effective in large -scale clinical trials for the treatment of 
cIAI in adults (Section 4.1.1.1 –Ceftolozane/Ta zobactam ). Subjects who are randomized to 
the comparator arm will receive meropenem, an antibacterial agent approved for treatment of 
cIAI in pediatric patients 3 months of age and older and adults (Section 4.1.4.1 –Comparator 
Therap y). 
  05L65F
Product:   MK-7625A 39
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialAlthough potential ly more frequent than the standard ofcare, the planned study  procedures 
(see Section 6.0 –Trial Flow Chart) are generally  typical procedures performed for this 
patient population. Trial procedures, including the number of blood draws for PK sampling, 
arelimited in order to minimize risk. Additional burden may be incurred due to visits after 
release from the hospital ; however, the procedures performed at these visits are generall y not 
likely  to lead to significant harm (eg, blood draws, phy sical exam inations, vital signs) and are 
necessary  to support a robust evaluation of the safety  and efficacy  of the investigational drug.
Additional details regarding specific benefits and risks for subjects participating in this 
clinical trial may be found in the accomp anying ceftolozane/tazobactam IB and Informed 
Consent documents. 
5.0METHODOLOGY
Entry Criteria
Diagnosis/Condition for Entry into the Trial
Male and female subjects from birth (defined as >32 weeks gestational age and ≥7 days 
postnatal) to <18 years of agewith cIAI will be enrolled in this trial .
Subject Inclusion Criteria
In order to be eligible for participation in this trial, the subject must:
1. Have a legal ly acceptable representative who provides documented informed 
consent /assent for the trial.
2. Be a male or female from birth (defined as >32 weeks gestational age and ≥7days 
postnatal) to <18 years of age. 
NOTE: In Ukraine, enrollment age of a male or female subject will be limited to 2 
years to < 18 years (Groups 1-3). Subjects <2 years old(Groups 4-5) are not 
permitted to enroll into the study at Ukrainian sites.
3. Be able to comply  with the protocol for the duration of the trial.
4. Require IV antibacterial therap y for the treatment of presumed or documented cIAI 
as demonstrated b yeither:
Operative diagnosis (laparotomy , laparoscop y or percutaneous drainage) of cIAI, 
defined as evidence of infection within the abdominal cavity  extending beyond the 
hollow viscus of origin into the peritoneal space as demonstrated by either abscess 
formation or peritonitis.
OR
Preoperative diagnosis of cIAI, defined as meeting both of the criteria below:
a)Clinical evidence of cIAI as indicated by one or more systemic signs or 
symptoms that accompany  cIAI, such as fever, leukocy tosis, hypotension,  
  05L65F
Product:   MK-7625A 40
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidentialabdom inal pain, nausea/vomiting, anorexia, abdominal mass on clinical 
examination, or altered mental status. 
b)Radiographic evidence consistent with cI AI.
NOTE: Approximately  90% of the randomized population will consist of subjects 
with a diagnosis of complicated appendicitis .
5. Have an operative procedure for the current diagnosis and management of cIAI 
planned or completed within 24 hours of the first dose of an antibacterial drug.
NOTE: Subjects with a diagnosis of NEC are exempt from this inclusion criteria and 
are not required to have surgery  planned or completed in order to be eligible for 
enrollment. 
6. Have baseline intra-abdominal specimen collection in compliance with Section 
7.1.3.4 – Intra-abdominal Samples for Culture .Subjects enrolled preprocedure
should have a sample obtained during the interventional procedure performed to 
comply  with Section 7.1.3.4.
NOTE: Subjects with NEC that do not require surgical intervention are exempt from 
this inclusion criteria and are not required to have an intra-abdominal culture. 
7. Meet one of the following categories:
a)The subject is a male who is not of reproductive potential, defined as a male
who has azoospermia (whether due to being prepubertal, having had a 
vasectom y, or an underl ying medical condition).
b)The subject is a female not of reproductive potential, defined as a female who 
either: (1) Has not undergone menarche, (2) has had a hysterectom y and/or 
bilateral oophorectomy , bilateral salpingectomy , or bilateral tubal 
ligation/occlusion at least 6 weeks prior to screening, or (3) has a congenital or 
acquired condition that prevents childbearing.
c)The subject is a female or a male of reprodu ctive potential who agrees to avoid 
becoming pregnant or impregnating a partner during screening, while receiving 
study  treatment and for at least 30 days after the last dose of study  treatment by 
comply ing with one of the following: (1) Practice abstinenc eafrom heterosexual 
activity  OR (2) use (or have their partner use) acceptable contraception during 
heterosexual activity . 
Acceptable methods of contraception areb:
Single method (1 of the following is acceptable):
Intrauterine device 
Vasectom y of a fem ale subject’s male partner 
Contraceptive rod implanted into the skin 
  05L65F
Product:   MK-7625A 41
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialCombination method (requires use of 2 of the following):
Diaphragm with spermicide (cannot be used in conjunction with cervical 
cap/spermicide)
Cervical cap with spermicide (nulliparous females only)
Contraceptive sponge (nulliparous females onl y)
Male condom or female condom (cannot be used together)
Hormonal contraceptive: Oral contraceptive pill (estrogen/progestin pill or 
progestin -only pill), contraceptive skin patch, vaginal contrac eptive ring, 
or subcutaneous contraceptive injection
aAbstinence (relative to heterosexual activity ) can be used as the sole 
method of contraception if it is consistently  used as the subject’s 
preferred and usual lifesty le and if considered acceptable by local 
regulatory  a gencies and Ethics Review Committees 
(ERCs )/Institutional Review Boards (IRBs ). Periodic abstinence (eg, 
calendar, ovulation, symptothermal, postovulation methods, etc.) and 
withdrawal are not acceptable methods of contraception.
bIf a contraceptive method listed above is restricted by local 
regulations/guidelines, then it does not qualify as an acceptable 
method of contraception for subjects participating at sites in this 
country /region.
8. Meet the following criter ia for a female subject who is of reproductive potential:
a)The subject is not pregnant (as confirmed by serum pregnancy  test at 
screening) and not planning to become pregnant within 30 days of the 
last day  of treatment administration,
AND 
b)The subject is nonlactating
Subject Exclusion Criteria
The subject must be excluded from participating in the trial if the subject:
1. Is currentl y participating in or has participated in an interventional clinical trial with 
an investigational compound or device within 30 days prior to the first dose of study  
treatment in this current trial.
2. Has previousl y participated in any trial of ceftolozane or ceftolozane/tazobactam or 
has enrolled previously  in the current trial and been discontinued.
3. Has a history  or current evidence of any condition, therap y, laboratory  abnormality , 
or other circumstance that, in the opinion of the investigator, might expose the 
subject to increased risk by participating in the trial, confound the results of the trial, 
or interfere with the subj ect’s participation for the full duration of the trial. 
  05L65F
Product:   MK-7625A 42
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential4. Has a history  of any moderate or severe hypersensitivity  (eg, anaphy laxis), allergic 
reaction, or other contraindication to any of the following: β-lactam antibiotics (eg, 
penicillins, cephalosporins, and carbapenems), β-lactamase inhibitors (eg, 
tazobactam, sulbactam, clavulanic acid, avibactam), or metronidazole.
NOTE: A history  of mild rash to any of these agents is not a contraindication to 
enrollment.
5. Has an IAI within the past 1yearprior to randomization known to be caused by a 
pathogen resistant to either IV stud y treatment.
6. Has a concomitant infection at the time of randomization that requires nonstudy  
systemic antibacterial therapy  in addition to IV study treatment or oral step-down 
therap y (medications with only gram-positive activity  [eg, vancom ycin, linezolid] 
are allowed).
7. Has received potentiall y therapeutic antibacterial therap y (eg, with gram -negative 
activity ) for a duration more than 24 hours during the 48 hours preceding the first 
dose of study  treatment, unless the subject is considered to be failing antibiotic 
therap y for cIA I.
NOTE: A subject considered to be failing a previous antibiotic regimen must meet 
all of the following criteria:
a)Has received the s ystemic antiba cterial treatment for at least 48 hours 
b)Has clinical and operative or radiographic findings clearl y indicating ongoing 
infection 
c)Has planned operative intervention no more than 24 hours after first dose of 
study  treatment 
d)Has not received an y further nonstudy  antibiotics postoperativel y
8. Has an y of the following:
a)Intractable cIAI that the investigator anticipates would require more than 14 
days of study  treatment
b)Abdominal wall abscess
c)Small bowel obstruction 
d)Ischemic bowel disease without perforation 
e)Traumatic bowel perforation with surgery  within 12 hours of perforation
f)Perforation of gastroduodenal ulcers requiring surgery  within 24 hours of 
perforation (these are considered situations of peritoneal soiling before the 
infection has become established) 
g)Suspected uncomplicated intra-abdominal infection (eg, cholecy stitis without 
rupture or extension beyond the gallbladder wall) 
h) Acute suppurative cholangitis
i)Infected necrotizing pancreatitis  
  05L65F
Product:   MK-7625A 43
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidentialj)Pancreatic abscess
9. Has moderate or severe impairment of renal function, defined as an estimated 
creatinine clearance (CrCL )<50mL/min/1.73 m2based on the revised Schwartz 
equation [12] or requirement for peritoneal dialysis, hemodialysis, or hemofiltration.
10. Has one or more of the following laboratory  abnormalities in a specimen obtained at 
baseline:
a)Absolute neutrophil count (ANC) <1000 /mm3
b)Aspartate aminotransferase (AST) oralanine aminotransferase (ALT) ≥3 × the 
upper limit of normal (ULN)
c)Total bilirubin ≥2 × ULN (if 7 to ≤28 days of age and breastfeeding, total 
bilirubin >10 mg/dL OR ≥2 × ULN)
11. Has a seizure disorder or is anticipated to be treated with divalproex sodium or 
valproic acid during the course of stud y treatment.
12. Is receiving, or is expected to receive, an y of the following medications:
a)Immunosuppressive agents
NOTE: Short -term treatment with systemic (IV or oral) steroids of <1 week 
duration (eg, treatment for an acute asthma exacerbation or acute skin condition) 
is allowed. Topical steroids for the treatment of skin conditions are also allowed.
b)Probenecid
c)Valproic acid or divalproex sodium
d)Disulfiram
e)Ergot derivatives
f)Ethanol -containing medications
g)Nonstudy  systemic (IV or oral) antibacterial treatments
NOTE: Subjects who require empiric enterococcal coverage for the index cIAI 
may receive concomitant therap y with an enterococcal antibiotic with activity  
limited to gram -positive coverage (eg, vancom ycin, daptomy cin, teicoplanin, 
linezolid). One dose of prophy lactic antibiotic with gram -negative activity  is 
allowed.
Subjects who require empiric antifungal coverage for the index cIAI may 
receive concomitant antifungal coverage with an azole, echinocandin, or 
polyene antifungal as chosen by  the investigator based on local standard of care.
13. Has any rapidl y progressing disease or immediately  life-threatening illness, 
including acute hepatic failure, respiratory  failure, or septic shock.
14. Has an immunocompromising condition, including established acquired immune 
deficiency  syndrome (AIDS), hematological malignancy , or bone marrow 
transplantation, or is receiving immunosuppressive therap y including cancer 
chemotherap y,medications for prevention of organ transplantation rejection, or  
  05L65F
Product:   MK-7625A 44
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidentialchronic administration of systemic corticosteroids (defined as the systemic 
equivalent of ≥2 mg/kg total daily  dose of prednisone for participants ≤20 kg, or 
>40mg of prednisone per day  for participants >20 kg, administered continuously  for 
more than 14 day s in the 30 day s prior to the first dose of ceftolozane/tazobactam) .
15. Has a history  of malignancy  ≤5 years prior to providing documented informed 
consent except for adequately  treated basal cell or squamous cell skin cancer or in 
situ cervical cancer. 
16. Planned receipt of suppressive/proph ylactic antibiotics with gram -negative activity  
after completion of study treatment.
17. Is or has an immediate family  member (e.g., spouse ,parent/ legal guardian , sibling or 
child) who is investigational site or Sponsor staff directly involved with this trial.
Trial Treatment(s)
The treatments to be used i n this trial areoutlined below in Table 6 and Table 7.
Intravenous Trial Treatment s
The IV treatment regimens to be used in th is trial are outlined in Table 6 .
After receiving at least 9 doses of double -blind IV study  treatment, subjects in either 
treatment arm may be switched to open -label, standard ofcare oral step-down antibiotic 
therap y at the investigator’s discretion (Section 5.2.2 –Optional Oral Step-down Therap y). 
Total antibiotic duration (IV onl y or IV + oral) is a minimum of 5days and a maximum of 14 
days.
NOTE : In Ukraine, enrollment will be limited to subjects 2 years to < 18 years of age 
(Groups 1 -3). Study  treatments for Groups 4 and 5 arenot applicable at Ukrainian sites.
Table 6 Intravenous Trial Treatments
Drug Dose/PotencyDose 
FrequencyaRoute of 
AdministrationbTreatm ent 
PeriodbUse
Group 1 ( 12 to <18 years [n ≥50combined with Group 2 ])c
Ceftolozane/
tazobactamCeftolozane 1 g and 
tazobactam 0.5gEvery 
8 hoursIV 5-14 days Experimental
Metronidazole Metronidazole 
10mg/kg 
(maximum dose 
1.5g/day)Every 
8 hoursIV 5-14 days Adjunctive
Meropenem 
and placebo for 
metronidazoleMeropenem 
20mg/kg 
(maximum 1g/dose)Every 
8 hoursIV 5-14 days Active
comparator 
  05L65F
Product:   MK-7625A 45
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialDrug Dose/PotencyDose 
FrequencyaRoute of 
AdministrationbTreatm ent 
PeriodbUse
Group 2 (6 to <12 years [n ≥50 combined with Group 1])c
Ceftolozane/
tazobactamCeftolozane 
20mg/kg and 
tazobactam 
10mg/kg
(maximum 
ceftolozane 1 g and 
tazobactam 
0.5g/dose)Every 
8 hoursIV 5-14 days Experimental
Metronidazole Metronidazole 
10mg/kg 
(maximum dose 
1.5g/day)Every 
8 hoursIV 5-14 days Adjunctive
Meropenem 
and placebo for 
metronidazoleMeropenem 
20mg/kg 
(maximum 1g/dose)Every 
8 hoursIV 5-14 days Active
comparator
Group 3 (2 to <6 years [n ≥57combined with sam e age group in MK -7625A -034])c
Ceftolozane/
tazobactamCeftolo zane 
20mg/kg and 
tazobactam 
10mg/kg
(maximum 
ceftolozane 1 g and 
tazobactam 
0.5g/dose)Every 
8 hoursIV 5-14 days Experimental
Metronidazole Metronidazole 
10mg/kg 
(maximum dose 
1.5 g/day)Every 
8 hoursIV 5-14 days Adjunctive
Meropenem 
and placebo for 
metronidazoleMeropenem
20mg/kg 
(maximum 1g/dose)Every 
8 hoursIV 5-14 days Active
comparator
Group 4 (3 m onths to <2 years [n ≥24 combined with same age group in MK -7625A -034])c
Ceftolozane/
tazobactamCeftolozane 
20mg/kg and 
tazobactam 
10mg/kg
(maximum 
ceftolozane 1 g and 
tazobactam 
0.5g/dose)Every 
8 hoursIV 5-14 days Experimental
Metronidazole Metronidazole 
10mg/kg 
(maximum dose 
1.5 g/day)Every 
8 hoursIV 5-14 days Adjunctive 
  05L65F
Product:   MK-7625A 46
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialDrug Dose/PotencyDose 
FrequencyaRoute of 
AdministrationbTreatm ent 
PeriodbUse
Meropenem 
and placebo for 
metronidazoleMeropenem 
20mg/kg 
(maximum 1g/dose)Every 
8 hoursIV 5-14 days Active
comparator
Group 5 (Birthdto <3 m onths [n ≥21combined with sam e age group in MK -7625A -034])c
Ceftolozane/
tazobactamCeftolozane 
20mg/kg and 
tazobactam 
10mg/kg
(maximum 
ceftolozane 1 g and 
tazobactam 
0.5g/dose)Every 
8 hoursIV 5-14 days Experimental
Metronidazole Subjects >28 days of 
age:
Metronidazole 
10mg/kg every  
8 hours (maximum 
dose 1.5 g/day)
For subjects ≤28 
days of age, the 
suggested dosing 
regimen is listed 
below ;however ,
other site -specific 
standard ofcare 
metronidazole 
dosing may be used 
at the investigator’s 
discretion.
Subjects ≤28 days of 
age and ≤2 kg:
Metronidazole 
15mg/kg loading 
dose, then 
7.5mg/kg/dose 
every 12 h ours
Subjects ≤28 days of 
age and >2 kg:
Metronidazole 
15mg/kg loading 
dose, 10 mg/kg dose 
every 8 hoursEvery 
8-12hoursfIV 5-14 days Adjunctive
Meropenem 
and placebo for 
metronidazolefMeropenem 
20mg/kg 
(maximum
1g/dose)eEvery 
8 hoursIV 5-14 days Active
comparator 
  05L65F
Product:   MK-7625A 47
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialDrug Dose/PotencyDose 
FrequencyaRoute of 
AdministrationbTreatm ent 
PeriodbUse
IV = intravenous
aEach dose of ceftolozane/tazobactam or metronidazole or meropenem or placebo is administered as a 60-minute 
(±10 minutes) infusion. Ceftolozane/tazobactam plus metronidazole or meropenem plus placebo are to be dosed 
every 8 hours (±1 h our) after the previous infus ion. The second IV dose has a ±4-h ourwindow for dosing to 
facilitat e adjustment of the dosing schedule (once every 8 hours ) to be carried out throughout the dosing period.
bAfter receiving at least 9 doses of double -blind IV study treatment, subjects may be switched to open -label, standard
ofcare, oral step -down therapy at the investigator’s discretion. The total duration of study treatment (IV only or IV + 
oral) is a minimum of 5days and a maximum of 14 days.
cThe total minimum number of subjects in the 5age groups combined across MK-7625A -034 and MK -7625A -035 is 
202. After the minimum enrollment targets for each age group are met, additional subjects (combined across MK-
7625A -034 and MK -7625A -035) will be enrolled in any of the 5age groups.
dBirth is defined as >32 weeks gestati onal age and ≥7 days postnatal.
eSome literature supports a higher meropenem dosage (up to 30 mg/kg every 8 hours) for subjects 14days to 
<3months of age;therefore ,meropenem dosing up to 30 mg/kg every 8 hours may be used for subjects 14 days to 
<3 months of age at the investigator’s discretion.
fSubjects 7to 28 days of age who receiv emetronidazole with a frequency other than every 8 hours must receive 
placebo at the same frequency to maintain blinding .
Optional Oral Step -down Therapy
After receiving at least 9 doses of double -blind, IV study  treatment, subjects may  be switched 
to open -label, standard ofcare, oral step- down antibiotic therapy  at the investigator’s 
discretion. Total antibiotic duration (IV only or IV +  o ral) is a minimum of 5 days to a 
maximum of 14 days. Optional oral step- down therap y is considered study  treatment in this 
trial.
Oral step- down therapy  should be guided by culture results and consistent with the local 
standard ofcare. Table 7 lists recommended options for oral step- down therapy .
Table 7 Recommended Oral Step -down Therap y Options
Antibiotic or Antibiotic Classa
β-lactam/β -lactamase inhibito r combination
Second or third generation cephalosporin in combination with metronidazole
Quinolone (if ciprofloxacin or levofloxacin are chosen, it should be used in combination with 
metronidazole)
aThe choice of oral step -down therapy should be guided by culture results and based on local anti biotic 
susceptibility patterns.
NOTE: Regimens not listed above must be approved by the Sponsor. 
  05L65F
Product:   MK-7625A 48
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential
Trial Treatments: Administrative Considerations
Trial treatment should begin as soon as possible after randomization and at the latest within 
24 hours of randomization. There should be no medicall y inappropriate delay  in 
randomization and subsequent study treatment. 
All supplies indicate d inTable 6 andTable 7above will be provided centrally  by the Sponsor 
or locally  by the trial site, subsidiary  or designee, depending on local country  operational or 
regulatory  requirements.
For any commercially  available product that is provided by the trial site, subsidiary  or 
designee every  attempt will be made to source these supplies from a single lot/batch number. 
The trial site is responsible for recording the lot number, manufacturer, and expiry  date for 
any locally  purchased product as per local guidelines unless otherwise instructed by the 
Sponsor.
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate suppl y, storage, handling, distri bution and usage of trial 
treatments in accordance with the protocol and an y applicable laws and regulations.
Dose Selection
Dose Selection (Preparation)
The following doses are to be used in this trial:
12 to <18 years of age: Ceftolozane 1 g with tazobactam 0.5 g via a 60-minute (±10 
minutes) IV infusion every 8 hours
<12 years of age: Ceftolozane 20 mg/kg with tazobactam 10 mg/kg via a 60-minute 
(±10 minutes) IV infusion every  8 hours (not to exceed a dose of ceftolozane 1 g and 
tazobact am0.5g)
The rationale for selection of doses to be used in this trial is provided in Section 4.2.2 –
Rationale for Dose Selection/Regimen . The dosing calculations and drug preparation are 
described in detail in the pharmacy  manual.
Timing of Dose Administration
Ceftolozane/tazobactam plus metronidazole or meropenem plus placebo are to be dosed 
every  8hours *(±1 hour) after the previous infusion. The second IV dose has a ±4-hour 
window for dosing to facilitate adjustment of the dosing schedule (once every  8hours) to be 
carried out throughout the IV dosing period. The final day  of study  treatment may  extend into 
Day 15 to accommodate different start and stop times of the IV study  treatment and/or dosing 
schedules of the oral step -down therap y. 
  05L65F
Product:   MK-7625A 49
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential*Sub jects who are7-28 days old may be dosed every  12hours with metronidazole. Please 
refer to Table 6in Section 5.2.1 –Intravenous Trial Treatments for metronidazole dosing 
recommendations in this age group .
Trial Blinding 
A double -blinding technique with in-house blinding will be used.  Ceftolozane/tazobactam 
plus metronidazole and meropenem plus placebo will be packaged identically  so that 
blinding is maintained. The subject, the investigator and Sponsor personnel or delegate(s) 
who are involved in the treatment or clinical evaluation of the subjects are unaware of the 
group assignments.
An unbli nded pharmacist will prepare IV study treatment. In addition, infusion bags, IV 
lines, and an y other dispensing devices will be covered as needed to maintain blinding.
The standard ofcare oral step- down therap y used at the discretion of the investi gator after 
completion of IV study  treatment will not be blinded.
Specific blinding procedures required for this study can be found in the p harmacy  manual.
See Section 7.1.4.4 , Subject Blinding/Unblinding, for a description of the method of 
unblinding a s ubject during the trial, should such action be warranted.
Randomization
Treatment randomization will occur centrall y using aninteractive voice response system / 
integrated web response sy stem (IVRS/I WRS). There are 2treatment arms.  Subjects will be 
assigned randomly  in a 3:1 ratio to ceftolozane/tazobactam plus metronidazole or 
meropenem plus placebo , respectivel y. 
Stratifi cation
Treatment randomization will be stratified across 5age groups as defined in Section 2.1–
Trial Design. After the minimum enrollment targets in Section 2.1 for each age group are met 
(202subjects total), additional subjects (combined across MK-7625A -034 and MK-7625A -
035) will be enrolled in any  of the 5 age groups.
Concomitant Medications /Vaccinations (Allowed & Prohibited )
Medications specificall y prohibited in the exclusion criteria are not allowed during the 
ongoing trial.  If there is a clinical indication for any medication specifically  prohibited 
during the trial, discontinuation from trial therapy  may be required. The investigator should 
discuss any  questions regarding this with the Sponsor Clinical Director. The final decision on 
any supportive therap y rests with the investigator and/or the subject’s primary  physician; 
however, the decision to continue the subject on trial therap y requires the mutual agreement 
of the investigator, the Sponsor, and subject/subject’s legal representative. 
  05L65F
Product:   MK-7625A 50
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialThe following concomitant medications/therapies are not permitted in this study : 
Immunosuppressive agents
NOTE: Short -term treatment with systemic (IV or oral) steroids of <1 week durat ion 
(eg, treatment for an acute asthma exacerbation or acute skin condition) is allowed. 
Topical steroids for the treatment of skin conditions are also allowed.
Valproic acid or divalproex sodium
Probenecid
Disulfiram
Ergot derivatives
Ethanol -containing medications
Nonstudy  systemic (IV or oral) antibacterial treatments
NOTE: Subjects who require empiric enterococcal coverage for the index cIAI may 
receive concomitant therapy  with an enteroc occal antibiotic with activity limited to 
gram -positive coverage (eg, vancom ycin, daptomy cin, teicoplanin, linezolid). One 
dose of proph ylactic antibiotic with gram- negative activity  is allowed.
Subjects who require empiric antifungal coverage for the index cIAI may receive 
concomitant antifungal cove rage with an azole, echinocandin or poly ene antifungal as 
chosen b y the investigator based on local standard ofcare.
The following medications are permitted, although their efficacy  and safet y should be 
clinically  monitored and/or serum levels followed with appropriate dosage adjustments as 
necessary  at the initiation of study  drug, periodicall y during treatment, and after 
discontinuation of study  drug:
Lithium
Pheny toin
Warfarin
Carbamazepi ne 
Medications resulting in prolonged QT interval
All other conco mitant medications necessary  for the 
health and well -being of the subject are 
permitted . 
  05L65F
Product:   MK-7625A 51
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential
Rescue Medications & Supportive Care
No rescue or supportive medications are specified to be used in this trial.
Diet/Activity/Other Considerations
Intravenous study treatment may be administered without regard to food orcaffeine 
consumption, tobacco use, or activity . Subjects should not consume alcohol while on IV 
study  treatment due to potential interaction with metronidazole.
Oral step- down study  therap ymay have different dietaryconsiderations from IV study 
treatment and should be administered according to the product label .
Subject Withdrawal/Discontinuation Criteria
Discontinuation of Treatment
Discontinuation of IV study  treatment or oral step- down therapy does not represent 
withdrawal from the trial.
As certain data on clinical events beyond study  treatment discontinuation areimportant to the 
study , they must be collected through the subject’s last scheduled follow -up, even if the 
subject has discontinued study  treatment .  Therefore, all subjects who discontinue trial 
treatment prior to completion of the treatment period will still continue to participate in the 
trial as specified in Section 6.0 - Trial Flow Chart and Section 7.1.5.9 –Subjects Who 
Prematurel y Discontinue from Study Treatment or the Trial .
Subjects may discontinue study  treatment at any time for any reason or be dropped from 
study  treatmen tat the discretion of the investigator should any untoward effect occur.  In 
addition, a subject may be discontinued from study  treatment by the investigator or the 
Sponsor if study  treatment is inappropriate, the trial plan is violated, or for administrat ive 
and/or other safet y reasons.  Specific details regarding procedures to be performed at study  
treatment discontinuation are provided in Section 7.1.4 –Other Procedures.
A subject must be discontinued from IV study treatment or oral step-down therapy but 
continue to be monitored in the trial for an y of the following reasons :
○ The subject or subject’s lega lly acceptable representative requests to discontinue study  
treatment .
oThe subject has a medical condition or personal circumstance which, in the opinion of the 
investigator and/or Sponsor, places the subject at unnecessary  risk from continued 
administration of study  treatment .
oDevelopment of moderate or severe impairment of renal function, including an estimated 
CrCL  <50mL/min/1.73 m2based on the revised Schwartz equation [12] or requirement 
for peritoneal dialysis, hemodialy sis,or hemofiltration (required for IV study treatment 
only). 
  05L65F
Product:   MK-7625A 52
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialoTheinvestigator feels it is in the best interest of the subject to discontinue for any  reason, 
including, but not limited to, the need for nonstudy  antibacterial therapy  due to 
insufficient therapeutic effect of th e study  treatment.
oSafety  issues:
Occurrence of an AE or clinicall y significant laboratory  abnormalit y that, in the 
opinion of the Investigator, warrants the subject’s permanent discontinuation from IV 
study  treatment or oral step -down therapy . In the even t that IV stud y treatment or oral 
step- down therapy  is discontinued due to the occurrence of an AE, the trial site 
should notify  the Sponsor as soon as possible.
Susp ected or confirmed pregnancy  or breastfeeding during the IV study  treatment or 
oral step- down therap y administration period. Female subjects whose pregnancy  test 
becomes positive during study  treatment must be followed through the immediate 
postnatal period or until termination of the pregnancy . 
Discontinuation from study  treatment is “permanent.” Once a subject is discontinued, he/she 
shall not be allowed to restart study  treatment .
Withdrawal from the Trial
A subject must be withdrawn from the trial if the subject or subject ’s legally  acceptable 
representative withdraws consent from the trial.
If a subject withdraws from the trial, they will no longer receive study  treatment or be 
followed at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from the trial 
including the procedures to be performed should a subject repeatedl y fail to return for 
scheduled visits and/or if the study  site is unable to contact the subject, are outlined in 
Section 7.1.4 – Other Procedures.
Subject Replace ment Strategy
A subject who discontinues from study treatment or withdraws from the trial will not be 
replaced.
Beginning and End of the Trial
The overall trial begins when the first subject (or their legally  acceptable representative) 
provides documented informed consent.  The overall trial ends when the last data are
available in either MK -7625A -034or MK -7625A -035 (whichever is later). 
  05L65F
Product:   MK-7625A 53
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential
Clinical Criteria for Early Trial Termination
The clinical trial may be terminated early if the extent (incidence and/or severity ) of 
emerging effects/clinical endpoints is such that the risk/benefit ratio to the trial population as 
a whole is unacceptable.  In addition, further recruitment in the trial or at (a) particular trial 
site(s) may be stopped due to insufficient compliance with the protocol, GCP and/or other 
applicable regulatory  requirements, procedure -related problems or the number of 
discontinuations for administrative reasons is too high. 
  05L65F
Product:   MK-7625A 54
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential6.0TRIAL FLOW CHART
Trial Period: Screening Treat ment (5 to 14 days)aFollow -up
Visit Number: 1 2 3 to 16 17 18 19 20 21
Visit Title: ScreeningbRandomizationbIV Clinical 
Assess mentsa,bEOIVc
(all 
subjects)Oral Clinical 
Assess mentd,e
(only for IV to 
oral sw itch)EOTd
(only for IV 
to oral 
switch)TOC
(all subjects)LFUf
(all 
subjects)
Scheduled Day or Timing: 48 h Day 1 Day 2 up to Day 15<24 h 
after last 
IV dose(after ≥7 days 
on oral step -
down therapy)<48h after 
last oral 
dose7 to 14 days 
after final 
dose21 to 28 
days after 
final dose
Administrative Procedures
Informed consent X
Inclusion/exclusion criteria X
Subject identification card X X
Medical history X
Prior orconcomitant medication review X X X X X X X X
Randomize to treatment (prior to 
administration of study treatment)X
Administer IV ceftolozane/tazobactam + 
metronidazole or IV meropenem + 
placebo every 8 hX X
Standard ofcare oral step -down therapya X
Clinical Procedures/Assessments
Body weight X Xg,hXg,hXgXg,hXg
Height X
Vital signs (heart rate, respiratory rate, 
blood pressure, and temperature)X X X X X X X Xg,i
Full physical examination X
Directed physical examinationXjX X X X Xg,i
Record surgical wound examinationgXgXgXgXgXgXgXgXg,i
Abdominal sign/symptom assessment X X X X X X X Xg,i
Record summary of operative procedures 
(as indicated/done)X X X X X X X 
  05L65F
Product:   MK-7625A 55
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialTrial Period: Screening Treat ment (5 to 14 days)aFollow -up
Visit Number: 1 2 3 to 16 17 18 19 20 21
Visit Title: ScreeningbRandomizationbIV Clinical 
Assess mentsa,bEOIVc
(all 
subjects)Oral Clinical 
Assess mentd,e
(only for IV to 
oral sw itch)EOTd
(only for IV 
to oral 
switch)TOC
(all subjects)LFUf
(all 
subjects)
Scheduled Day or Timing: 48 h Day 1 Day 2 up to Day 15<24 h 
after last 
IV dose(after ≥7 days 
on oral step -
down therapy)<48h after 
last oral 
dose7 to 14 days 
after final 
dose21 to 28 
days after 
final dose
Record radiological examination XgXgXgXgXgXgXgXg
AEmonitoringkX X X X X X X
Assess clinical outcome X X X
Laboratory Procedures/Assessments
Blood for hematology and chemistry 
safety evaluationsX XjXlX XlX Xg,i
Coombs test (direct) X X
Serum pregnancy testm XmXm
Assessment of CrCL X XgXgXgXg
Intra -abdominal sample for culture and 
susceptibility testingXnXgXgXgXgXg
Blood for culture and susceptibility 
testinggXgXgXg
Blood for PK analyses (Day 3 only [after 
≥6 doses of IV study treatment])oXo 
  05L65F
Product:   MK-7625A 56
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialAE = adverse event; CrCL = creatinine clearance; eCRF = electronic case report form; EOIV = End of IV Treatment; EOT = End of Treatment; h = hour(s); IV = intravenous; 
LFU = Last Follow -up; PK = pharmacokinetic (s); SAE = serious adverse event; TOC = Test of Cure
aAfter recei ving at least 9 doses of double -blind IV study treatment, subjects in either treatment arm may be switched to ope n-label, standard ofcare oral step-down antibiotic 
therapy at the investigator’s discretion. Total duration of study treatment (IV only or IV + oral) is a minimum of 5 days and a maximum of 14 days, except the final day of 
study treatment may extend into Day 15 to accommodate different start and stop times of the IV study treatment and/or dosing schedules of the oral step-down therapy From 
Day 1through the last day of IV study treatment, each subject’s assessments should be performed at a consistent time of day (eg, every morning) on each calendar day, as 
much as possible. Subjects cannot go home on IV study treatment. If subjects are switched t o oral step -down therapy, the oral step -down therapy must be initiated within <24 
hours after stopping IV study treatment.
bScreening, randomization, and first dose of study treatment may all occur on the same day.Assessments (eg, laboratory procedures, vital signs) performed prior to providing 
documented informed consent may be used if collected during the routine care of the patient, so long as they were conducted within 48 ho urs prior to the start of 
administrat ion of the first dose of IV study treatment.
cFor subjects who receive only IV study treatment and are notswitched to oral step-down therapy, the EOIV Visit serves as the EOT Visit and these subjects do not have a 
separate EOT Visit . Subjects who areswitched to oral step -down therapy will have both an EOIV and an EOT Visit.
dOnly for subjects who are switched to oral step -down therapy.
eAnOral Clinical Assessment Visit should be performed once if a subject receives ≥7 days oforal step-down therapy. This visit can be performed ±24 hours after 7 days of 
oral step-down therapy. Subjects who receive <7 days of oral step-down therapy will not undergo the Oral Clinical Assessment Visit . Any AE that comes to the attention of 
the investigator before the Oral Clinical Assessment Visit should be recorded at this visit, but any SAE must be reported within 24 hours. The Oral Clinical Assessment Visit
will be the same whether the subject is still in the hospital or has been discharged to home.
fThe LFU Visit willbe conducted by telephone ; however ,if the subject has abnormal laboratory values or AEs that require follow -up, an in -person visit is required.
gIf clinically indicated.
hAs needed to calculate CrCL or changes in weight-based dosing, if the subject’s w eight is expected to change over the course of IV study treatment.
iTo be performed only if LFU Visit is conducted in person instead of by telephone.
jProcedures to be completed on Day 3 and then once weekly while the subject is receiving study treatment (IV or oral).
kThe reporting period for AEs outlined in Section 7.2 . All serious adverse events will be followed until resolution, stabilization, withdrawal of consent, or death.
lIf blood samples for chemistry and hematology safety evaluations were collected within 24 hours prior to the EOIV or EOT Visit, blood samples for these evaluations are not 
required at the visit.
mFemale subjects of child bearing potential only. A urine pregnancy test instead of a serum pregnancy test may be performed at the TOC Visit , if deemed clinically appropriate 
by the investigator.
nBaseline intra -abdominal specimen collection in compliance with Section 7.1.3.4 –Intra -abdominal Samples for Culture . Subjects who are enrolled preprocedure should have 
a sample obtained during the interventional procedure performed to comply with Section 7.1.3.4.
oBlood samples for ceftolozane ,tazobactam , and tazobactam M1 concentration assays will be collected from all subjects over one 8-h dosing period on Day 3 of the treatment 
period after administration of at least 6 doses of IV study treatment (see Section 7.1.3.6 – Pharmacokinetic Evaluations ). OnDay 3, 250µL of blood will be collected at the 
following times: At the end of infusion ( collected within 10minutes after the end of total dose administration ); between 2.5and 3.5hours post start of infusion; and between 
5.0and 6.0hours post start of infusion but prior to the start of the next dose of study treatment. If sampling on Day 3 is logistically difficult, sampling may be performed at 
comparable time points after Day 3 in subjects who are continuing to receive IV study treatment . Plasma will be separated from blood and sent to the central laboratory for PK 
testing. Procedures for collection, processing, storage, and shipment of PK samples from blood (plasma) will be provided separately in a laboratory manual. Actual whole 
blood s ample collection dates and times should be recorded on the appropriate eCRF. 
  05L65F
Product:   MK-7625A 57
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential7.0TRIAL PROCEDURES
Trial Procedures
The Trial Flow Chart -Section 6.0summarizes the trial procedures to be performed at each 
visit.  Individual trial procedures are described in detail below.  It may be necessary  to 
perform these procedures at unscheduled time points if deemed clinically necessary  by the 
investigator.
Furthermore, additional evaluations/testing may  be deemed necessary  by the investigator and 
or the Sponsor for reasons related to subject safety . In some cases, such evaluation/testing 
may be potentially  sensitive in nature (e.g., HIV, Hepatitis C, etc.), and thus local regulations 
may require that additional informed consent , and assent if applicable, be obtained from the 
subject.  In these cases, such evaluations/testing will be performed in accordance with those 
regulations.
Administrative Procedures
Informe d Consent /Assent
The investigator or medically qualified designee (consistent with local requirements) must 
obtain documented informed consent , and assent if applicable, from each potential subject or 
each subject’s legally  acceptable representative prior to participating in thisclinical trial. If 
there are changes to the subject’s status during the trial (e.g.,health or age of majorit y 
requirements ), the investigator or medicall y qualified designee must ensure the appropriate 
documented consent /assent is in place. 
7.1.1.1.1 General Informed Consent/Assent
Informed consent/assent given by the subject or their legall y acceptable representative must 
be documented on a consent/assent form. The form must include the trial protocol number, 
trial protocol title, dated signature, and agreement of the subject (or his/her legall y acceptable 
representative) and of the person conducting the consent discussion.
A copy of the signed and dated informed consent/assent form should be given to the subject 
(or their legall y acceptable representative) before participation in the trial.
The initial informed consent/assent form, any subsequent revised informed consent/assent 
form and any written information provided to the subject must receive the IRB/IEC’s 
appro val/favorable opinion in advance of use.  The subject or his/her legally  acceptable 
representative should be informed in a timel y manner if new information becomes available 
that may be relevant to the subject’s willingness to continue participation in the trial.  The 
communication of this information will be provided and documented via a revised 
consent/assent form or addendum to the original consent/assent form that captures the 
subject’s or the subject’s legally  acceptable representative’s dated signatur e.
Specifics about a trial and the trial population are to be included in the trial informed
consent/assent form.   
  05L65F
Product:   MK-7625A 58
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialInformed consent will adhere to IRB/IEC requirements, applicable laws and regulations and 
Sponsor requirements. The assent, as applicable , will adhere to IRB/ERC requirements, 
applicable laws and regulations, and Sponsor requirements.
Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by  the investigator or qualified designee 
to ensure that the subject qualifies for the trial.
Subject Identification Card
All subjects will be given a Subject Identification Card identify ing them as participants in a 
research trial. The card will contain trial site contact information (including direct telephone 
numbers) tobe utilized in the event of an emergency . The investigator or qualified designee 
will provide the subject with a Subject Identification Card immediately  after the subject 
provides documented informed consent /assent .At the time of treatment 
allocation/randomization, site personnel will add the treatment/randomization number to the 
Subject I dentification Card.
The subject identification card also contains contact information for the emergency  
unblinding call center so that a health care provider can obtain information about trial 
medication/vaccination in emergency  situations where the investigator is not available.
Medical History
A medical history  will be obtained by the investigator or qualified designee. In addition to 
the evaluation of a subject’s medic al history  in terms of study  eligibility , all medical 
conditions present during the 5 years prior to study  entry will be documented at the 
Screening Visit on the appropriate eCRF. Any history  of prior cIAI episodes or conditions 
that may predispose a subje ct to the development of cIAI will also be documented on the 
appropriate eCRF, even if the prior episode or predisposing condition was diagnosed more 
than 5 y ears prior to study  entry .
Prior and Concomitant Medications Review
7.1.1.5.1 Prior Medications
At Screening , the investigator or qualified designee will review prior medication use and 
record prior medication taken by the subject within 7 days before the first dose of trial 
medication (or within 14 days before the first dose of trial medication for all antibact erial 
agents, and within 30 days before the first dose of trial medication for any other 
investigational drug). For subjects who are breastfeeding, prior medication use by the 
subject’s mother will be recorded similarl y.
Any blood or blood product transfusions in the previous 48 hours before first dose of trial 
medication will be recorded. 
  05L65F
Product:   MK-7625A 59
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential7.1.1.5.2 Concomitant Medications
The investigator or qualified designee will record medication, if any, taken by the subject 
during the trial (from the first dose of trial medication to the last trial evaluation). For 
subjects who are breastfeeding, concomitant medication use by the subject’s mother will be 
recorded similarly .
Assignment of Screening Number
All consented subjects will be given a unique screening number that will be used to identify 
the subject for all procedures that occur prior to randomization .  Each subject will be 
assigned only one screening number.  Screening numbers must not be re-used for different 
subjects.
Specific details on the Screening Visit requirements are provided in Section 7.1.5.1 -
Screening .
Assignment of Treatment/ Randomization Number
All eligible subjects will be randoml y allocated and will receive a treatment/ randomization 
number.  The treatment/ randomization number identifies the subject for all procedures 
occurring after randomization.  Once a treatment/randomization number is assigned to a 
subject, it can never be re -assigned to another subject.
A single subject cannot be assigned more than 1 treatment/ randomization number.
Trial Compliance (Medication)
Interruptions from the protocol specified IV study  treatment for ≥2 consecutive doses or ≥3 
nonconsecutive doses require consultation between the investigator and the Sponsor and 
written documentation of the collaborative decision on subject management.
Clinical Procedures/Assessments
Clinical procedures and assessments will occur as specified in Section 6.0 –Trial Flow 
Chart. This section provides additional details. Clinical procedure/assessment data will be 
recorded in source documents and the appropriate location in the eCRF.
Body Weight, Height , and Vital Signs
The investigator or qualified designee will record body  weight (kg) and height (cm) as 
indicated in Section 6.0 – Trial Flow Chart. Body  weight will be measured without shoes, 
jacket, or diaper (in subjects using diapers).
The investigator or qualified designee will record vital signs (heart rate, respiratory  rate, 
blood pressure, and temperature [oral, tympanic, recta l, axillary , or temporal ]) as indicated in 
Section 6.0 – Trial Flow Chart. Systolic and diastolic blood pressure will be measured on the 
same arm. Heart rate and blood pressure will be measured simultaneousl y. 
  05L65F
Product:   MK-7625A 60
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential
Physical Examination
The investigator or qualified designee will perform full or directed physical examinations as 
indicated in Section 6.0 – Trial Flow Chart. The investigator or qualified designee will also 
perform a fullor directed physical examination at other times at the investigator’s discretion, 
if an AE or abnormality is suspected.
The fullphysical examination will include examination of body  systems (including, but not 
limited to,general appearance, skin, neck, eyes, ears, nose, throat, breast, lungs, heart, 
abdomen, back, l ymph nodes, extremities, and nervous sy stem).
The directed physical examination should be based on the subject’s condition and 
circumstances, at the investigator’s discretion. The directed phy sical ex amination should note 
any changes in the subject’s condition (body  systems) since the last examination and does not 
preclude examination of any  of the body  systems as clinically  indicated.
Changes in physical examination findings (abnormalities) that the investigator considers 
clinically  significant will be recorded on the medical history  eCRF page if observed prior to 
administration of the first dose of IV study  treatment. Changes in physical examination 
findings (abnormalities) that the investigator considers clinically  significant must be recorded 
as AEs if observed after the start of the first dose of IV stud y treatment .
Surgical Woun d Examination
Surgical wound examination is performed as clinically  indicated and noted in Section 6.0 –
Trial Flow Chart to assess signs of infection such as skin erythema, induration, tenderness, 
warmth, fluctuance, swelling, and wound pain. If signs of infection are present, findings will 
be recorded and categorized as present, absent, or unable to assess .If wound discharge is 
present, the nature of the discharge (nonpurulent or purulent) will be assessed. This 
assessment should ideally be performed at the same time each day .
Abdominal Sign and Symptom Assessment
The abdominal signs and symptoms of cIAI (see Section 5.1.2 -Subject Inclusion Criteria, 
Criterion 4)will be evaluated and graded as absent, present, or unable to assess at the visits 
specified in Section 6.0 – Trial Flow Chart. The signs and symptoms of cIAI (eg, fever, 
leukocy tosis, hypotension, abdominal pain, nausea/vomiting, anorexia, abdominal mass on 
clinical examination, and altered mental status) will be assessed at Screening by clinical 
examination of the abdomen and noted as absent, present, or not able to assess/ not 
performed .
At visits after Screening, the investigator will assess each observed sign or symptom 
according to the categories above. The clinical signs and symptoms of cIAI are not 
considered AEs, unless a sign or s ymptom qualifies as a nSAE. 
  05L65F
Product:   MK-7625A 61
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential
Summary of Operative Procedures
A summary  of interventional operative procedures to treat cIAI will be recorded. The 
anatomic site of infection, the presence of one or more abscesses, the extent of peritonitis, 
and the etiological mechanism (eg, trauma, postoperative, or spontaneous rupture) must be 
recorded. Copies of all surgical reports must be retained for review during monitoring visits.
Radiological Examinat ion
Specific radiographic examinations are not required for this study  unless the subject is 
enrolled preoperativel y. Radiological examinations should only be performed as required for 
routine clinical management. Radiological evaluations might include plain abdominal 
radiograph, computed tomograph y (CT)scan, ultrasound, and/or magnetic resonance 
imaging (MRI )scan, with or without contrast. The results of any such studies should be 
recorded. Copies of all interventional radiological reports and diagnostic study  reports must 
be retained for review during monitoring visits.
Adverse Event Monitoring
Assessment and recording of AEs is described in Section 7.2–Assessing and Recording 
Adverse Events . All SAEs will be followed until resolution, stabilization, withdrawal of 
consent, or death.
Assessment of Clinical Outcome
At the visits indicated in Section 6.0 –Trial Flow Chart, the investigator or qualified 
designee will assign the subject’s clinical outcome to a category  (cure, partial improvement, 
failure, or indeterminate) as described in Section 4.2.3.2 –Rationale for Efficacy  Endpoints.
Assessment of Microbio logical Outcome
All microbiological outcomes will be assessed by the Sponsor based on culture results, as 
defined in Section 4.2.3.2 –Rationale for Efficacy  Endpoints. Investigators are not 
responsible for assessment of microbiological outcomes.
Assessment of Emergent Infection
Emergent pathogens (ie, those isolated after Screening) will be assessed by the Sponsor for 
the outcome of superinfection or new infection, as defined in Section 4.2.3.2 –Rationale for 
Efficacy  Endpoints. Investigators are not responsible for assessment of emergent infections .
Laboratory Procedures/Assessment s
Details regarding specific laboratory  procedures/assessments to be performed in this trial are 
provided below. Laboratory  procedure/assessment data will be recorded in source documents 
and the appropriate location in the eCRF. 
  05L65F
Product:   MK-7625A 62
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialThe total amount of blood to be drawn/collected over the course of the trial (from screening 
to the last trial evaluation ), including approximate blood volumes drawn/collec ted by visit 
per subject ,can be found in Appendix 12.2.
Laboratory Safety Evaluations (Hematology and Chemistr y)
At the visits specified in Section 6.0 – Trial Flow Chart, blood samples will be obtained for 
theindicated laboratory tests (hematology  and chemistry ;Table 8). See Appendix 12.2 –
Approximate Blood Volumes Drawn/Collected by Trial Visit for the maximum expected 
blood volumes needed for laboratory tests.
At Screening, blood samples will be collecte d for laboratory  safety evaluations to determine 
trial eligibility , as follows: serum creatinine, ANC, AST, ALT, and total bilirubin. These 
laboratory  safety evaluations for trial eligibility  will be performed by the local laboratory . A 
blood sample will also be collected at Screening for the direct Coombs test, which the site 
will send to the central laboratory for testing .
Blood samples collected for laboratory  safety evaluations after the Screening Visit will be 
tested by the local laboratory . At the EOIV Visit , a blood sample will be collected for the 
direct Coombs test, which the site will send to the central laboratory  for testing .The blood 
sample for direct Coombs test may be drawn on Day  3 (with the blood samples for chemistry 
and hematology  safety  evaluations) if the EOIV Visit is planned for Day  4.
Blood samples for laboratory  safety evaluations will be collected without regard to meals or 
study  treatment.
Table 8 Laboratory  Safet y Evaluations
Hematology Chemistry
Hematocrit Albumin
Hemoglobin Alkaline phosphatase
Platelet s ALT
Leukocyte s (total and differential) AST
Direct Coombs test Bicarbonate
Calcium
Chloride
Creatinine
Glucose
Phosphorus
Potassium
Sodium
Total bilirubin
Direct bilirubin, if total bilirubin is >ULN
Total protein
BUN
ALT = alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; ULN = 
upper limit of normal
NOTE: All laboratory safety evaluations will be performed by  the local laboratory, except the direct Coom bs 
test; sites will send blood samples for the direct Coombs test to the central laboratory for testing. 
  05L65F
Product:   MK-7625A 63
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential
Pregnancy Testing
Pregnancy  testing will be performed by the local laboratory  on female subjects of 
child- bearing potential at the visits specified in Section 6.0 – Trial Flow Chart. Prior to 
randomization, the investigator will ensure serum pregnancy  tests are negative in female 
subjects of child- bearing potential.
A urine pregnancy  test instead of a serum pregnancy  test may  be performed at the TOC Visit
by the local laboratory , if deemed clinicall y appropriate b y the investigator.
Assessment of Creatinine Clearance
Blood samples for serum creatinine will be obtained as indicated in Section 6.0 – Trial Flow 
Chart and evaluated by the local laboratory . The subject’s CrCL will be estimated using the 
serum creatinine value , height, and the revised Schwartz equation [12], as follows :
Glomerular filtration rate (GFR )(mL/min per 1.73 m2) = 0.413 *H/S cr, where
GFR = glomerular filtration rate (mL/min per 1.73 m2)
H = height (cm)
Scr= serum creatinine (mg/dL)
For subjects with unstable renal function (CrCL is close to 50 mL/min/1.73 m2) while 
receiving IV study  treatment, obtain serum creatinine value and monitor CrCL  at least daily. 
Subjects with CrC L<50 m L/min/1.73 m2must be disc ontinued from the IV study  treatment .
Intra -abdominal Samples for Culture
The investigator or qualified designee will obtain intra-abdominal specimens at the visits 
specified in Section 6.0 – Trial Flow Chart for culture of aerobic and anaerobic organisms 
during the interventional procedure. Specimens should be collected at the beginning of the 
interventional procedure prior to debridement, removal ,or disinfection of the primary  site of 
infection. Aspirates (collected with a needle or syringe) or tissue orbiopsy  samples are 
recommended, and swabs of purulent material are discouraged. Specimens should not be 
obtained from in situ abdominal drains. 
Thereafter, specimens for culture are to be obtained from the site of infection, if clinicall y 
indicated (eg, if re-intervention is required, collection during the additional surgery  in 
subjects with clinical failure) to evaluate the microbiological assessment. Specimens should 
not be obtained from in situ abdominal drains. Culture of the intra-abdominal specimen,
isolation of pathogen(s) ,initial identification of pathogen(s) , and susceptibility  testing will be 
conducted by the local laboratory . The result of culture and initial identification of 
pathogen(s) at the local laboratory should be recorded in the source document and eCRF. The 
sites should ship the isolated pathogen(s) to the central microbiolo gy laboratory  forre-
identification and MIC testing. Further details of the procedures to be followed for sample 
collection, storage, and shipment will be provided in a laboratory  manual. 
  05L65F
Product:   MK-7625A 64
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential
Blood Samples for Culture
Blood samples are collected for culture asspecified in Section 6.0 – Trial Flow Chart. Blood 
samples for culture should be collected if signs of sepsis appear at any  time during the study . 
Further details of the procedures to be followed for sample collection, storage, and shipment 
will be provided in a laboratory manual.
Blood samples for culture will be obtained for all subjects at Screening if clinically  indicated. 
Culture of the blood specimen, isolation of pathogen(s) ,initial identification of pathogen(s) , 
and susceptibility  testing will be conducted by the local laboratory  and recorded. The sites 
will ship the isolated pathogen(s) to the central microbiology  laboratory  for re-identification 
and MIC testing. Further details of the procedures to be followed for sample collection, 
storage, and shipment will be provided in a laboratory manual.
Pharmacokinetic Evaluations
Whole blood to obtain plasma samples will be collected for population PK analy sisof 
ceftolozane and tazobactam as specified in Section 6.0 – Trial Flow Chart. These samples 
may also be used in the assessment of the clinical relationship between ceftolozane and 
tazobactam plasma concentrations and efficacy , as appropriate.
Blood samples for ceftolozane ,tazobactam , and tazobactam M1concentration assay s and 
plasma PK parameters (for ceftolozane and tazobactam) will be collected from all subjects 
over one 8-hour dosing period on Day 3  of the treatment period after administration of at 
least 6 doses of IV study  treatment . These blood samples will be collected at the following 
times: At the end of infusion (collected within 10 minutes after the end of total dose 
administration); between 2.5 and 3.5h post start of infusion; and between 5.0 and 6.0 hours 
post start of infusion but prior t o the start of the next dose of study  treatment.
Pharmacokinetic sample collection may occur on Day 4 if the last dosing period of Day 3 is 
selected for PK sample collection. Additionally , if sampling on Day 3 is logistically  difficult, 
sampling may be performed at comparable time points after Day 3  in subjects who are 
continuing to receive IV study  treatment.
Plasma will be separated from blood and sent to the central laboratory  for PK testing .Details 
of the procedures for collection, processing, storage, and shipment of PK samples from blood 
(plasma) will be provided separatel y in a laboratory  manual. Actual whole blood sample 
collection dates and times must be recorded .
Other Procedures
Withdrawal/Discontinuation
Subjects who discontinue study  treatment prior to completion of the study  treatment regimen 
(IV only or IV + oral) should be encouraged to continue to be followed for all remaining 
study  visits. 
  05L65F
Product:   MK-7625A 65
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialWhen a subject discontinues/withdraws from participation in the trial, all applicable activities 
scheduled for the EOIV or EOT Visit ,as described in Section 7.1.5.9 –Subjects Who 
Prematurel y Discontinue From Study  Treatment or the Trial, should be performed a t the time 
of discontinuation. An y AEs that are present at the time of discontinuation/withdrawal should 
be followed in accordance with the safet y requirements outlined in Section 7.2 -Assessing 
and Recording Adverse Events.
Lost to Follow -up
If a subject fails to return to the clinic for a required trial visit and/or if the site is unable to 
contact the subject, the following procedures willbe performed:
The site must attempt to contact the subject and reschedule the missed visit. If the 
subject is contacted, the subject should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
The investigator or designee must make every  effort to regain contact with the 
subject at each missed visit (eg,phone calls and/or a certified letter to the 
subject’s last known mailing address or locally  equivalent methods). These 
contact attempts should be documented in the subject’s medical record.
NOTE:  A subject is not considered lost to follow- up until the last scheduled visit for the 
individual subject.  The amount of missing data for the subject will be managed via the 
pre-specified data handling and anal ysis guidelines.
Unblinded Pharmacist
Subjects will receive the IV study  treatment ,following preparatio n by an unblinded 
pharmacist (Section 5.2.6 – Trial Blinding ), for a maximum of 14 days. Preparation of study 
drug by the unblinded pharmacist is detailed in the pharmacy  manual. Importantly , the 
unblinded pharmacist will be uninvolved in any of the postin fusion evaluations for the 
subject . All study  personnel involved with the postinfusion evaluations of safety  and efficacy 
outcomes, including the study  coordinator(s), investigator, or subinvestigator(s), must have 
no access to the treatment group assignme nt or the preparation of the study infusion.
Subject Blinding/Unblinding
When the investigator or delegate needs to identify  the drug used by  a subject and the dosage 
administered in case of emergency  e.g., the occurrence of serious adverse events , he/she will 
contact the emergency  unblinding call center by  telephone and make a request for emergency  
unblinding.  As requested by the investigator or delegate the emergency  unblinding call 
center will provide the information to him/her promptly  and rep ort unblinding to the S ponsor .  
Prior to contacting the emergency  unblinding call center to request unblinding of a subject’s 
treatment assignment, the investigator or delegate must enter the intensity  grade of the 
adverse events observed, the relation to study  drug, the reason thereof, etc., in the medical 
chart etc. 
  05L65F
Product:   MK-7625A 66
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialSubjects whose treatment assignment has been unblinded by the investigator/delegate and/or 
nonstudy treating ph ysician should continue to be monitored in the trial.
Additionally , the investiga tor must go into the IVRS system and perform the unblind in the 
IVRS system to update drug disposition.  In the event that the emergency  unblinding call 
center is not available for a given site in this trial, IVRS/I WRS should be used for emergency 
unblindi ng in the event that this is required for subject safet y.
Treatment/Vaccine identification information is to be unmasked ONLY if necessary  for the 
welfare of the subject.  Every effort should be made not to unblind the subject unless 
necessary . 
In the event that unblinding has occurred, the circumstances around the unblinding (e.g., 
date, reason and person performing the unblinding) must be documented promptly , and the 
Sponsor Clinical Director notified as soon as possible. Once an emergency  unblinding has
taken place, the principal investigator, site personnel, and Sponsor personnel may be 
unblinded so that the appropriate follow -up medical care can be provided to the participant .
Subjects whose treatment assignment has been unblinded should continue to receive study  
medication.
Calibration of Critical Equipment
The investigator or qualified designee has the responsibility  to ensure that any critical device
or instrument used for a clinical evaluation/test during a clinical trial that provides important 
information about inclusion/exclusion criteria and/or safet y or efficacy  parameters shall be 
suitably  calibrated and maintained to ensure that the data obtained is reliable and/or 
reproducible.  Documentation of equipment calibration must be retained as source 
documentation at the trial site.
Critical Equipment for this trial includes:
Refrigerators or freezers used to store study  medication or subject samples/specimens 
that will be sent to the central laboratory .
Visit Requirements
Visit requirements are outlined in Section 6.0-Trial Flow Chart. Specific procedure -related 
details are provided above in Section 7.1 - Trial Procedures.
Screening
Screening assessments areperformed within 48 hours prior to the start of administration of 
the first dose of IV study  treatment. Assessments (eg, laboratory  procedures, vital signs) 
performed prior to providing documented informed consent may be used if collected during 
the routine care of the subject, solong as they were conducted within 48 hours prior to the 
start of administration of the first dose of IV study  treatment. Potential subjects are evaluated 
at the Screening Visit to determine ifthey fulfill the entry  requirements in Section 5.1– 
  05L65F
Product:   MK-7625A 67
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialEntry  Criteria . All Screening results must be available prior to randomization. Screening, 
randomization, and first dose of study  treatment may  all occur on the same day .
Randomization Visit
The Randomi zation Visit is the date subjects are randomized to treatment arms, and may  then
receive the first dose of double -blind IV study treatment. Screening, randomization, and first 
dose of study  treatment may  all occur on the same day .
Clinical Assessment Visits onIntravenous Study Treatment
Clinical Assessment Visit sonIV study treatment occur daily on Day 2 through the last dose 
of IV study treatment . At these visits, each subject’s assessment should be performed at a 
consistent time each day (eg, every  morning), as much as possible. Safety  laboratory  tests 
and a directed physical examination should be completed on Day 3 (±24 hours) and then 
once weekl y while the subject is receiving IV study  treatment. Subjects cannot go home on 
IV study  treatment.
Blood iscollected for PK analy ses on Day 3  ( after ≥6 doses of IV study treatment ). 
Pharmacokinetic sample collection may occur on Day 4 if the last dosing period of Day 3 is 
selected for PK sample collection. Additionally , if sampling on Day  3 is logistically  difficult, 
sampling may be performed at comparable time points after Day 3  in subjects who are 
continuing to receive IV study  treatm ent.
End of IV Treatment Visit
The EOIV Visit occurs in all subjects within 24 hours after the last dose of IV study
treatment. For subjects who receive only IV study  treatment and are notswitched to oral 
step- down therap y, the EOIV Visit serves as the EOT Visit and these subjects do not have a 
separate EOT Visit . Subjects who areswitched to oral step-down therapy  will have both an 
EOIV and EOT Visit .If subjects are switched to oral step- down therapy , the oral step- down 
therap y must be initiated <24 hours after stopping IV study  treatment. If blood samples for 
chemistry  and hematology  safety evaluations were collected within 24 hours prior to the 
EOIV Visit, blood samples for these evaluations are not required at this visit.
Clinical Assessment Visit onOral Step -down Therapy
The Oral Clinical Assessment Visit is completed only for subjects who are switched to oral 
step- down therapy . If subjects are switched to oral step- down therapy , the oral step- down 
therap y must be initiated <24 hours after stopping IV study treatment. This visit should be 
performed once ifthe subject receives ≥7 days oforal step-down therapy. This visit can be 
performed ±24 hours after 7 days on oral step- down therapy . Subjects who receive <7 days 
of oral step- down therapy  will notundergo this visit. Any AE that comes to the attention of 
the investigator before the Oral Clinical Assessment Visit should be recorded at this visit, but 
any SAE must be reported within 24 hours. This visit will be the same whether the subject is 
still i n the hospital or has been discharged to home. If the Oral Clinical Assessment Visit and 
EOT Visit are on the same day , only the EOT Visit should be completed . 
  05L65F
Product:   MK-7625A 68
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential
End of Treatment Visit
The EOT Visit occurs only in subjects who are switched to oral step-down therap y. These 
subjects will have both an EOIV and EOT Visit . This visit will occur within 48hours after 
the last dose of oral step- down therap y.If blood samples for chemistry and hematology 
safet y evaluati ons were collected within 24 hours prior tothe EOT Visit, blood samples for 
these evaluations are not required at this visit.
Test of Cure Visit
The TOC Visit occurs in all subjects 7 to 14 days after the final dose of study  treatment (IV 
or oral) .
Last F ollow -up Visit
The LFU Visit occurs in all subjects 21 to 28 days after the final dose of study  treatment (IV 
or oral). The LFU Visit will be conducted by  telephone ; however ,if the subject has abnormal 
laboratory  values or AEs that require follow -up, an in- person visit is required .
Subjects Who Prematurely Discontinue From Study Treatment or the Trial
Subjects who discontinue from study  treatment prior to completion of the study treatment 
regimen (IV only or IV + oral) will continue to be monitored in the trial according to Section 
6.0 – Trial Flow Chart.
For subjects who prematurel y withdraw from the trial, see Section 7.1.4.1 –
Withdrawal/Discontinuation and Section 7.1.4.2 – Lost to Follow -up.
Assessing and Recording Adverse Events
An adverse event is defined as any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not necessarily 
have to have a causal relationship with this treatment. An adverse event can therefore be any 
unfavourable and unintended sign (including an abnormal laboratory  finding, for example), 
symptom, or disease temporally  associated with the use of a medicinal product or protocol -
specified procedure, whether or not considered related to the medicinal product or protocol -
specified procedure.  Any worsening (i.e., any clinically  significant adverse change in 
frequency  and/or intensity ) of a preexisting condition that is temporally  associated with the 
use of the Sponsor’s product, is also an adverse event.
Changes resulting from normal growth and development that do not vary significantl y in 
frequency  or severit y from expected levels are not to be considered adverse events.  
Examples of this may include, but are not limited to, teething, typical crying in infants and 
children and onset of menses or menopause occurring at a ph ysiologically  appropriate time.
Sponsor's product includes any pharmaceutical product, biological product, device, 
diagnostic agent or protocol -specified procedure, whether investigational (including placebo  
  05L65F
Product:   MK-7625A 69
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidentialor active comparator medication) or marketed, manufactured by, licensed by, provided by or 
distributed by  the Sponsor for human use.
Adverse events may occur during clinical trials, or as prescribed in clinical practice, from 
overdose (whether accidental or intentional), from abuse and from withdrawal.
All adverse events that occur after the subject provides documented informed consent but 
before treatment allocation/randomization must be reported by the investigator if they cause 
the subject to be excluded from the trial, or are the result of a protocol -specified intervention, 
includi ng but not limited to washout or discontinuation of usual therapy , diet, placebo 
treatment or a procedure. From the time of treatment allocation/ randomization through the 
last trial evaluation (Last Follow -up visit, 21 to 28 days after final dose) , all adverse events 
must be reported b y the investigator. Such events will be recorded at each examination on the 
Adverse Event case report forms/worksheets.  The reporting timeframe for adverse events 
meeting any serious criteria is described in section 7.2.3.1. The investigator will make every 
attempt to follow all subjects with non -serious adverse events for outcome.
Electronic reporting procedures can be found in the Electronic Data Capture (EDC )data 
entry  guidelines. Paper reporting procedures can be found in the Investigator Trial File 
Binder (or equivalent).
Definition of an Overdose for This Protocol and Reporting of Overdose to the 
Sponsor
In this trial, an overdose is any dose greater than 1.5 times higher than the weight -based 
dosing specified for the subject’s age group for ceftolozane/tazobactam ,meropenem , and 
metronidazole . For oral step- down antibiotic therap y, refer to the manufacturer’s label for 
overdose criteria. Additiona l details are described in the p harmacy  manual .
If an adverse event(s) is associated with (“results from”) the overdose of Sponsor's product or 
vaccine, the adverse event(s) is reported as a non-serious adverse event, unless other serious
criteria are met.
If a dose of Sponsor's product or vaccine meeti ng the protocol definition of overdose is taken 
without any associated clinical symptoms or abnormal laboratory  results, the overdose is 
reported as a non-serious adverse event using the terminology  “accidental or intentional 
overdose without adverse effec t.”
All reports of overdose with and without an adverse event must be reported by the 
investigator within 24 hours to the Sponsor either by electronic media or paper. Electronic 
reporting procedures can be found in the EDC data entry  guidelines. Paper reporting 
procedures can be found in the I nvestigator Trial File Binder (or equivalent) .
Reporting of Pregnancy and Lactation to the Sponsor
Although pregnancy  and lactation are not considered adverse events, it is the responsibility  of 
investigators or their designees to report any pregnancy  or lactation in a subject  
  05L65F
Product:   MK-7625A 70
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential(spontaneousl y reported to them), including the pregnancy  of a male subject's female partner 
that occurs during the trial .
Pregnancies and lactations of subjects and female partners of male subjec ts from the time the 
documented informed consent form is provided but before treatment 
allocation/ randomization must be reported by the investigator if they cause the subject to be 
excluded from the trial, or are the result of a protocol -specified interven tion, including but 
not limited to washout or discontinuation of usual therap y, diet, placebo treatment or a 
procedure.  Pregnancies and lactations of subjects and female partners of male subjects that 
occur from the time of treatment allocation/randomizat ion through 14 days following 
cessation of Sponsor’s product must be reported. All reported pregnancies must be followed 
to the completion/termination of the pregnancy. Pregnancy  outcomes of spontaneous 
abortion, missed abortion, benign hydatidiform mole, blighted ovum, fetal death, intrauterine 
death, miscarriage and stillbirth must be reported as serious events (Important Medical 
Events). If the pregnancy  continues to term, the outcome (health of infant) must also be 
reported.
Such events must be reported within 24 hours to the Sponsor either by electronic media or 
paper. Electronic reporting procedures can be found in the EDC data entry guidelines. Paper 
reporting procedures can be found in the Investigator Trial File Binder (or equivalent).
Immediate Reporting of Adverse Events to the Sponsor
Serious Adverse Events
A serious adverse event is any adverse event occurring at any dose or during any use of 
Sponsor's product that:
●Results in death;
●Is life threatening;
●Results in persistent or significant disability /incapacity ;
●Results in or prolongs an existing inpatient hospitalization;
●Is a congenital anomal y/birth defect;
●Is an other important medical event.
Note: In addition to the above criteria, adverse events meeting either of the below criteria, 
although not serious per ICH definition, are reportable to the Sponsor in the same timeframe 
as SAEs to meet certain local requirements. 
●Is a cancer;
●Is associated with an overdose .
Refer to Table 9for additional details regarding each of the above criteria.
For the time period beginning when the subject provides docu mented informed consent until 
treatment allocation/ randomization, any serious adverse event, or follow up to a serious 
adverse event, including death due to any cause, that occurs to any subject must be reported 
within 24 hours to the Sponsor if it causes the subject to be excluded from the trial, or is the 
result of a protocol -specified intervention, including but not limited to washout or 
discontinuation of usual therap y, diet, placebo treatment or a procedure. 
  05L65F
Product:   MK-7625A 71
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialFor the time period beginning at treatment allocation/ randomization through the last trial 
evaluation (Last Follow -up visit, 21 to 28 day s after final dose) , any  serious adverse event, or 
follow up to a serious adverse event, including death due to any  cause, whether or not related 
to the Spo nsor's product, must be reported within 24 hours to the Sponsor either by  electronic 
media or paper. For the time period from the signing of informed consent through treatment 
allocation/randomization, only serious adverse events that either cause the participant to be 
excluded from the trial or are the result of a protocol -specified intervention, must be reported 
within 24 hours to the Sponsor either by electronic media or paper. Electronic reporting 
procedures can be found in the EDC data entry  guidelines . Paper reporting procedures can be 
found in the Investigator Trial File Binder (or equivalent). All serious adverse events will be 
followed until resolution, stabilization, withdrawal of consent, or death.
Additionally , any serious adverse event, consider ed by an investigator who is a qualified 
physician to be related to the Sponsor's product that is brought to the attention of the 
investigator at any time outside of the time period specified in the previous paragraph also 
must be reported immediately  to the Sponsor.
All subjects with serious adverse events must be followed up for outcome.
Events of Clinical Interest
Selected non-serious and serious adverse events are also known as Eve nts of Clinical I nterest 
(ECI) and must be reported to the Sponsor.
For the time period beginning when the subject provides documented informed consent until 
treatment allocation/ randomization, any ECI, or follow up to an ECI, that occurs to any 
subject must be reported within 24 hours to the Sponsor if it causes the subject to be 
excluded from the trial, or is the result of a protocol -specified intervention, including but not 
limited to washout or discontinuation of usual therap y, diet, placebo treatment or a 
procedure.
For the time period beginning at treatment allocation/ randomization through the last trial 
evaluation (Last Follow -up visit, 21 to 28 days after final dose) , any ECI, or follow up to an 
ECI, whether or not related to the Sponsor’s product, must be reported within 24 hours to the 
Sponsor, either by electronic media or paper.  Electronic reporting procedures can be found 
in the EDC data entry guidelines.  Paper reporting procedures can be found in the 
Investigator Trial File Binder (or equivalent).
Events of clinical interest for this trial include:
1.An elevated AST or ALT lab value that is greater than or equal to 3X the upper limit 
of normal and an elevated total bilirubin lab value that is greater than or equal to 2X 
the upper limit of normal and, at the same time, an alkaline phosphatase lab value tha t 
is less than 2X the upper limit of normal, as determined by way of protocol -specified 
laboratory  testing or un scheduled laboratory  testing.*
*Note:  These criteria are based upon available regulatory  guidance documents. The purpose 
of the criteria is to specify  a threshold of abnormal hepatic tests that may require an  
  05L65F
Product:   MK-7625A 72
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidentialadditional evaluation for an underly ing etiology . The trial site guidance for assessment and 
follow up of these criteria can be found in the Investigator Trial File Binder (or equivalent).
2. An overdose of Sponsor's product, as defined in Section 7.2.1 -Definition of an 
Overdose for This Protocol and Reporting of Overdose to the Sponsor, that is not 
associated with clinical symptoms or abnormal laboratory  results .
Evaluating Adverse Events
An investigator who is a qualified physician will evaluate all adverse events with respect to 
the elements outlined inTable 9. The investigator’s assessment of causality  is required for 
each adverse event.  Refer to Table 9 for instructions in evaluating adverse events. 
  05L65F
Product:   MK-7625A 73
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialTable 9 Evaluating Adverse Events
Maximum Mild awareness of sign or symptom, but easily tolerated  (for pediatric trials, awareness of symptom, but easily tolerated)
Intensity Moderate discomfort enough to cause interference with usual activity (for pediatric trials, definitely acting like something is wrong)
Severe incapacitating with inability to work or do usual activity (for pediatric trials, extremely distressed or unable to do usual activities)
Seriousness A serious adverse event (AE) is any adverse event occurring at any dose or during any use of Sponsor's product that:
†Results in death ; or
†Is life threatening; or places the subject, in the view of the investigator, at immediate risk of death from the event as it occurred [Note: This does not include an 
adverse event  that, had it occurred in a more severe form, might have caused death.]; or
†Results in a persistent or significant disability/incapacity (substantial disruption of one’s ability to conduct normal life functions); or
†Results in or prolongs an existing inpatient hospitalization (hospitalization is defined as an inpatient admission, regardless of length of stay, even if the 
hospitalization is a precautionary measu re for continued observation.  (Note: Hospitalization for an elective procedure to treat a pre-existing condition that has not 
worsened is not a serious adverse event.  A pre -existing condition is a clinical condition that is diagnosed prior to the use of a Merck product and is documented in the 
patient’s medical history. ); or
†Is a congenital anomaly/birth defect  ( in offspring of subject taking the product regardless of time to diagnosis); or
Is a cancer (although not serious per IC Hdefinition, is reportable to the Sponsor within 24 hours to meet certain local requirements) ;or
Overdose, although not serious per ICH definition, whether accidental or intentional, with or without an accompanying adverse event/serious adverse event, is 
reportable to the Sponsor within 24 hours to meet certain local requirements.
Other important medical events that may not result in death, not be life threatening, or not require hospitalization may be considered a serious adverse eve nt when, 
based upon appropriate medical judgment, the event may jeopardize the subject and may require medical or surgical interventio n to prevent one of the outcomes listed 
previously (designated above by a †).
Duration Record the start and stop dates of the adve rse event.  If less than 1 day, indicate the appropriate length of time and units
Action taken Did the adverse event cause the Sponsor's product to be discontinued?
Relationship to 
Sponsor's 
ProductDid the Sponsor's product cause the adverse event? The determination of the likelihood that the Sponsor's product caused the adverse event will be provided by an 
investigator who is a qualified physician.  The investigator’s signed/dated initials on the source document or worksheet that supports the causality noted on the AE 
form, ensures that a medically qualified assessment of causality was done.  This initialed document must be retained for the required regulatory time frame.  The 
criteria below are intended as reference guidelines to assist the investigator in assessing the likelihood of a relationship between the test drug and the adverse even t 
based upon the available information
The following components are to be used to assess the relationship between the Sponsor's pro duct and the AE; the greater the correlation with the components 
and their respective elements (in number and/or intensity), the more likely the Sponsor's product caused the adverse event:
Exposure Is there evidence that the subject was actually exposed to the Sponsor's product such as:  reliable history, acceptable compliance assessment (pill 
count, diary, etc.), expected pharmacologic effect, or measurement of drug/metabolite in bodily specimen?
Time Course Did the AE follow in a reasonable temporal sequence from administration of the Sponsor's product? 
Is the time of onset of the AE compatible with a drug -induced effect (applies to trials with investigational medicinal product)?
Likely Cause Is the AE notreasonably explained by another etiology such as underlying disease, other drug(s)/vaccine(s), or other host or environmental
factors 
  05L65F
Product:   MK-7625A 74
Protocol/Amendment No.: 035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialRelationship The following components are to be used to assess the relationship between the Sponsor's product and the AE:  (continued)
to Sponsor's 
Product
(continued) Dechallenge Was the Sponsor's product discontinued or dose/exposure/frequency reduced?
      If yes, did the AE resolve or improve?
           If yes, this is a positive dechallenge.    If no, this is a negative dechallenge.
(Note:  This criterion is not applicable if:  (1) the AE resulted in death or permanent disability; (2) the AE resolved/impro ved despite 
continuation of the Sponso r's product; (3) the trial is a single -dose drug trial); or (4) Sponsor's product(s) is/are only used one time.)
Rechallenge Was the subject re- exposed to the Sponsor's product in this trial?
      If yes, did the AE recur or worsen?
          If yes, this is a positive rechallenge.    If no, this is a negative rechallenge.
(Note:  This criterion is not applicable if:  (1) the initial AE resulted in death or permanent disability, or (2) the trial is a single -dose drug trial); 
or (3) Sponsor's product(s) is/are used only one time.)
NOTE:  IF A RECHALLENGE IS PLANNED FOR AN ADVERSE EVENT WHICH WAS SERIOUS AND WHICH MAY HAVE BEEN 
CAUSED BY THE SPONSOR'S PRODUCT, OR IF RE- EXPOSURE TO THE SPONSOR'S PRODUCT POSES ADDITIONAL POTENTIAL 
SIGNIFICANT RISK TO THE SUBJECT THEN THE RECHALLENGE MUST BE APPROVED IN ADVANCE BY THE SPONSOR
CLINICAL DIRECTOR AND THE INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE.
Consistency 
with Trial 
Treatment 
ProfileIs the clinical/pathological presentation of the AE consistent with previous knowledge regarding the Sponsor's product or dru g class 
pharmacology or toxicology?
The assessment of relationship will be reported on the case report forms /worksheets by an investigator who is a qualified physician according to his/her best clinical judgment, including 
consideration of the above elements.
Record one of the following : Use the following scale of criteria as guidance (not all criteria must be present to be indicative of a Sponsor's product relationship).
Yes, there is a reasonable 
possibility of Sponsor's product 
relationship.There is evidence of exposure to the Sponsor's product.  The temporal sequence of the AE onset relative to the administration of the Sponsor's 
product is reasonable.  The AE is more likely explained by the Sponsor's product than by another cause. 
No, the re is not a reasonable 
possibility of Sponsor's product 
relationshipSubject did not receive the Sponsor's product OR temporal sequence of the AE onset relative to administration of the Sponsor' s product is not 
reasonable OR the AE is more likely explained by another cause than the Sponsor’s product.  (Also entered for a subject with overdose without 
an associated AE.) 
  05L65F
Product:   MK-7625A 75
Protocol/Amendment No.:   035- 03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential
Sponsor Responsibility for Reporting Adverse Events
AllAdverse Events will be reported to regulatory authorities, IRB/IECs and investigators in 
accordance with all applicable global laws and regulations , i.e., per ICH Topic E6 (R1) 
Guidelines for Good Clinical Practice .
TRIAL GOVERNANCE AND OVERSIGHT
Executive Oversight Committee
The EOC comprises members of Sponsor Senior Management. The EOC will receive and 
decide upon an y recommendations made b y the DMC regarding the trial.
Data Monitoring Committee
To supplement the routine trial monitoring outlined in this protocol, an external DMC will 
monitor the interim data from this trial.  The voting members of the committee are external to 
the Sponsor.  The members of the DMC must not be involved with the trial in any other way 
(e.g., they cannot be trial investigators) and must have no competing interests that could 
affect their roles with respect to the trial.
The DMC will make recommendations to the EOC regarding steps to ensure both subject 
safet y and the continued ethical integrity of the trial. Also, the DMC will review interim trial 
results, consider the overall risk and benefit to trial participants (see Section 8.7-Interim 
Analy ses) and recommend to the EOC if the trial should continue in accordance with the 
protocol.
Specific details regarding composition, responsibilities, and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team; meeting 
facilitation; the trial governance stru cture; and requirements for and proper documentation of 
DMC reports, minutes, and recommendations will be described in the DMC charter that is 
reviewed and approved by all the DMC members.
8.0STATISTICAL ANALYSIS PLAN
This section outlines the statistical analysis strategy  and procedures for the trial. Changes to 
analyses made after the protocol has been finalized, but prior to final database lock, will be 
documented in a supplemental Statistical Analy sis Plan (sSAP) and referenced in the Clinical 
Study  Report (CSR) for the trial. For any analy ses in the sSAP and protocol, the sSAP will 
supersede those described in the protocol. Post hoc exploratory  analyses will be detailed in 
the CSR.
Key elements of the Statistical Analysis Plan are summarized inSection 8.1. The 
comprehensive plan is provided in Sections 8.2 through 8.12. 
  05L65F
Product:   MK-7625A 76
Protocol/Amendment No.:   035- 03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential
Statistical Analysis Plan Summary
Trial Design Overview A Phase 2, randomized, active comparator -controlled, multicenter, double -
blind, clinical trial to study the safety and efficacy of 
ceftolozane/tazobactam (MK -7625A) plus metronidazole versus 
meropenem in pediatric subjects with complicated intra-abdom inal 
infections.
Treatment Assignment Approximately 240 pediatric subjects (combined across MK-7625A -034 
and MK-7625A -035) in 5age groups will be enrolled and random ized in a 
3:1 ratio to receive IV ceftolozane/tazobactam plus metronidazole or IV 
meropenem plus placebo , respectively . The total duration of study 
treatment will be a minimum of 5 days to a maximum of 14days. 
Randomization will be stratified by age group. See Table 6for target 
enrollments and IV dosage regimens for each age group.
Analysis Populations Safety: All Subjects as Treated (ASaT) Population
Pharmacokinetics: PK Population
Efficacy: Modi fied Intent -to-Treat (MITT), Microbiological Modified 
Intent -to-Treat (mMITT), Microbiologically Evaluable (ME), and 
Clinically Evaluable (CE) Populations
Primary Endpoints The primary safety parameters w ill include the following safety evaluations: 
AEs
Clinical laboratory tests
Vital signs
Key Secondary Endpoints Clinical success at the EOT and TOC V isits
Per-subject microbiological eradication at the EOT and TOC Visit s
Statistical Methods for Key 
Efficacy/PK AnalysesA 2-sided 95% confidence interval (CI) based on the M&N method [20]
stratified by age group will be provided to evaluate the treatment 
differences for clinical success at the EOT and TOC Visit s and per-subject 
microbiological eradication at the EOT and TOC Visit s.
There w ill be no efficacy hypothesis testing in this estimation trial.
Statistical Methods for Key 
Safety AnalysesTier 2 endpoints include AEs of elevated laboratory values; the percentage 
of subjects with any AE, any SAE, and any treatment -related AE;any 
serious and study treatment -related AE; the percentage of subjects who 
discontinue due to an AE; and AEs (specifi c preferred terms), system organ 
classes, or values outside of the local laboratory’s reference range with 
frequency ≥6 subjects in the experimental treatment arm and/or ≥2 subjects 
in the comparator treatment arm. The 95% CIs will be provided for 
betw een-treatment differences in the percentage of subjects with events; 
these analyses will be performed using the unstratified M&N method [20], 
an unconditional, asymptotic method.
Changes in laboratory and vital sign values from baseline will be 
summarized as Tier 3 events using descriptive statistics.
Interim Analyses No interim analyses for efficacy are planned for this trial.  However, an 
external DMC will convene to review  combined safety data from the present 
trial and the companion Phase 2 trial in pediatric subjects with cUTI (MK -
7625A -034). Additional details are available in the e xternal DMC charter .
Multiplicity There w ill be no adjustment f or multiplicity in this estimation trial. 
  05L65F
Product:   MK-7625A 77
Protocol/Amendment No.:   035- 03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialSample Size and Pow er Approximatel y 240 subjects (combined across MK-7625A -034 and MK-
7625A -035) will be enrolled with approximately 180 subjects in the 
ceftolozane/tazobactam plus metronidazole arm and approxima tely 60 
subjects in the meropenem plus placebo arm. The estimated differences and 
95% CIs for event rateunder various scenarios for the combined trials are 
presented in Table 14. For example, if the overall event rate is 10% across 
both treatment arms (18 out of 180 and 6 out of 60 subjects, respectively), 
the 95% CI for the between -treatment difference is - 13.4, 8.5.
Responsibility for Analyses/In -house Blinding
The statistical analysis of the data obtained from this trial will be the responsibility  of the 
Sponsor’s Clinical Biostatistics department.
This trial will be conducted as a double -blind trial under in-house blinding procedures. The 
official, final database will not be unblinded until medical/scientific review has been 
performed, protocol deviations have been identified, and data have been declared final and 
complete.
The Clinical Biostatistics depart ment will generate the randomized allocation schedule(s) for 
study  treatment assignment. Randomization will be implemented via an IVRS/I WRS. 
The interim review of the safet y data will be performed b y the e xternal DMC (Section 7.3.2 –
Data Monitoring Commi ttee). Treatment level results will be provided by the external 
unblinded statistician to the external DMC. Limited additional Sponsor personnel may be 
unblinded to the treatment level results of the safety  analyses, if required, inorder to act on 
the recommendations of the external DMC. The extent to which individuals are unblinded 
with respect to results of safety review will be documented by the unblin ded statistician.
The external DMC will serve as the primary  review erof the safety  results from this study 
with respect to the safety  reviews and will make recommendations for discontinuation of or 
modifications to the study to the EOC of the Sponsor (Section 7.3.1 – Executive Oversight 
Committee) . If the external DMC recommends modifications to the design of the protocol or 
discontinuation of the study , the EOC (internal to the Sponsor) may  be unblinded to results at 
the treatment level in order to act on these recommendations. Additional logistic details will 
be provided in the external DMC c harter.
Prior to final study  unblinding, the unblinded statistician will not be involved in any 
discussions regarding modifications to the protocol, statistical methods, identification of 
protocol violators, or data validation efforts after the interim safet y review(s) .
Pharmacokinetic data will be unblinded early  for the purpose of preparing a population PK 
model. A separate Modeling and Simulation Plan authored by  the department of Quantitative 
Pharmacology  and Pharmacometrics will describe the modeling work to be performed. A 
small team, who are separate from the protocol team, will be unblinded for the purpose of 
preparing the population PK model. Efficacy  and safet y data will not be unblinded. Interim 
data or results will not be shared with the protocol team before study  unblinding. 
  05L65F
Product:   MK-7625A 78
Protocol/Amendment No.:   035- 03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential
Hypotheses/Estimation
Objectives of the trial are stated in Section 3.0–Objective (s)& Hypothes is(es). No efficacy  
or safet y hypothesis testing will be conducted in this estimation trial. 
Analysis Endpoints
Safety  and efficacy  endpoints that will be evaluated for between -treatment differences are 
listed below, followed b y the descriptions of the derivati ons of selected endpoints.
Safety Endpoints
In order to evaluate the safet y and tolerabilit y of ceftolozane/tazobactam, the following 
safet y endpoints will be summarized based on the ASaT population: AEs, laboratory  data, 
and vital signs.
An initial descri ption of safety  measures is provided in Section 4.2.3 .1–Rationale for Safety 
Endpoints and Events of Clinical Interest (ECIs) are defined in Section 7.2.3.2 –ECIs. The 
proportion of subjects who experience AEs of elevated laboratory  values that are reported as 
ECIs during the stud y treatment period will be estimated.
Adverse Events
The proportion of subjects with AEs of the following types at any time from the first dose of 
study  treatment to the last trial evaluation will be investigated: (1) Any AE, (2) any SAE, 
(3)any drug-related AE, (4) any serious and drug-related AE, and (5) any AE leading to 
study  treatment discontinuation.
Laboratory Data
For the summaries of laboratory  tests, subjects must have both a baseline and 
postrandomization on-treatment measurement to be included. Subjects’ laboratory  values 
(based on their most abnormal laboratory  test values, in the direction of interest, while on 
study  treatment) will be classified as to whether or not they fall outside of the local 
laboratory ’s reference range and are worse in grade (ie, more abnormal in the direction of 
interest ) than at baseline.
Summaries of laboratory changes from baseline to the EOIV, EOT, and TOC Visit s, and 
from baseline to the LFU Visit , as data permit , will be presented.
The number and percentage of subjects in each treatment armwith an elevated AST or ALT
level (>3 × ULN, >5 × ULN, and >10 × ULN) andbilirubin level (>1.5 × ULN and >2 × 
ULN) will be presented by trial visit (as specified in Section 6.0 - Trial Flow Chart) for the 
ASaT population.
A listing of subjects who meet the following predetermined laboratory  criteria will also be 
provided for the ASaT population , including 1) ALT or AST >3 × ULN, alkaline  
  05L65F
Product:   MK-7625A 79
Protocol/Amendment No.:   035- 03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidentialphosphatase ≤2 × ULN, and total bilirubin >1.5 × ULN and 2) ALT or AST >3 × ULN, 
alkaline phosphatase ≤2 × ULN, and total bilirubin >2 × ULN.
Vital Signs
Vital sign parameters will include heart rate (beats per minute), respiratory rate (breaths per 
minute), systolic and diastolic BP in mm mercury (Hg), and temperature in degrees Celsius 
(°C) by  treatment group and trial day /visit.
Other safet y parameters include phy sical examinations and standard laboratory  safety  tests at 
time points specified in Section 6.0 -Trial Flow Chart.
Efficacy Endpoints
There are no primary  efficacy  endpoints for this study ; the primary  endpoints are safet y 
parameters (Section 8.4.1 –Safety  Endpoints).
Secondary Efficacy Endpoints
The secondary  efficacy  endpoints are as follows:
Clinical success rate at the EOT and TOC Visits, defined as the proportion of subjects 
in the anal ysis population who have a clinical response of cure.
Per-subject microbiological success rate at the EOT and TOC Visit s, defined as the 
proportion of subjects in the analysis population who have microbiological 
eradication or presumed eradication of all baseline pathogens .
NOTE: For subjects who receive IV study  treatment only (without optional oral step- down 
therap y), a separate assessment does not need to be performed at the EOT Visit; the EOIV 
Visit will serve as the EOT Visit.
Clinical outcome categories are defined in Table 3and microbiological outcome categories 
are defined in Table 4 in Section 4.2.3.2 –Rationale for Efficacy  Endpoints.
Exploratory Efficacy Endpoints 
The exploratory  efficacy  endpoints are as follows:
Clinical success rate at the EOIV Visit , defined as the proportion of subjects in the 
analysis population who have a clinical response of cur eor partial improvement.
NOTE: At EOIV, clinical success is defined as cure or partial improvement. At EOT 
and TOC, clinical success is defined as cure. The definition for clinical success at the 
EOIV Visit includes partial improvement to accommodate those subjects with partial 
improvement who are switched to oral step- down therap y at this time point.  
  05L65F
Product:   MK-7625A 80
Protocol/Amendment No.:   035- 03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialPer-subject microbiological success rate at the EOIV Visit , defined as the proportion 
of subjects in the analy sis population who have a microbiological outcome of 
eradication or presumed eradication of all baseline pathogens.
Per-pathogen microbiological success rate at the EOIV, EOT, and TOC Visit s, 
defined as the proportion of baseline pathogens that have an outcome of 
microbiological er adication or presumed eradication .
NOTE: For subjects who receive IV study  treatment only (without optional oral step- down 
therap y), a separate assessment does not need to be performed at the EOT Visit; the EOIV 
Visit will serve as the EOT Visit .
Clinical outcome categories are defined in Table 3andmicrobiological outcome categories 
are defined in Table 4 in Section 4.2.3.2 –Rationale for Efficacy  Endpoints.
The percentage of subjects with superinfection or new infection will also be estimated.
Emergent infec tion categories are defined in Table 5in Section 4.2.3.2 –Rationale for 
Efficacy  Endpoints.
Pharmacokinetic Endpoints
Plasma concentration for ceftolozane , tazobactam, and tazobactam M1 will be determined. 
The data will be used to update the existing ceftolozane and tazobactam pediatric population 
PK models, which will be used to perform simulations to evaluate target attainment at 
suitable doses.
The PK target that best correlates with efficacy  is % fT>MIC and % fT>Ct for ceftolozane 
and tazobactam, respectively . Therefore, in addition to plasma exposure (AUC 0-8and Cmax), 
% fT>MIC and % f T>C twill be derived for ceftolozane and tazobactam, respect ively .
Plasma concentrations for tazobactam M1 will be reported separatel y.
Analysis Populations
Safety Analysis Populations
The ASaT population will be used for the analysis of safety  data in this trial. The ASaT 
population will consist of all randomized subjects who receive any amount of study  
treatment. Subjects will be included in the treatment arm corresponding to the IV study 
treatment they actuall y received, irrespective of the treatment to which they were 
randomized. If any subject receives study  treatment from both treatment arms, he or she will 
be assigned to the treatment arm from which more study treatment was receive d.
Efficacy Analysis Populations
The efficacy  analysis populations are defined inTable 10. Additional details about 
evaluability  criteria for each efficacy  analysis population will be provided in anevaluability  
guideline document. 
  05L65F
Product:   MK-7625A 81
Protocol/Amendment No.:   035- 03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialTable 10 Efficacy  Anal ysis Populations
PopulationaDefinitiona
Modified Intent -to-Treat 
(MITT)The MITT population will consist of all random ized subjects who receive any 
amount of study treatment . Subjects will be categorized based on the IV study 
treatment that subjects were randomized to, irrespective of what treatment 
they actually received .
Microbiological Modified 
Intent -to-Treat (mMITT)The mMITT population will be the subset of subjects in the MITT population 
who have at least 1 pathogen identified from the baseline intra-abdom inal 
culture, regardless of susceptibility to study treatment. 
Clinically Evaluable (CE) The CE population will be the subset of subjects in the MITT population who 
adhere to trial procedures and have a clinical outcome at the visit of interest. 
An interpretable culture is not required at thevisit of interest . All subjects 
must have an evalua ble clinical outcome at the visit of interest ; subjects with 
an indeterminate clinical outcome are excluded from the CE population.
Microbiologically 
Evaluable (ME)The ME population will be the subset of subjects in the CE population who 
have at least 1 causative pathogen identified from the baseline intra-
abdominal culture.
aAdditional details about evaluability criteria for each efficacy analysis population will be provided in an
evaluability guideline document .
Details on the approach to handling missing data for safet y anal yses are provided in Section 
8.6 - Statistical Me thods.
Statistical Methods
Statistical Methods for Safety Analyses
Safety  and tolerability  will be assessed b y clinical re view of all relevant parameters including
AEs, laboratory  tests, and vital signs measurements.
The analysis of safet y results for this trial will follow a tiered approach (Table 11). The tiers
differ with respect to the analyses that will be performed. Based upon review of adult and 
pediatric trial safet y data, no Tier 1 AEs of interest have been identified for this trial.  
Therefore, all safet y parameters will be considered Tier 2 or Tier 3. Tier 2 parameters will be 
assessed via point estimates with 95% CIs provided for between- group comparisons; only 
point estimates by  treatment arm are provided for Tier 3 safety  parameters.
Tier 2 endpoints for this trial include the percentage of subjects with AEs of elevated 
laboratory  values, any AE, any treatment -related AE, any SAE, any AE that is both 
treatment -related and serious, and subjects who discontinued due to an AE. The 95% CIs will 
be provided for between -treatment differences in the percentag e of subjects with events; 
these analyses will be performed using the unstratified M&N method [20], an unconditional, 
asymptotic method.
Adverse events (specific preferred terms), sy stem organ classes, or values outside of the local 
laboratory ’s reference range with at least 6 events in the experimental treatment arm and/or 2  
  05L65F
Product:   MK-7625A 82
Protocol/Amendment No.:   035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidentialevents in the comparator treatment arm will be classified as belonging to Tier 2. Adverse 
events (specific preferred terms), system organ classes, or values outside of the local 
laboratory ’s reference range with frequenc iesless than these criteria in both treatment arms 
combined will be classified as belonging to Tier 3.
These thresholds were chosen because the 95% CI for the between -group difference in 
percentage will include zero when these thresholds are not met and thus would add little to 
the interpretation of potentially  meaningful differences.
Because many 95% CIs may be provided without adjustment for multiplicity , the CIs should 
be regarded as a helpful descriptive measure to be used in review, not a formal method for 
assessing the statistical significance of between -group differences in AEs.
Continuous measures such as changes from baseline in laboratory  parameter and vital sign 
values will be considered Tier 3 safet y parameters. Summary  statistics for baseline, 
on-treatment, and change from baseline values will be provided by treatment arm in table 
format. In addition, summary  statistics for both treatment swill be provided. Safet y 
summaries by treatment methods (IV study  treatment or oral step-down therap y) and age 
groups will also be generated.
Missing safet y parameters will be handled 
using the data asobserv ed (DAO) approach, that 
is, any subject with a missing value will be excluded from the anal ysis. Change from baseline 
summaries require a baseline value. If a baseline value is missing, the latest pretreatment 
value will be used instead. If no pretreatment result is available, that subject will not be
included in the summary. The safety  summarization of results will be presented by treatment 
arm unless otherwise specified. Additional subgroup safety  analysis summaries for the dosed 
subjects may  be requested as needed.
Table 11 A nalysis Strategy for Safety  Parameters
Safety Tier Safety Endpoint95% CI for 
Treatm ent 
ComparisonDescriptive 
Statistics
Tier 2 AEs of elevated laboratory values X X
Any AE X X
Any SAE X X
Any treatment -related AE X X
Any serious and treatment -related AE X X
Discontinuation from trial treatment due to AE X X
AEs (specific preferred terms), system organ classes, or 
values outside of the local laboratory’s reference range 
with frequency ≥6 subjects in the experimental treatment 
arm and/or ≥2 subjects in the comparator treatment armX X 
  05L65F
Product:   MK-7625A 83
Protocol/Amendment No.:   035- 03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialSafety Tier Safety Endpoint95% CI for 
Treatm ent 
ComparisonDescriptive 
Statistics
Tier 3 AEs (specific preferred terms), system organ classes, or 
values outside of the local laboratory’s reference range 
with frequency < 6 subjects in the experimenta l treatment 
arm and frequency < 2 subjects in the comparator 
treatment armX
Change from baseline in laboratory param eter and vital 
sign valuesX
AE = adverse event ; CI = confidence interval; SAE = serious adverse event
Statistical Methods for Efficacy Analyses
For clinical and microbiological responses, missing data will be primarily  handled with a 
treatment failure approach for the M ITT and mMITT population and a DAO approach for the 
ME and CE populations ( Table 12) , with the following definitions:
For the anal ysis of clinical response in the MITT and microbiological response in the 
mMI TT population, subjects with missing clinical response or microbiological 
response (eg, indeterminate) will be considered treatment failur es.
For the analyses in the ME or CE population, subjects with a missing clinical 
response or microbiological response (eg, indeterminate) will be excluded from the 
population.
A missing clinical outcome at the TOC Visit will be considered an indeterminate 
outcome unless the clinical outcome at the EOIVor EOT Visit is failure. A clinical 
response of failure at the EOIV or EOT Visit will be carried forward to the TOC 
Visit .
A missing microbiological outcome at the TOC Visitwill be considered 
indeterminate if the clinical outcome at the TOC Visit is indeterminate as well. 
Microbiological response will be presumed from clinical response when there is no 
suitable intra-abdominal specimen to culture on/after the EOT/EOIV Visitthrough 
the TOC Visit .
The M&N statistical method [20] with data stratified by age group will be used to make 
between -group comparisons for binary  outcomes (Table 13), but no tests of hypotheses are 
planned in this estimation trial. 
  05L65F
Product:   MK-7625A 84
Protocol/Amendment No.:   035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialTable 12 Analy sis Strategy  for Efficacy  Variables
Endpoint/Variablea
(Description, Timepoint)Prim ary (P) or 
Supportive (S) 
ApproachAnalysis 
PopulationMissing Data Approach
Secondary Endpoints
Clinical success rate at the EOT and TOC 
Visit sP MITT Treatment Failure 
S mMITT Treatment Failure
S CE Data As Observed
Per-subject microbiological eradication rate 
at the EOT and TOC VisitsP mMITT Treatment Failure 
S ME Data As Observed
Exploratory Endpoints
Clinical success rate at the EOIV VisitP MITT Treatment Failure 
S mMITT Treatment Failure
S CE Data As Observed
Per-subject microbiological eradication rate 
at the EOIV VisitP mMITT Treatment Failure 
S ME Data As Observed
Per-pathogen microbiological eradication 
rate at the EOIV, EOT, and TOC Visit sP mMITT Treatment Failure 
S ME Data As Observed
CE = clinically evaluable; EOIV = End of IV Treatment; EOT = End of Treatment; ME = Microbiologically 
Evaluable; MITT = Modified Intent -to-Treat; mMITT = m icrobiological Modified Intent -to-Treat; TOC = Test
ofCure
aThe Miettinen and Nurminen statistical method [20] will be used for all analyses and will include
stratification by age.
NOTE: For subjects who receive IV study treatment only (without optional oral step -down therapy), a separate 
assessment does not need to be performed at the EOT Visit; the EOIV Visit will serve as the EOT Visit.
Table 13 Estimated Two-sided 95% Confidence Intervals Based on Different Assumed 
Observed Rates of Efficacy  Endpoints
Sam e Observed Clinical 
Success or Per- subject 
Microbiological Response
Rate Across Both Arm sCeftolozane/tazobactam
(n=90)Meropenem
(n=30) Estimate (95% CI)
70% 63 (70.0%) 21 (70.0%) 0.00 ( -17.20, 20.08)
80% 72 (80.0%) 24 (80.0%) 0.00 ( -14.50, 18.88)
90% 81 (90.0%) 27 (90.0%) 0.00 ( -10.60, 16.46)
CI = confidence interval 
  05L65F
Product:   MK-7625A 85
Protocol/Amendment No.:   035- 03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential
Summaries of Baseline Characteristics, Demographics, and Other Analyses
Analyses of Baseline Characteristics and Demographics
No statistical hy pothesis tests will be performed on demographic and baseline characteristics. 
The number and percentage of subjec ts screened, randomized/allocated, the primary  reasons 
for screening failure, and the primary  reasons for discontinuation will be display ed. 
Demographic variables (as follows), baseline characteristics, primary  diagnosis, prior and 
concomitant therapies, and medical history  will be summarized by treatment using 
descriptive statistics for continuous or categorical variables ,as appropriate. Summaries of 
baseline pathogens and signs and s ymptoms will also be provided.
Demographic variables include but are notlimited tothe following : Age, sex, race, body 
weight, bod y mass index, and geographic region of enrollment.
Baseline characteristics include but are not limited to the following:
CrCL  group (<50 mL/min, ≥50 to <80 mL /min, ≥80 mL /min)
Baseline diagnosis 
Baseline signs and s ymptoms of cIAI
Primary  site of infection
Anatomic site of infection
Presence of abscess
Number of abscesses (single, multiple)
Presence of peritonitis (yes, no)
Peritonitis ty pe
Localized complicated appendicitis (y es, no)
Etiological mechanism
Failure of prior therap y
Procedure t ype
Wound closure
All abscesses confirmed drained (y es, no)
Site of infection (appendix, non appendix )  
  05L65F
Product:   MK-7625A 86
Protocol/Amendment No.:   035- 03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialPrior antibiotic use
Presence of bacteremia at baseline (y es, no)
Number of baseline pathogens (poly microbial, monomicrobial)
ESBL status of Enterobacteriaceae (ESBL, non -ESBL)
AmpC overexpression status
In addition, for randomized subjects, baseline characteristics will be presented by age 
category  and treatment arm .
Populati on P harmacokinetic Analyses
Based on PK data obtained within this study , a separate population PK analysis will be 
performed for ceftolozane and tazobactam . The prospective details of this analy sis will be 
specified in a separate population PK analy sis plan and the results will be included in a 
separate report .
Interim Analyses
No interim analy ses for efficacy  are planned for this trial. However, an external DMC will 
convene to review combined safet y data from the present trial and the companion Phase 2 
trial in pediatric subjects with cUTI (MK- 7625A -034). Additional details are available in the 
external DMC charter .
Multiplicity
There will be no multiplicity  adjustments in the analy ses of this estimation trial.
Sample Size and Power Calculations
This is an estimation trial; no formal statistical testing will be performed for the efficacy  or 
safet y endpoints. In this trial, approximately  240subjects (combined across MK-7625A -034 
and MK-7625A -035) will be enrolled with an expected 180 subjects in the 
ceftolozane/tazobactam plus metronidazole treatment arm and an expected 60 subjects in the 
meropenem plus placebo treatment arm. With a sample size of 180 ceftolozane/taz obactam -
treated subjects in both this trial and the tandem c UTI tr ial (MK- 7625A -034) (Section 4.2.1.1 
–Rationale for Sample Size), AEs with an underly ing true incidence of at least 2% in the 
treatment arm are anticipated to occur with a probability  of at least 97%.
The primary  objective of this trial is assessment of the accumulated safet y data. Trial -specific 
safet y assessments are described in Section 8.6.1 –Statistical Methods for Safet y Anal yses;
however, safet y data will be combined across MK-7625A -034 and MK -7625A -035. Table 14
shows estimate d treatment differences and associated 2-sided 95% CIs for events under 
varying assumptions of the observed number ofsubjects having a certain event combined 
across trials . These calculations are based on the unstratified M&N method [20]. 
  05L65F
Product:   MK-7625A 87
Protocol/Amendment No.:   035- 03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialTable 14 Estimated Treatment Differences and Two -sided 95% Confidence Intervals
Sam e Expected Event Rate 
Across Both Treatm ent GroupsCeftolozane/tazobactam
(n=180 )Meropenem
(n=6 0) Estimate (95% CI)
2% 4(2.2%) 2(3.3%) -1.1 (- 9.30, 3.05)
4% 8(4.4%) 4(6.7%) -2.2 (- 1.18, 3.57)
10% 18(10.0%) 6(10.0%) 0.0 (- 10.80, 7.64)
15% 28(15.6%) 10(16.7%) -1.1 (- 13.42, 8.53)
CI = confidence interval
NOTE: Given the same expected event rate across both treatment groups, treatment difference estimates are 
not always zero given the discrete nature of events. The number of events within each treatment group is 
selected based on the minimum number of events required to match or exceed the expected event rate across 
both groups.
Subgroup Analyses
To assess the consistency  of clinical and microbiological response at the EOT and TOC 
Visits, the response rates with 95% CIs will be estimated for each treatment arm within each 
category  listed below.
Age category  (birth to <3 months, 3 months to <2 years, 2 years to <6 years, 6 years 
to <12 y ears, 12 years to <18 y ears)
Sex (male, female)
Region of enrollment
Duration of IV stud y treatment
Primary  site of infection (bowel [small or large], other site of infection)
Etiological mechanism (nosocomial infection [postoperative/hospital acquired 
infection] , community -acquired infection [trauma, spontaneous rupture, malignancy  
or other ])
Number of abscesses (single, multiple)
Peritonitis ty pe (local, diffuse)
Procedure t ype (percutaneous aspiration, laparoscopy , laparotomy , other)
Prior antibiotic use (y es, no)
Site of infection (appendix, nonappendix)
Baseline bacteremia (y es, no) 
  05L65F
Product:   MK-7625A 88
Protocol/Amendment No.:   035- 03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialNumber of baseline pathogens (poly microbial, monomicrobial)
Pathogen MIC (susceptible, intermediate, resistant as defined in the SAP) and 
pathogen classification
ESBL sta tus of Enterobacteriaceae (ESBL , non -ESBL) 
AmpC overexpression status 
Additional subgroup analy sis summaries for randomized subjects with regard to other factors 
may be considered as needed.
Compliance (Medication Adherence)
Each subject will be scheduled to receive IV study treatment every  8 hours ( 3 times dail y)for 
at least 9 doses . After that, subjects may  be switched to open- label, standard ofcare oral step -
down antibiotic therapy at the investigator’s discretion.  Oral step-down therapy  is 
considered study  treatment.  The total duration of study  treatment (IV only or IV + oral) is a 
minimum of 7 day s and a maximum of 14 day s.  
In this study ,the dosing of IV study treatment will be documented in the study  intervention 
CRF page by recording the date, time, and whether or not each dose of IV study treatment
was completel y infused. The amount of oral step- down therap y taken by each subject will be 
recorded in the concomitant medication CRF page.  This information will be used to 
calculate the IV study  treatment and overall study  treatment compliance rates.  Details of the 
compliance calculations will be provided in the sSAP and/or CSR. 
Extent of Exposure
The extent of exposure during IV study  treatment and the total study  treatment exposure will 
be summarized as both continuous and categorical variables alongside counts and 
percentages for the “Number of Days on Therapy ” by treatment arm in the ASaT population. 
The summary  of exposure by  treatment arms andage group will also be provided.
9.0LABELING, PACKAGING, STORAGE AND RETURN OF CLINICAL 
SUPPLIES
Investigational Product
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate suppl y, storage, handling, distribution and usage of 
investigational product in accordance with the protocol and any applicable laws and 
regulations.
Clinical Supplies will be provided b y the Sponsor as summarized in Table 15. 
  05L65F
Product:   MK-7625A 89
Protocol/Amendment No.:   035- 03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialTable 15 Product Descriptions
Treatment 
GroupProduct Name 
and Dosage Form Dose PotencyTotal 
Dosage 
FormsAdditional 
Information
1Ceftolozane/
tazobactam -IVCohort 
dose1 g/0.5 g 1.5 g/vialCommercial 
Zerbaxa product –
clinically labeled
1 Metronidazole -IVCohort 
dose0.5 g0.5g/
100-mL 
bagor 
0.5g/vialCommercial 
metronidazole
product – clinically 
labeled
2 Meropenem -IVCohort 
dose1.0g 1.0 g/vialCommercial 
meropenem product 
–clinically labeled
Product Name & Potency Dosage Form Source/Additional Information
Ceftolozane 1 g/
tazobactam 0.5 g1 g/0.5 g lyophilized vial Provided centrally by the Sponsor 
Metronidazole 0.5 g 0.5 g/100- mL bag or 
0.5g/vialProvided centrally by the Sponsor 
Meropenem 1 g 1-g lyophilized vial Provided centrally by the Sponsor 
Placebo IV Site sourced
All supplies indicated inTable15will be provided per the “Source/Additional Information” 
column depending on local country  operational requirements .
Any commercially  available product not included inTable15will be provided by the trial 
site, subsidiary  or designee .Every  attempt should be made to source these supplies from a 
single lot/batch number. The trial site is responsible for recording the lot number, 
manufacturer, and expiry  date for any locally  purchased product as per local guidelines
unless otherwise instructed by  the Sponsor.
Packaging and Labeling Information
Clinical supplies will be affixed with a clinical label in accordance with regulator y 
requirements.
The clinical supplies will be open -labeled and each vial/dosage form will contain a 
component identification (CID) number for management of the supplies through an 
IVRS/I WRS. Subject s will receive the IV study  treatment following preparation by an 
unblinded pharmacist (Section 5.2.6 – Trial Blinding) , for a maximum of 14days. The
subject 's parent (or guardian) will remain blinded to the IV study  treatment that the subject
receives. Importantly , the unblinded pharmacist will be uninvolved in any  of the postinfusion 
evaluations for the subject . All study  personnel involved with the postinfusion evaluations of  
  05L65F
Product:   MK-7625A 90
Protocol/Amendment No.:   035- 03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidentialsafet y and efficacy  outcomes, including the study  coordinator(s), investigator, or 
subinvestigator(s), must have no access to the treatment group assignment or the preparation 
of the study  infusion.
Clinical Supplies Dis closure
The emergency  unblinding call center will use the treatment/ randomization schedule for the 
trial to unblind subjects and to unmask IV study  treatment identity . In the event that the 
emergency  unblinding call center is not available for a given sitein this trial, the central 
electronic treatment allocation/ randomization system (IVRS/I WRS) should be used in order 
to unblind subjects and to unmask treatment/vaccine identity . The Sponsor willnotprovide 
random code/disclosure envelopes or lists with the clinical supplies.
See Section 7.1.4.4 , Subject Blinding/Unblinding, for a description of the method of 
unblinding a subject during the trial, should such action be warranted.
Storage and Handling Requirements
Clinical supplies must be stored in a secure, limited -access location under the storage 
conditions specified on the label.  
Receipt and dispensing of trial medication must be recorded by an authorized person at the 
trial site.
Clinical supplies may  not be used for an y purpose other than tha t stated in the protocol.
Discard/Destruction/ Returns and Reconciliation
The investigator is responsible for keeping accurate records of the clinical supplies received 
from the Sponsor or designee, the amount dispensed to and returned by the subjects and the 
amount remaining at the conclusion of the trial. For all trial sites, the local country  Sponsor 
personnel or designee will provide appropriate documentation that must be completed for 
drug accountability  and return, or local discard and destruction if appropriate.  Where local 
discard and destruction is appropriate, the investigator is responsible for ensuring that a local 
discard/destruction procedure is documented.
Standard Policies
Trial site personnel will have access to a central electronic treatmen t 
allocation/ randomization system (IVRS/I WRS system) to allocate subjects, to assign study  
treatment to subjects and to manage the distribution of clinical supplies. Each person 
accessing the IVRS system must be assigned an individual unique PIN.  They must use only 
their assigned PIN to access the system, and they must not share their assigned PIN with 
anyone. 
  05L65F
Product:   MK-7625A 91
Protocol/Amendment No.:   035- 03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential10.0 ADMINISTRATIVE AND R EGULATORY DETAILS
Confidentiality
Confidentiality of Data
By signing this protocol, the investigator affirms to the Sponsor that information furnished to 
the investigator by the Sponsor will be maintained in confidence, and such information will 
be divulged to the institutional review board, ethics review committee (IRB/ERC) or similar 
or expert committee; affiliated institution and employ ees, only under an appropriate 
understanding of confidentiality  with such board or committee, affiliated institution and 
employ ees.  Data generated by this trial will be considered confidential by the investigator, 
except to the extent that it is included in a publication as provided in the Publications section 
of this protocol.
Confidentiality of Subject Records
By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/ERC, or regulatory  authori ty representatives may consult and/or copy  trial documents in 
order to verify  worksheet/case report form data.  By providing documented informed
consent, the subject agrees to this process.  If trial documents will be photocopied during the 
process of verifying worksheet/case report form information, the subject will be identified by  
unique code onl y; full names/initials will be masked prior to transmission to the Sponsor.
By signing this protocol, the investigator agrees to treat all subject data used and disclosed in 
connection with this trial in accordance with all applicable privacy laws, rules and 
regulations.
Confidentiality of Investigator Information
By signing this protocol, the investigator recognizes that certain personal identify ing 
information with respect to the investigator, and all subinvestigators and trial site personnel, 
may be used and disclosed for trial management purposes, as part of a regulatory  
submissions, and as required b y law.  This information may include:
1. name, address, telephone number and e -mail address;
2. hospital or clinic address and telephone number;
3. curriculum vitae or other summary  of qualifications and credentials; and
4. other professional documentation.
Consistent with the purposes described above, this information may be transmitted to the 
Sponsor, and subsidiaries, affiliates and agents of the Sponsor, in your country  and other 
countries, including countries that do not have laws protecting such information.  
Additionally , the investigator’s name and business contact information may be included 
when reporting certain serious adverse events to regulatory  authorities or to other 
investigators.  By signing this protocol, the investigator expressly  consents to these uses and 
disclosures. 
  05L65F
Product:   MK-7625A 92
Protocol/Amendment No.:   035- 03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialIf this is a multicenter trial, in order to facilitate contact between investigators, the Sponsor 
may share an investigator’s name and contact information with other participating 
investigators upon request.
Confidentiality of IRB/IEC Information
The Sponsor is required to record the name and address of each IRB/IEC that reviews and 
approves this trial.  The Sponsor is also required to document that each IRB/IEC meets 
regulatory  and ICH GCP requirements by requesting and maintaining records of the names 
and qualifications of the IRB/IEC members and to make these records available for 
regulatory  agency  review upon request b y those agencies.
Compliance with Financial Disclosure Requirements
Financial Disclosure requirements are outlined in the US Food and Drug Administratio n 
Regulations, Financial Disclosure by Clinical Investigators (21 CFR Part 54).  It is the 
Sponsor's responsibility to determine, based on these regulations, whether a request for 
Financial Disclosure information is required.  It is the investigator's/subi nvestigator's 
responsibility  to comply  with any  such request.  
The investigator/subinvestigator(s) agree, if requested by the Sponsor in accordance with 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements.  
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Disclosure Form, commonly  known as a financial disclosure form, provide d by 
the Sponsor . The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the United States for these purposes.  This may involve the 
transmission of information to countries that do not have laws protecti ng personal data.
Compliance with Law, Audit and Debarment
By signing this protocol, the investigator agrees to conduct the trial in an efficient and 
diligent manner and in conformance with this protocol; generall y accepted standards of Good 
Clinical Pract ice (e.g., International Conference on Harmoni sation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice: 
Consolidated Guideline and other generally  accepted standards of good clinical practice); and 
all applicable federal, state and local laws, rules and regulations relating to the conduct of the 
clinical trial.
The Code of Conduct, a collection of goals and considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored by  Merck, is provided in Section 12.1 -
Merck Code of Conduct for Clinical Trials.
The investigator also agrees to allow monitoring, audits, IRB/IEC review and regulatory  
authority  inspection of trial- related documents and procedures and provide for direct access 
to all trial -related source data and documents.
The investigator agrees not to seek reimbursement from subjects, their insurance providers or 
from government programs for procedures included as part of the trial reimbursed to the 
investigator b y the Sp onsor. 
  05L65F
Product:   MK-7625A 93
Protocol/Amendment No.:   035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialThe investigator shall prepare and maintain complete and accurate trial documentation in 
compliance with Good Clinical Practice standards and applicable federal, state and local 
laws, rules and regulations; and, for each subject participating in the trial, provide all data, 
and, upon completion or termination of the clinical trial, submit any other reports to the 
Sponsor as required by  this protocol or as otherwise required pursuant to any  agreement with 
the Sponsor.
Trial documentation will be promptly  and fully disclosed to the Sponsor by the investigator 
upon request and also shall be made available at the trial site upon request for inspection, 
copy ing, review and audit at reasonable times by representatives of the Sponsor or any 
regulatory  author ities.  The investigator agrees to promptly  take any  reasonable steps that are 
requested b y the Sponsor as a result of an audit to cure deficiencies in the trial documentation 
and worksheets/case report forms.
The investigator must maintain copies of all documentation and records relating to the 
conduct of the trial in compliance with all applicable legal and regulatory  requirements.  This 
documentation includes, but is not limited to, the protocol, worksheets/case report forms, 
advertising for subject participation, adverse event reports, subject source data, 
correspondence with regulatory  authorities and IRBs/ERCs, consent forms, investigator’s 
curricula vitae, monitor visit logs, laboratory  reference ranges, laboratory  certification or 
quality  control pro cedures and laboratory  director curriculum vitae.  By  signing this protocol, 
the investigator agrees that documentation shall be retained until at least 2 years after the last 
approval of a marketing application in an ICH region or until there are no pendi ng or 
contemplated marketing applications in an ICH region or until at least 2 years have elapsed 
since the formal discontinuation of clinical development of the investigational product.  
Because the clinical development and marketing application process is variable, it is 
anticipated that the retention period can be up to 15 years or longer after protocol 
database 
lock. The Sponsor will determine the minimum retention period and notify  the investigator 
when documents may be destro yed.  The Sponsor will determine the minimum retention 
period and upon request, will provide guidance to the investigator when documents no longer 
need to be retained.  The Sponsor also recognizes that documents may  need to be retained for 
a longer period if required by local regul atory  requirements. All trial documents shall be 
made available if required by relevant regulatory  authorities. The investigator must consult 
with and obtain written approval b y the Sponsor prior to destro ying trial and/or subject files.  
ICH Good Clinical Practice 
guidelines recommend that the investigator inform the subject’s 
primary  physician about the subject’s participation in the trial if the subject has a primary  
physician and if the subject agrees to th e primary  physician being informed.
The investigator will promptly  inform the Sponsor of any regulatory  authority  inspection 
conducted for this trial.
Persons debarred from conducting or working on clinical trials by any court or regulatory 
authority  will not be allowed to conduct or work on this Sponsor’s trials.  The investigator 
will immediately  disclose in writing to the Sponsor if any person who is involved in 
conducting the trial is debarred or if any proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
In the event the Sponsor prematurel y terminates a particular trial site, the Sponsor will 
promptly  notify  that trial site’s I RB/IEC. 
  05L65F
Product:   MK-7625A 94
Protocol/Amendment No.:   035- 03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialAccording to European legislation, a Sponsor must designate an overall coord inating 
investigator for a multi- center trial (including multinational).  When more than one trial site 
is open in an EU country, Merck, as the Sponsor, will designate, per country , a national 
principal coordinator (Protocol CI), responsible for coordinati ng the work of the principal 
investigators at the different trial sites in that Member State, according to national 
regulations.  For a single -center trial, the Protocol CI is the principal investigator.  In 
addition, the Sponsor must designate a principal or coordinating investigator to review the 
trial report that summarizes the trial results and confirm that, to the best of his/her 
knowledge, the report accuratel y describes the conduct and results of the trial [Clinical Study  
Report (CSR) CI].  The Sponsor may consider one or more factors in the selection of the 
individual to serve as the Protocol CI and or CSR CI (e.g., availabilit y of the Protocol/CSR 
CI during the anticipated review process, thorough understanding of clinical trial methods, 
appropriate enrollment of subject cohort, timely achievement of trial milestones).  The 
Protocol CI  must be a participating trial investigator.
Compliance with Trial Registration and Results Posting Requirements
Under the terms of the Food and Drug Administration Ame ndments Act (FDAAA) of 2007 
and the European Medicines Agency  (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the trial is solely  responsible for determining whether the trial and its results are subject to 
the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries.  Merck, as Sponsor of this trial, will 
review this protocol and submit the information necessary  to fulfill these requirements. 
Merck entries are not limited to FDAAA or the EMA clinical trial directive mandated trials.  
Information posted will allow subjects to identify  potentiall y appropriate trials for their 
disease conditions and pursue participation by calling a central contact number for further 
information on appropri ate trial locations and trial site contact information.  
By signing this protocol, the investigator acknowledges that the statutory  obligations under 
FDAAA, the EMA clinical trials directive or other locall y mandated registries are that of the 
Sponsor and agrees not to submit any information about this trial or its results to those 
registries.
Quality Management System
By signing this protocol, the Sponsor agrees to be responsible for implementing and 
maintaining a quality  management system with written development procedures and 
functional area standard operating procedures (SOPs) to ensure that trials are conducted and 
data are generated, documented, and reported in compliance with the protocol, accepted 
standards of Good Clinical Practice, and all applicable federal, state, and local laws, rules and 
regulations relating to the conduct of the clinical trial.
Data Management
The investigator or qualified designee is responsible for recording and verify ing the accuracy 
of subject data.  By signing this protocol, the investigator acknowledges that his/her 
electronic signature is the legall y binding equivalent of a written signature.  By enterin g 
his/her electronic signature, the investigator confirms that all recorded data have been 
verified as accu rate. 
  05L65F
Product:   MK-7625A 95
Protocol/Amendment No.:   035- 03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialDetailed information regarding Data Management procedures for this protocol will be 
provided separatel y.
Publications
This trial is intended for publication, even if terminated prematurel y. Publication may  include 
any or all of the following: posting of a synopsis online, abstract and/or presentation at a 
scientific conference, or publication of a full manuscript.  The Sponsor will work with the 
authors to submit a manuscript describing trial results within 12 months after the last data 
become availab le, which may take up to several months after the last subject visit in some 
cases such as vaccine trials.  However, manuscript submission timelines may  be extended on 
OTC trials.  For trials intended for pediatric -related regulatory  filings, the investiga tor agrees 
to delay  publication of the trial results until the Sponsor notifies the investigator that all 
relevant regulatory  authority  decisions on the trial drug have been made with regard to 
pediatric -related regulatory  filings. Merck will post a synops is of trial results for approved 
products on www.clinicaltrials.gov by 12 months after the last subject's last visit for the 
primary  outcome, 12 months after the decision to discontinue development, or product 
marketing (dispensed, administered, delivered or promoted), whichever is later.
These timelines may be extended for products that are not yet marketed, if additional time is 
needed for analysis, to protect intellectual property , or to compl y with confidentiality 
agreements with other parties.  Authors of the primary  results manuscript will be provided 
the complete results from the Clinical Study  Report, subject to the confidentiality  agreement. 
When a manuscript is submitted to a biomedical journal, the Sponsor's policy  is to also 
include the protocol and statistical analy sis plan to facilitate the peer and editorial review of 
the manuscript.  If the manuscript is subsequently accepted for publication, the Sponsor will 
allow the journal, if it so desires, to post on its website the key sections of the protocol that 
are relevant to evaluating the trial, specifically  those sections describing the trial objectives 
and hypotheses, the subject inclusion and exclusion criteria, the trial design and procedures, 
the efficacy  and safet y measures, the statistical analy sis plan, and any  amendments relating to 
those sections.  The Sponsor reserves the right to redact proprietary information.
For multicenter trials, subsequent to the multicenter publication (or after public disclosure of 
the results online at www.clin icaltrials.gov if a multicenter manuscript is not planned), an 
investigator and his/her colleagues may publish their data independentl y.  In most cases, 
publication of individual trial site data does not add value to complete multicenter results, 
due to statistical concerns.  In rare cases, publication of single trial site data prior to the main 
paper may be of value.  Limitations of single trial site observations in a multicenter trial 
should alway s be described in such a manuscript.
Authorship credit should be based on 1) substantial contributions to conception and design, 
or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising 
it critically  for important intellectual content; and 3) final approval of the version to be 
published. Authors must meet conditions 1, 2 and 3.  Significant contributions to trial 
execution may also be taken into account to determine authorship, provided that 
contributions have also been made to all three of the preceding authorship criter ia.  Although 
publication planning may  begin before conducting the trial, final decisions on authorship and 
the order of authors’ names will be made based on participation and actual contributions to  
  05L65F
Product:   MK-7625A 96
Protocol/Amendment No.:   035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidentialthe trial and writing, as discussed above. The first author is responsible for defending the 
integrit y of the data, method(s) of data anal ysis and the scientific content of the manuscript.
The Sponsor must have the opportunity  to review all proposed abstracts, manuscripts or 
presentations regarding this trial 45days prior to submission for publication/presentation. 
Any information identified by the Sponsor as confidential must be deleted prior to 
submission; this confidentiality  does not include efficacy  and safety  results. Sponsor review 
can be expedited to me et publication timelines.
11.0 LIST OF REFERENCES
[1] Solomkin JS, Mazuski JE, Bradley  JS, Rodvold KA, Goldstein EJC, Baron EJ, 
et al. Diagnosis and management of complicated 
intra-abdominal infection in 
adults and children:  guidelines by the surgical infection societ y and the 
infectious diseases society of America. Clin I nfect Dis 2010;50:133-64.
[2] Thompson AE, Marshall JC, Opal SM. Intraabdominal infections in infants 
and children: descriptions and definitions. Pediatr Crit Care Med. 2005 
May;6(3 Suppl):S30-5.
[3] Claud EC. Neonatal necrotizing enterocolitis -inflammation and intestinal 
immaturity . Antiinflamm Antiallergy  Agents Med Chem. 2009 Sep;8(3):248 -
259.
[4] Newman N, Wattad E, Greenberg D, Peled N, Cohen Z, Leibovitz E. 
Community -acquired complicated intra -abdominal infections in children 
hospitalized during 1995 -2004 at a paediatric surgery  department. Scand J 
Infect Dis. 2009;41(10):720-6.
[5] Nance ML, Adamson WT, Hedrick HL. Appendicitis in the young child: a 
continuing diagnostic cha
llenge. Pediatr Emerg Care. 2000 Jun;16(3):160-2.
[6] Sartelli M, Catena F, Coccolini F, Pinna AD. Antimicrobial management of 
intra-abdominal infections: literature's guidelines. World J Gastroenterol. 2012 
Mar 7;18(9):865 -71.
[7] Brook I. Bacterial studies of peritoneal cavity and postoperative surgical 
wound drainage following perforated appendix in children. Ann Surg. 1980 
Aug;192(2):208-12.
[8] Dupont H. The empiric treatment of nosocomial intra-abdominal infections. 
Int J I nfect Dis. 2007 May ;11 Su ppl 1:S1 -6.
[9] Spirt MJ. Complicated intra-abdominal infections: a focus on appendicitis and 
diverticulitis. Postgrad Med. 2010 Jan;122(1):39-51. 
  05L65F
Product:   MK-7625A 97
Protocol/Amendment No.:   035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential[10] Goldin AB, Sawin RS, Garrison MM, Zerr DM, Christakis DA. 
Aminogl ycoside -based triple -antibiotic therap y versus monotherapy for 
children with ruptured appendicitis. Pediatrics. 2007 May ;119(5):905-11.
[11] Bradley  JS, Ang JY, Arrieta AC, Larson KB, Rizk ML, Caro L, et al. 
Pharmacokinetics and safety  o f single intravenous doses of 
ceftolozane/tazobactam in children with proven or suspected Gram -negative 
infection. Pediatr Infect Dis J. 2018 Nov;37(11):1130-6.
[12] Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady  BA, et al. 
New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 
2009 Mar;20(3):629-37.
[13] Craig W, Andes D. In Vivo Activities of Ceftolozane, a New Cephalosporin, 
with and without Tazobactam against Pseudomonas aeruginosa and 
Enterobacteriaceae, Including Strains with Extended -Spectrum  -Lactam ases, 
in the Thighs of Neutropenic Mice.  Antimicrob Agents Chemother 2013, 
57(4): p. 1577–1582
[14] Xiao AJ, Caro L, Popejoy  MW, Huntington JA, Kullar R. PK/PD Target 
Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in 
Patients With Various Degrees of Renal Function, Including Augmented 
Renal Clearance and End-Stage Renal Disease. Infect Dis Ther. 2016 Dec 24. 
doi: 10.1007/s40121 -016-0143-9.
[15] Cohen
-Wolkowiez M, Poindexter B, Bidegain M, Weitkamp JH, Schelonka 
RL, Randolph DA, et al. Safety  and effectiveness of meropenem in infants 
with suspected or complicated intra -abdominal infections. Clin Infect Dis. 
2012 Dec;55(11):1495 -502.
[16] Pickering LK, Baker CJ, Kimberlin DW, Long SS. Red Book: 2012 Report of 
the committee on infectiou s diseases. Clostridium difficile. 29 ed. Elk Grove 
Village: American Academy  of Pediatrics, 2012:285 -7.
[17] U.S. Prescribing Information: MERREM I.V. (meropenem for Injection): 
2013.
[18] Smith PB, Cohen-Wolkowiez M, Castro LM, Poindexter B, Bidegain M, 
Weitkamp JH, et al. Population pharmacokinetics of meropenem in plasma 
and cerebrospinal fluid of infants with suspected or complicated intra-
abdominal infections. Pediatr Infect Dis J. 2011 Oct;30(10):844-9.
[19] Lee LS, Kinzig -Schippers M, Nafziger AN, Ma L, Sörgel F, Jones RN, 
Drusano GL, Bertino JS Jr. Comparison of 30-min and 3-h infusion regimens 
for imipenem/cilastatin and for meropenem evaluated by Monte Carlo 
simulation. Diagn Microbiol I nfect Dis. 2010 Nov;68(3):251 -8. 
  05L65F
Product:   MK-7625A 98
Protocol/Amendment No.:   035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential[20] Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 
1985;4:213-26. 
  05L65F
Product:   MK-7625A 99
Protocol/Amendment No.:   035- 03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential12.0 APPENDICES
Merck Code of Conduct for Clinical Trials
Merck *
Code of Conduct for Clinical Trials
I. Introduction
A. Purpose
Merck, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials in 
compliance with the highest ethical and scientific standards. Protection of subject safety is the overriding concern in 
the design of clinical trials. In all cases, Merck clinical trials will be conducted in compliance with local and/or 
national regulations and in accordance with the ethical principles that have their origin in the Declaration of Helsinki. 
B. Scope
Such standards shall be endorsed for all clinical interventional investigations sponsored by Merck irrespective of the 
party (parties) employed for their execution (e.g., contract research organizations, collaborative research efforts). This 
Code is not intended to apply to trials which are observational in nature, or which are retrospective. Further, this Code 
does not apply to investigator -initiated trial s which are not under the control of Merck.
II.Scientific Issues
A. Trial Conduct
1.Trial Design
Except for pilot or estimation trials, clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynami c indices of Merck or comparator products.  Alternatively, Merck may 
conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to determine 
subject preferences, etc.  
The design (i.e., subject population, duration , statistical power) must be adequate to address the specific purpose 
of the trial.  Research subjects must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
Merck selects investigative sites based on medical expertise, access toappropriate subjects, adequacy of facilities 
and staff, previous performance in Merck trials, as well as budgetary considerations.  Prior to trial initiation, sites 
are evaluated by Merck personnel to assess the ability to successfully conduct the trial.
3.Site Monitoring/Scientific Integrity
Trial sites are monitored to assess compliance with the trial protocol and general principles of Good Clinical 
Practice.  Merck reviews clinical data for accuracy, completeness and c onsistency. Data are verified versus source 
documentation according to standard operating procedures.  Per Merck policies and procedures, if fraud, 
misconduct or serious GCP -non-Compliance are suspected, the issues are promptly investigated. When necessary, 
the clinical site will be closed , the responsible regulatory authorities and ethics review committees notified and 
data disclosed accordingly. 
B. Publication and Authorship
To the extent scientifically appropriate, Merck seeks to publish the results of trials it conducts.  Some early phase or 
pilot trials are intended to be hypothesis -generating rather than hypothesis testing.  In such cases, publication of 
results may not be appropriate since the trial may be underpowered and the analyses complicated by statistical issues 
of mul tiplicity.
Merck’s policy on authorship is consistent with the requirements outlined in the ICH-Good Clinical Practice 
guidelines. In summary, authorship should reflect significant contribution to the design and conduct of the trial, 
performance or interpr etation of the analysis, and/or writing of the manuscript.  All named authors must be able to 
defend the trial results and conclusions.  Merck funding of a trial will be acknowledged in publications.  
  05L65F
Product:   MK-7625A 100
Protocol/Amendment No.:   035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialIII. Subject Protection
A.IRB/ERC review
All clinical trials will be reviewed and approved by an independent IRB/ERC before being initiated at each site.  
Significant changes or revisions to the protocol will be approved by the IRB/ERC prior to implementation, except that 
changes required urgentl y to protect subject safety and well-being may be enacted in anticipation of IRB/ERC 
approval. For each site, the IRB/ERC and Merck will approve the subject informed consent form. 
B.Safety
The guiding principle in decision -making in clinical trials is that subject welfare is of primary importance.  Potential 
subjects will be informed of the risks and benefits of, as well as alternatives to, trial participation. At a minimum, trial 
designs will take into account the local standard of care.  Subjects are ne ver denied access to appropriate medical care 
based on participation in a Merck clinical trial. 
All participation in Merck clinical trials is voluntary.  Subjects are enrolled only after providing informed consent for 
participation.  Subjects may withdraw from a Merck trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C.Confidentiality
Merck is committed to safeguarding subject confidentiality, to the greatest extent possible. Unless required by law, 
only the investigator, Sponsor (or representative) and/or regulatory authorities will have access to confidential medical 
records that might identify the research subject by name.  
D.Genomic Research
Genomic Research will only beconducted in accordance with informed consent and/or as specifically authorized by 
an Ethics Committee.
IV.Financial Considerations
A.Payments to Investigators
Clinical trials are time- and labor-intensive.  It is Merck’s policy to compensate investigat ors (or the sponsoring 
institution) in a fair manner for the work performe d in support of Merck trials.  Merck does not pay incentives to 
enroll subjects in its trials.  However, when enrollment is particularly challenging, additional payments may be made 
to compensate for the time spent in extra recruiting efforts.
Merck does not pay for subject referrals.  However, Merck may compensate referring physicians for time spent on 
chart review to identify potentially eligible subjects.
B.Clinical Research Funding 
Informed consent forms will disclose that the trial is sponsored by Merck, and that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial.  However, the local IRB/ERC may wish to alter 
the wording of the disclosure statement to be consistent with financial practices at that institution.  As noted above, 
publications resulting from Merck trials will indicate Merck as a source of funding.
C.Funding for Travel and Other Requests
Fundin g of travel by investigators and support staff (e.g.,to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices including, in the U.S., those established by the American Medical 
Association (AMA). 
V. Inves tigator Commit ment
Investigators will be expected to review Merck’s Code of Conduct as an appendix to the trial protocol, and in signing 
the protocol, agree to support these ethical and scientific standards.
* In this document, "Merck" refers to Merck Sharp & Dohme Corp. and Schering Corporation, each of which is a 
subsidiary of Merck & Co., Inc.  Merck is known as MSD outside of the United States and Canada.  As warranted by 
context, Merck also includes affiliates and subsidiaries of Merck & Co., Inc." 
  05L65F
Product:   MK-7625A 101
Protocol/Amendment No.:   035- 03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential
Approximate Blood Volumes Drawn/ Collected by Trial Visit
The approximate maximum blood volumes to be collected at each trial visit are summarized 
in Table 16.
Table 16 Approximate Blood Volumes Collect ed by  Trial Visit
Approximate Blood Sample Volume ( mL)
Trial Period: Screening Treat ment (5 to 14 days) Follow -up
Visit Number: 1 3 to 16 17 18 19 20 21
Trial Visit: ScreeningIV Clinical 
Assess mentsEOIV 
(all 
subjects)Oral Clinical 
Assess ment
(only for IV 
to oral 
switch)EOT
only for IV 
to oral 
switch)TOC
(all 
subjects)LFUa
(all 
subjects)
Safety 
hematology and 
chemistry , serum 
creatinine3.5 3.5b3.5 3.5 3.5 3.5 3.5c,d
Coombs test 
(direct)1.0 0 1.0 0 0 0 0
Serum pregnancy 
teste3.0 0 0 0 0 3.0e0
Blood for culture 7.0c7.0c,f0 0 0 0 0
Blood for PK 
analyse s (Day 3 
only)g0 0.75g0 0 0 0 0
Maximum 
expected total 
blood volume14.5 11.25 4.5 3 .5 3.5 6.5 3.5
EOIV = End of IV Treatment; EOT = End of Treatment; IV = intravenous; LFU = Last Follow -up; PK = 
pharmacokinetics; TOC = Test of Cure
aAt the discretion of the investigator, the LFU Visit may be conducted by telephone, unless the subject has abnormal 
laboratory values or AEs that require follow -up.
bTo be completed on Day 3 and then once weekly while the subject is receiving IV study tre atment .
cIf clinically indicated.
dTo be performed only if LFU Visit is conducted in person instead of by telephone.
eFemale subjects of child bearing potential only. A urine pregnancy test instead of a serum pregnancy test may be 
performed at the TOC Visit, if deemed clinically appropriate by the investigator.
fBlood samples for culture should be collected if signs of sepsis appear at any time during the study .
gBlood samples for ceftolozane ,tazobactam , and tazobactam M1concentration assays  will be collected from all 
subjects over one 8 -hourdosing period on Day 3 of the treatment period after administration of at least 6 doses of IV 
study treatment (see Section 7.1.3. 6 –Pharmacokinetic Evaluations ).  
  05L65F
Product:   MK-7625A 102
Protocol/Amendment No.:   035- 03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential
List of Abbreviations and Definitions of Terms
Abbreviation or 
Term Definition
%CV Coefficient of variation
% fT>MIC Percentage of dosing interval during which free concentration of drug 
(ceftolozane) exceeds the MI C
% fT>Ct Percentage of dosing interval during which free concentration of drug 
(tazobactam) exceeds the Ct
AE Adverse event
AIDS Acquired Immune Deficiency  Syndrome
ALT Alanine aminotransferase
ANC Absolute neutrophil count
ASaT All Subjects as Treated
AST Aspartate aminotransferase
AUC Area under the concentration -time curve
BLI β-lactamase inhibitor
BP Blood pressure
CE Clinically  evaluable
CI Confidence interval
cIAI Complicated intra -abdominal infection
CID Component identification
CL Clearance
CLSI Clinical and Laboratory  Standards Institute
Cmax Maximum observed concentration
CrCL Creatinine clearance
CRF Case Report Form
CSR Clinical study  report
Ct Threshold drug concentration
CT Computed tomograph y
cUTI Complicated urinary  tract infection
DAO Data as observed
DMC Data Monitoring Committee
eCRF Electronic case report form 
  05L65F
Product:   MK-7625A 103
Protocol/Amendment No.:   035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialAbbreviation or 
Term Definition
EDC Electronic data capture
eGFR Estimated glomerular filtration rate
EMA European Medicines Association
EOC Executive Oversight Committee
EOIV End of IV Treatment (Visit)
EOT End of Treatment (Visit)
ERC Ethics Review Committee
ESBL Extended -spectrum β -lactamase
EU European Union
FDA Food and Drug Administration
FDAAA FDA Amendments Act
GCP Good Clinical Practice
GI Gastro intestinal
Hg Mercury  (for BP, mm Hg)
HIV Human immunodeficiency virus
IAI Intra -abdominal infection
IB Investigator’s Brochure
ICH International Council for Harmonis ation
IDSA Infectious Disease Society  of America
IRB Institutional Review Board
IV Intravenous
IVRS Interactive voice response sy stem
IWRS Integrated web response sy stem
LFU Last Follow -up (Visit)
M&N Miettinen and Nurminen (statistical method)
MDR Multidrug -resistant
ME Microbiologically  evaluable
MIC Minim uminhibitory  concentration
MITT Modified Intent -to-Treat
mMI TT Microbiological Modified Intent -to-Treat
MRI Magnetic resonance imaging 
  05L65F
Product:   MK-7625A 104
Protocol/Amendment No.:   035-03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
ConfidentialAbbreviation or 
Term Definition
MRSA Methicillin -resistant Staphylococcus aureus
NEC Necrotizing enterocolitis
NP Nosocomial pneumonia
OTC Over the counter
PIN Personal identification number
PK Pharmacokinetic(s)
PTA Probability  of target attainment
Q Intercompartmental clearance
SAE Serious adverse event
SD Standard deviation
SOP Standard operating procedure
sSAP Supplemental Statistical Analy sis Plan
T>MI C Time above MIC
t½ Elimination half-life
TEAE Treatment -emergent adverse event
TOC Test of Cure (Visit)
ULN Upper limit of normal
US United States (of America)
UTI Urinary  tract infection
Vc Central volume of distribution
Vp Peripheral volume of distribution
WBC White blood cell 
  05L65F
Product:   MK-7625A 105
Protocol/Amendment No.:   035- 03 
MK-7625A -035-03 Final Protocol 14-Sep-2020
Confidential13.0 SIGNATURES
Sponsor's Representative
TYPED NAME
TITLE
SIGNATURE
DATE SIGNED
Investigator
I agree to conduct this clinical trial in accordance with the design outlined in this protocol 
and to abide by all provisions of this protocol (including other manuals and documents 
referenced from this protocol).  I  agree to conduct the trial in accordance with generally 
accepted standards of Good Clinical Practice.  I also agree to r eport all information or data in 
accordance with the protocol and, in particular, I agree to report any serious adverse events 
as defined in Section 7.0–TRIAL PROCEDURES (Assessing and Recording Adverse 
Events ).  I also agree to handle all clinical suppl ies provided by the Sponsor and collect and 
handle all clinical specimens in accordance with the protocol.  I understand that information 
that identifies me will be used and disclosed as described in the protocol, and that such 
information may be transferr ed to countries that do not have laws protecting such 
information.  Since the information in this protocol and the referenced Investigator’s 
Brochure is confidential, I understand that its disclosure to any third parties, other than those 
involved in appro val, supervision, or conduct of the trial is prohibited.  I will ensure that the 
necessary  precautions are taken to protect such information from loss, inadvertent disclosure 
or access b y third parties.
TYPED NAME
TITLE
SIGNATURE
DATE SIGNED 
  05L65F